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Diseases
Abstract
The impact of EBV on human health is substantial, but vaccines that prevent primary EBV infections or
treat EBV-associated diseases are not yet available. The Epstein-Barr nuclear antigen 1 (EBNA1) is an
important target for vaccination because it is the only protein expressed in all forms of latency and in all
EBV-associated malignancies. The overarching goal throughout this dissertation was to determine if
EBNA1 is a suitable target for vaccine development. This was addressed in two ways. First, because an
improved understanding of EBNA1-specific T cell responses benefits EBV vaccine development, we
characterized responses against EBNA1 of the EBV-homologous rhesus lymphocryptovirus (rhLCV) in
naturally infected rhesus macaques. We assessed frequency, phenotype, and cytokine production profiles
of rhesus (rh)EBNA1-specific T cells by intracellular cytokine staining (ICS) and polychromatic flow
cytometry. We found that most naturally infected animals had CD4+ and/or CD8+ T cells against rhEBNA1
and rhBZLF1, an immediate-early lytic phase antigen of rhLCV. Peptide-specific CD8+ T cells showed a
more activated effector phenotype, while most peptide-specific CD4+ T cells exhibited a resting central
memory phenotype. T cells were highly functional and produced various combinations of the cytokines
IFN-γ, IL-2, and TNF-α. The differentiation status and functional profiles of rhEBNA1-specific T cells
suggests they are not impaired by chronic exposure to low levels of antigen, and rhEBNA1-specific T cells
therefore represent a viable population to target through vaccination. Similarities between our findings
and the human response further validate the rhLCV model for studying chronic EBV infection and for preclinical vaccine development. We then asked if vaccination could expand functional rhEBNA1-specific T
cells during persistent rhLCV infection. To test this, we developed two serologically distinct replicationdefective adenoviral vectors that expressed chimeric rhEBNA1 constructs fused to functional and nonfunctional versions of Herpes Simplex Virus- glycoprotein D (HSV-gD). HSV-gD has been shown to
augment T cell responses by inhibiting the immunosuppressive Herpes Virus Entry Mediator (HVEM)
pathway during T cell activation. After confirmation of vaccine specificity and antigenicity in vitro, rhesus
macaques were vaccinated in a prime-boost regimen, and responses in peripheral blood were measured
by ICS and polychromatic flow cytometry. Importantly, we found that vaccination induced the expansion
of highly functional rhEBNA1-specific CD8+ and CD4+ T cells in vivo, regardless of HSV-gD binding ability.
Vaccination did not increase rhBZLF1-specific T cell responses, thus indicating that rhEBNA1-specific
responses were vaccine-driven. Overall, these results serve as important proof-of-principle analyses of a
therapeutic EBNA1-based vaccine regimen and demonstrate that EBNA1 is a viable target that warrants
exploration in future vaccine studies.
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ABSTRACT

EBNA1-SPECIFIC T CELL RESPONSES DURING PERSISTENT RHESUS LCV
INFECTION AND THE DEVELOPMENT OF A NOVEL THERAPEUTIC PROTOTYPE
VACCINE FOR EBV-ASSOCIATED DISEASES

Rachel M. Leskowitz
Hildegund C.J. Ertl
The impact of EBV on human health is substantial, but vaccines that prevent primary
EBV infections or treat EBV-associated diseases are not yet available. The Epstein-Barr nuclear
antigen 1 (EBNA1) is an important target for vaccination because it is the only protein expressed
in all forms of latency and in all EBV-associated malignancies. The overarching goal throughout
this dissertation was to determine if EBNA1 is a suitable target for vaccine development. This
was addressed in two ways. First, because an improved understanding of EBNA1-specific T cell
responses benefits EBV vaccine development, we characterized responses against EBNA1 of the
EBV-homologous rhesus lymphocryptovirus (rhLCV) in naturally infected rhesus macaques. We
assessed frequency, phenotype, and cytokine production profiles of rhesus (rh)EBNA1-specific T
cells by intracellular cytokine staining (ICS) and polychromatic flow cytometry. We found that
+

+

most naturally infected animals had CD4 and/or CD8 T cells against rhEBNA1 and rhBZLF1, an
+

immediate-early lytic phase antigen of rhLCV. Peptide-specific CD8 T cells showed a more
+

activated effector phenotype, while most peptide-specific CD4 T cells exhibited a resting central
memory phenotype. T cells were highly functional and produced various combinations of the
cytokines IFN-γ, IL-2, and TNF-α.

The differentiation status and functional profiles of rhEBNA1-

specific T cells suggests they are not impaired by chronic exposure to low levels of antigen, and
rhEBNA1-specific T cells therefore represent a viable population to target through vaccination.
Similarities between our findings and the human response further validate the rhLCV model for
vi

studying chronic EBV infection and for pre-clinical vaccine development. We then asked if
vaccination could expand functional rhEBNA1-specific T cells during persistent rhLCV infection.
To test this, we developed two serologically distinct replication-defective adenoviral vectors that
expressed chimeric rhEBNA1 constructs fused to functional and non-functional versions of
Herpes Simplex Virus- glycoprotein D (HSV-gD). HSV-gD has been shown to augment T cell
responses by inhibiting the immunosuppressive Herpes Virus Entry Mediator (HVEM) pathway
during T cell activation. After confirmation of vaccine specificity and antigenicity in vitro, rhesus
macaques were vaccinated in a prime-boost regimen, and responses in peripheral blood were
measured by ICS and polychromatic flow cytometry.

Importantly, we found that vaccination
+

+

induced the expansion of highly functional rhEBNA1-specific CD8 and CD4 T cells in vivo,
regardless of HSV-gD binding ability.

Vaccination did not increase rhBZLF1-specific T cell

responses, thus indicating that rhEBNA1-specific responses were vaccine-driven. Overall, these
results serve as important proof-of-principle analyses of a therapeutic EBNA1-based vaccine
regimen and demonstrate that EBNA1 is a viable target that warrants exploration in future
vaccine studies.

vii

TABLE OF CONTENTS
ACKNOWLEDGEMENTS

IV

ABSTRACT

VI

LIST OF TABLES
LIST OF FIGURES
LIST OF ABBREVIATIONS
CHAPTER 1: INTRODUCTION

X
XI
XIII
1

1.1 EPSTEIN-BARR VIRUS (EBV)
1.2 THE ADAPTIVE IMMUNE RESPONSE AGAINST EBV
1.3 EBV-ASSOCIATED DISEASES
1.4 TREATMENT OF EBV-ASSOCIATED DISEASES
1.5 VACCINE STRATEGIES
1.6 AN ANIMAL MODEL FOR EBV: RHESUS LYMPHOCRYPTOVIRUS
1.7 OBJECTIVES AND SIGNIFICANCE

1
15
19
25
27
34
37

CHAPTER 2: T CELL RESPONSES TO LATENT ANTIGEN EBNA1 AND LYTIC ANTIGEN
BZLF1 DURING PERSISTENT RHLCV INFECTION OF RHESUS MACAQUES

40

ABSTRACT
INTRODUCTION
RESULTS PART I
DISCUSSION
RESULTS PART II
DISCUSSION

40
42
45
54
55
71

CHAPTER 3: ADENOVIRUS-BASED VACCINES TO RHESUS LYMPHOCRYPTOVIRUS
EBNA1: VECTOR DESIGN, MOUSE STUDIES, IN VITRO TESTING

79

ABSTRACT
INTRODUCTION
RESULTS
DISCUSSION

79
80
84
94

CHAPTER 4: ADENOVIRUS-BASED VACCINES TO RHESUS LYMPHYCRYPTOVIRUS
+
+
EBNA1 INDUCE EXPANSION OF CD8 AND CD4 T CELLS IN PERSISTENTLY INFECTED
RHESUS MACAQUES
96
ABSTRACT
INTRODUCTION
RESULTS
DISCUSSION

96
98
100
119

CHAPTER 5: DISCUSSION

125

SIGNIFICANCE
SUMMARY AND CONCLUSIONS
FUTURE DIRECTIONS

125
127
131
viii

CHAPTER 6: MATERIALS AND METHODS

136

6.1 T CELL RESPONSES TO LATENT ANTIGEN EBNA1 AND LYTIC ANTIGEN BZLF1 DURING PERSISTENT
RHLCV INFECTION OF RHESUS MACAQUES
136
6.2 ADENOVIRUS-BASED VACCINES TO RHEBNA1: VECTOR DESIGN, MOUSE STUDIES, IN VITRO
TESTING
144
+
+
6.3 ADENOVIRUS-BASED VACCINES TO RHEBNA1 INDUCE EXPANSION OF CD8 AND CD4 T CELLS IN
PERSISTENTLY INFECTED RHESUS MACAQUES
152
CHAPTER 7: REFERENCES

156

ix

LIST OF TABLES

CHAPTER 1:
Table 1-1: Subfamily classification of the human herpesviruses .....................................................3
Table 1-2: Patterns of latent gene expression and associated diseases.........................................9
Table 1-3: Diseases and their approximate association with EBV ................................................20

CHAPTER 2:
Table 2-1: List of rhesus macaques used in this study..................................................................46
+

+

Table 2-2: Numbers of rhEBNA1-specific CD4 and CD8 T cells ................................................50
+

+

Table 2-3: Total cytokine-secreting rhEBNA1- (A) and rhBZLF1- (B) specific CD4 and CD8 T
cells for each animal at both collection points ...............................................................................58

CHAPTER 4:
+

6

+

+

6

+

Table 4-1: Numbers of CD8 T Cells/10 live CD3 cells.............................................................103
Table 4-2: Numbers of CD4 T Cells/10 live CD3 cells.............................................................104
Table 4-3: Characteristics and responsiveness of rhesus macaques enrolled in this study........105

CHAPTER 6:
Table 6-1: List of antibodies.........................................................................................................140
Table 6-2: rhEBNA1 peptide sequences .....................................................................................142
Table 6-3: List of antibodies for ICS (mouse studies)..................................................................151

x

LIST OF FIGURES

CHAPTER 1:
Figure 1-1: The EBV genome in linear and episomal forms ............................................................5
Figure 1-2: The EBV life cycle .......................................................................................................14
Figure 1-3: EBV and rhLCV ORF homology..................................................................................36

CHAPTER 2:
+

+

Figure 2-1: Number of rhEBNA1-specific CD4 and CD8 T cell responses .................................49
+

+

Figure 2-2: RhEBNA1-specific CD4 and CD8 T cells over time .................................................53
Figure 2-3: Numbers of rhEBNA1- and rhBZLF1-specific T cells in PBMCs .................................59
Figure 2-4: Subset analysis of rhEBNA1-specific T cell responses...............................................62
Figure 2-5: Subset analysis of rhBZLF1-specific T cell responses................................................63
Figure 2-6: Multi-function analysis of rhEBNA1-specific T cell responses.....................................66
Figure 2-7: Multi-function analysis of rhBZLF1-specific T cell responses......................................67
Figure 2-8: PD-1 surface expression on rhEBNA1- and rhBZLF1-specific T cells ........................70

CHAPTER 3:
Figure 3-1: Enhanced T cell responses to antigens expressed as fusion proteins with HSV-gD ..83
Figure 3-2: In vitro testing of AdC-SgD-rhEBNA1 and AdC-NBEFSgD-rhEBNA1 vaccines..........86
+

+

Figure 3-3: Frequency and number of IFN-γ CD8 T cells following dose-escalation study ........89
+

Figure 3-4: Kinetics of peptide-specific CD8 T cells after vaccination..........................................90
+

Figure 3-5: Peptide-specific CD8 T cells after vaccination of C57/Bl6 and ICR mice ..................91
Figure 3-6: In vitro stimulation of rhEBNA1-specific T cells...........................................................93

CHAPTER 4:
Figure 4-1: Schedule of vaccinations and blood collection..........................................................102
xi

+

Figure 4-2: Magnitude of peptide-specific CD8 T cell responses upon vaccination...................108
+

+

Figure 4-3: Proportions of peptide-specific CD8 and CD4 T cell subsets upon vaccination.....109
+

Figure 4-4: Magnitude of peptide-specific CD4 T cell responses upon vaccination...................110
Figure 4-5: Cytokine profiles of rhLCV-specific T cells upon vaccination ....................................113
Figure 4-6: Granzyme B production by rhLCV-specific T cells ....................................................117
Figure 4-7: Expression of CCR7 before and after vaccination ....................................................118

CHAPTER 6:
Figure 6-1: Gating strategy and representative examples...........................................................141

xii

LIST OF ABBREVIATIONS

aa
Ad
AdHu
APC
BART
BCR
BL
BTLA
CMI
CNS
CR2
CTL
DC
DLBCL
DMSO
DRiP
EBER
EBNA
EBV
FACS
FBS
GAr
GC
g, gp
gp42, gp350/220
gH, gL, gD
HBSS
HCMV
HIV
HL
HLA
HHV
HSV
HVEM
ICS
IFN-γ
IL-2
IM
im
IR
ITR

Amino acid
Adenovirus
Human Adenovirus
Antigen presenting cell
BamHI A region rightward transcript
B cell receptor
Burkitt’s lymphoma
B and T lymphocyte attenuator
Cell mediated immunity
Central nervous system
Complement receptor 2
Cytotoxic T lymphocyte
Dendritic cell
Diffuse large B cell lymphoma
Dimethyl sulfoxide
Defective ribosomal product
Epstein-Barr virus-encoded RNA
Epstein-Barr nuclear antigen
Epstein-Barr virus
Fluorescence-activated cell sorting
Fetal bovine serum
Glycine-alanine rich repeat domain
Gastric cell carcinoma
Glycoprotein
Glycoprotein 42, 350/220
Glycoprotein H, L, D
Hank's balanced salt solution
Human cytomegalovirus
Human Immunodeficiency virus
Hodgkin’s lymphoma
Human leukocyte antigen
Human herpesvirus
Herpes simplex virus
Herpes virus entry mediator
Intracellular cytokine staining
Interferon gamma
Interleukin 2
Infectious mononucleosis
Intra-muscular
Internal repeat
Inverted terminal repeat
xiii

kb
kDA
KSHV
LCL
LCV
LMP
LP
MHC
MVA
NBEF
NF-κB
NHL
NHP
NK
NPC
ORF
oriP
PD-1
PMBC
PTLD
RBC
RDV
rhEBNA1
rhLCV
SAdV, AdC
SD
SgD
SIV
TCR
TCM cell
TEFF cell
TEM cell
TH
TMR
TNF-α
TR
UL
US
VCA
VZV
XLPD
YNPRC

Kilobase
Kilo Dalton
Kaposi’s sarcoma-associated herpesvirus
Lymphoblastoid cell line
Lymphocryptovirus
Latent membrane protein
Leader protein
Major histocompatibility
Modified vaccinia Ankara
Non-binding effect
Nuclear factor κB
Non-Hodgkin’s lymphoma
Non-human primate
Natural killer
Nasopharyngeal carcinoma
Open reading frame
Origin of plasmid replication
Programmed death 1
Peripheral blood monnuclear cell
Post-transplant lymphoproliferative disease
Red blood cell
Rhadinovirus
Rhesus Epstein-Barr nuclear antigen 1
Rhesus lymphocryptovirus
Simian, or chimpanzee Adenovirus
Standard deviation
Super glycoprotein D
Simian immunodeficiency virus
T cell receptor
Central memory T cell
Effector T cell
Effector memory T cell
T helper cell
Transembrane region
Tumor necrosis factor alpha
Terminal repeat
Unique long
Unique short
Viral capsid antigen
Varicella-zoster virus
X-linked lymphoproliferative disease
Yerkes National Primate Research Center

xiv

CHAPTER 1: INTRODUCTION
More than 95% of the human population is infected with the Epstein-Barr virus (EBV) by
1

adulthood , and EBV contributes to the development of about 1% of all human cancers

1, 2

. EBV

establishes a persistent infection through its latency in B cells, where it can occasionally
3

reactivate, but infections as well as reactivations are controlled by the adaptive immune system .
Although infection is typically benign, EBV is considered a carcinogen due to its strong
association with both lymphoid and epithelial cell malignancies, and the incidence of these
malignancies is highly elevated during immune suppression.

The impact of EBV on human

health is substantial, but vaccines that prevent primary EBV infections or treat EBV-associated
diseases are not yet available.

1.1 EPSTEIN-BARR VIRUS (EBV)
General properties
Discovery
Denis Burkitt, a surgeon working in East Africa in the late 1950s, was the first to propose
that an infectious agent was involved in the etiology of a human malignancy. He was studying a
novel childhood tumor, now known as Burkitt’s lymphoma (BL), which he noticed was unusually
common among areas with similar climatic factors around equatorial Africa

4, 5

. This idea caught

the attention of Dr. Anthony Epstein, who after attending a seminar given by Dr. Burkitt in 1961,
arranged to receive BL biopsy specimens.

Dr. Epstein and his Ph.D. student Yvonne Barr

successfully established a line of BL-derived cells in culture. They examined these cells under an
electron microscope and discovered “herpesvirus-like particles in a small proportion [of the
6

cells]” . These particles proved to be biologically and antigenically distinct from other members of

	
  

1

the human herpesvirus (HHV) family, thus marking the discovery of the first candidate human
tumor virus, also known as Epstein-Barr virus (EBV), or human herpesvirus 4 (HHV-4).
In the years to follow, serological studies revealed the vast prevalence of EBV worldwide.
In 1968, EBV was identified as the cause of infectious mononucleosis (IM) when a lab technician,
7

who had been studying EBV, developed IM and seroconverted . EBV was found to transform
8

9

human B cells in vitro in 1971 and to replicate in human epithelial cells in 1984 . Since its initial
discovery in BL cells, EBV has been found in a variety of human epithelial and lymphoid
10

malignancies and has also been linked to various autoimmune diseases .
Classification
EBV is a member of the Herpesviridae family, which is a large group of DNA viruses
characterized by their lifelong latency following primary infection. Currently, there are nine
10

herpesviruses known to infect humans . These include herpes simplex virus 1 and 2 (HSV1,
HHV-1; HSV-2, HHV-2), human cytomegalovirus (HCMV; HHV-5), varicella-zoster virus (VZV;
HHV-3), Epstein-Barr virus (EBV; HHV-4), human herpesviruses 6A, 6B, and 7 (HHV-6A, HHV6B, HHV-7), and Kaposi’s sarcoma-associated herpesvirus (KSHV; HHV-8). Herpesviruses are
classified into Alpha-, Beta-, and Gammaherpesvirinae subfamilies based on various biological
properties such as host range, reproductive cycle, and cell tropism. The gammaherpesviruses,
which includes EBV, are lymphotropic and usually establish latency in lymphoid tissue. EBV is
distinguished by its latent infection of B lymphocytes and its ability to transform B cells in vitro into
latently infected, immortalized, B-lymphoblastoid cell lines (LCLs) that proliferate indefinitely in the
presence of sufficient growth factors. Subfamily classification of human herpesviruses can be
found in Table 1-1.

	
  

2

Table 1-1: Subfamily classification of the human herpesviruses
Official name
Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human herpesvirus 4
Human herpesvirus 5
Human herpesvirus 6-A
Human herpesvirus 6-B
Human herpesvirus 7
Human herpesvirus 8

Common name
Herpes simplex virus 1 (HSV-1)
Herpes simplex virus 2 (HSV-2)
Varicella-zoster virus (VZV)
Epstein-Barr virus (EBV)
Human cytomegalovirus (CMV)
------Kaposi’s sarcoma-associated
herpesvirus (KSHV)

Subfamily
AlphaAlphaAlphaGammaBetaBetaBetaBetaGamma-

Subfamilies are further divided into a series of genera based on similarities in DNA
sequences and genome arrangement as well as immunologic and antigenic similarity of important
10

viral proteins . The gammaherpesvirus subfamily consists of the gamma 1 (Lymphocryptovirus,
LCV) genus, which includes EBV and related primate viruses, and the gamma 2 (Rhadinovirus,
RDV) genus, which includes KSHV and other related viruses of primate and non-primate species.
EBV is the only human member of the LCV genus, which also includes a number of simian
homologs including rhesus lymphocryptovirus (rhLCV), which is the only fully sequenced EBV
homolog with a repertoire of lytic and latent genes identical to that of EBV.
Genome and structure
Like all herpesviruses, EBV virions have a protein core that is wrapped by a double
stranded DNA viral genome and enclosed within an icosahedral nucleocapsid composed of 162
capsomeres. A protein-rich structure called the tegument separates the nucleocapsid from the
envelope and delivers pre-synthesized proteins to newly infected cells. The envelope itself is
spiked with several virus-encoded glycoproteins involved in cellular attachment and entry.
10

The EBV genome is approximately 172 kilobase (kb) pairs long , with two distinct
programs of gene expression that are broadly characterized as lytic or latent. EBV encodes
about 100 proteins as well as multiple non-coding RNAs

11

that are organized and expressed in a

linear fashion. Therefore, gene overlaps and multiple gene products that result from frame shifts,
alternative splicing, and internal translation initiation sites are common. The genome is divided
into 15 kb unique short (US) and 150 kb unique long (UL) regions that are separated by multiple
tandemly reiterated internal repeats (IRs). Tandemly reiterated terminal repeats (TRs) flank the
	
  
3

genome on both ends (Figure 1-1A). During latent infection, the viral genome takes the form of a
closed circular molecule from which only a small subset of genes are expressed (Figure 1-1B).
EBV DNA remains in this circular form during replication in latently infected cells.
Two distinct types of EBV (types 1 and 2) share between 70 to 85% sequence
10

homology , and strains within each type are distinguished by the number of genomic repeats.
Differences between the two types of EBV are based on sequence polymorphisms in four nuclear
proteins expressed during latency (EBNA2, -3A, -3B, and -3C).

Both types co-exist in all

10

populations that have been studied , but EBV-1 is more prevalent in the developed world than
10

EBV-2, which is common in equatorial Africa and New Guinea . Differences between type 1 and
2 are not correlated with human diseases, but it has been shown that EBV-1 isolates transform B
10

cells more efficiently in vitro .

Dual infections and intertypic recombinants are most often

observed during immune suppression, and infection with either type results in lifelong
persistence.
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Figure 1-1: The EBV genome in linear and episomal forms

A.

B.

Figure 1-1: (A) Structure of the EBV genome shown in linear form with the location of important
lytic and latent genes below. The genome is organized into series of unique short (US) and unique
long (UL) regions of internal repeats (IRs) flanked by terminal repeat domains (TRs). Figure was
12
adapted from Straus et al., 1993 . (B) Structure of EBV episome showing location and
transcription of latency genes. The origin of plasmid replication is shown in orange (OriP). Arrows
indicate the direction of transcription, with larger arrows showing exons. The thin green arrow
starting at the Cp or Wp promoters represents transcription of the EBNA proteins during latency III,
which are generated by differential splicing. EBNA1 is transcribed from the Qp promoter during
13
latency I and II (red arrow). Figure was adapted from Young et al., 2004 . LMP, latent membrane
protein; EBNA, Epstein-Barr nuclear antigen; gp, glycoprotein; BCRF1, BamH1 C rightward reading
frame; ZEBRA, Z Epstein-Barr virus replication activator, also known as ZTA (Z fragment trans
activator) or BZLF1 (BamH1 Z leftward reading frame).

	
  

5

Transmission
EBV is one of the most common known human viruses; 95 to 99% of adults in the U.S.
14

and over 95% of the population worldwide are seropositive . Primary infection occurs early in life
in most developing countries and is generally asymptomatic or produces only mild clinical
symptoms.

When infection is delayed until adolescence or adulthood, as is common in

developed countries, EBV can cause IM. IM is a benign, self-limited, lymphoproliferative disease
characterized by fever, sore throat, cervical lymphadenopathy, and fatigue.
EBV is transmitted orally through saliva; some individuals continue to shed virus even
after resolution of primary infection. At any given time, between 20 to 30% of healthy seropositive
adults are shedding low concentrations of EBV, and the incidence of shedding increases to 60 to
15

90% during immunosuppression . In addition to oral secretions, EBV can also be transmitted
11

through blood product transfusions and bone marrow or solid organ transplants . EBV has also
16

been found in genital secretions, which suggests that it can be transmitted sexually .
Cell tropism, attachment, and entry
The primary targets of EBV infection are squamous pharyngeal epithelial cells and B
cells. Initiation of infection and mechanisms of entry are different for epithelial cells and B cells,
which have different cell surface receptors that facilitate binding of EBV. The host range of EBV
is therefore partially influenced by receptor availability on target cells. EBV enters epithelial cells
via fusion with the plasma membrane and B cells via endocytosis followed by fusion with the
endocytic membrane. For B cell entry, EBV virions bind CD21, also known as the complement
receptor 2 (CR2), which is highly expressed on B cells. Binding of CD21 to the virus-encoded
glycoproteins (gp) 350/220 results in endocytosis. The viral and endocytic membranes fuse via
gp42, which binds to human leukocyte antigen (HLA) class II on B cells and forms a three part gp
complex with gH and gL (gp42gHgL) that triggers fusion. In contrast, epithelial cell attachment
and entry is mediated primarily through interactions between cell surface integrins and the viral
protein BMRF2. BMRF2 functions similarly to gp350/220 by tethering virions to target cells and
inducing signal transduction pathways. Following attachment, two part complexes (gH/gL) bind to
integrins and mediate epithelial cell membrane fusion. Therefore, in addition to surface receptors
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on target cells, tropism is also dictated by the composition of glycoproteins on the EBV virion,
which can differ depending on the cell in which the virion was produced. Virions produced in B
cells are deficient in gp42, as it remains bound to HLA class II. In contrast, virions produced in
epithelial cells, which do not express HLA class II, contain high levels of gp42/gH/gL complexes
on the surface. As a result, EBV virions produced in B cells are more infectious to epithelial cells,
17

and virions made in epithelial cells are more infectious to B cells . While epithelial cells and B
cells are the primary targets of EBV, infection of T-cells, monocytes, neutrophils, and natural killer
17

(NK) cells has also been described .
Phases of infection
EBV causes both lytic (productive) and latent infections that generally have different
primary target cells and express different sets of genes. Initial productive infection is primarily
localized to epithelial cells of the oropharynx, where mature infectious virions are assembled and
released, resulting in cell lysis. In contrast, latent infection usually occurs in B cells, where the
viral genome exists as a stable circular episome, gene expression is restricted, and infectious
viral particles are not produced. Latently infected B cells can be detected in peripheral blood, in
tonsils and adenoids in the oral cavity, and to a lesser extent in mesenteric lymph nodes and the
18

spleen . Latent EBV retains the capacity to reactivate to a lytic state and produce new infectious
virions; this can occur in the presence or absence of clinical symptoms.
EBV gene expression during latent infection
Genes expressed during latency are initially growth transforming; infection of naïve B
cells results in B cell activation, expansion, and maturation, which allows EBV to spread quickly
11

throughout the B cell compartment . Although the majority of these lymphoblasts are eventually
destroyed by the adaptive immune system, EBV persists within B cells by downregulating gene
expression and becoming essentially undetectable to host immune cells. Downregulation of latent
gene expression is accompanied by a transition to a resting memory B cell phenotype, and the
19

amount of virus detected in latently infected cells is drastically reduced . Latently infected B cells
15

in peripheral blood are present at a rate of about 1 to 60 per million B cells . Each cell carries
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less than five copies of the latent viral genome

19, 20

, and the frequency of latently infected cells

21

remains relatively stable over time .
Only a small subset of the nearly 100 EBV-encoded genes is expressed during latency.
These include six Epstein-Barr nuclear antigens (EBNAs; 1, 2, 3A, 3B, 3C, leader protein (LP)),
three latent membrane proteins (LMPs; 1, 2A, 2B), two EBV-encoded small non-polyadenylated
RNAs (EBERs), and rightward transcripts from the BamHI A region of the genome (BARTs).
10

EBNA1 and LMP1 are also expressed during lytic infection .
Programs of gene expression
Different programs of gene expression are associated with different phases of latency,
and the combination of genes expressed determines the extent of proliferation and the ability of
EBV to escape immune surveillance. The growth-transforming properties of latency occur when
all of the latency genes are expressed. This is known as latency III. The latency III program of
gene expression is also what causes transformation of B cells to LCLs in vitro. In vivo, pressures
of the immune system eventually cause a downregulation of gene expression, which allows EBV
to persist in a latent state. In latency II, EBNA1, LMP1, and LMP2 are expressed with the EBERs
and BamHI A RNAs. EBNA1 is the only protein expressed during latency I along with the EBERs
and BamHI A RNAs. Finally, a fourth program referred to as latency 0 has been used to describe
22

latently infected cells in the blood that do not express any viral genes except the EBERs . This
fourth stage of latency is most common among healthy virus carriers, however, transcripts for
EBNA1 and LMP2 have also been detected in the blood of such individuals

23, 24

.

In addition to establishing lifelong infection, the latency genes and their products are
implicated in the pathogenesis of many EBV-associated malignancies. A latency I pattern of
gene expression is associated with Burkitt’s lymphoma (BL), some diffuse large B cell lymphomas
(DLBCLs), and gastric cell carcinomas (GC). Latency II is associated with Hodgkin’s lymphoma
(HL), T/NK cell lymphomas, and nasopharyngeal carcinoma (NPC). Latency III is found in IM and
all EBV-associated Immunoblastic/lymphoproliferative diseases. A list of the different latency
programs, genes expressed, and associated diseases can be found in Table 1-2. EBVassociated diseases will be discussed in detail in a later section.
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Table 1-2: Patterns of latent gene expression and associated diseases
Latency
type

Genes expressed

Associated diseases

0

EBER1,2; occasional EBNA1
and/or LMP2

[latently infected B cells in peripheral blood]

I

EBNA1; EBER1,2; BamHI A
RNAs

Burkitt’s lymphoma
Centroblastic diffuse large B cell lymphoma
Gastric carcinoma

II

EBNA1; LMP1,2A,2B; EBER1,2;
BamHI A RNAs

Chronic active EBV
Hodgkin’s lymphoma
Nasopharyngeal carcinoma
T/NK cell lymphoma

III

EBNA1,2,3A,3B,3C,LP;
LMP1,2A,2B; EBER1,2; BamHI A
RNAs

B cell transformation to LCL in vivo
B cell lymphoproliferative disease
Immunoblastic diffuse large B cell lymphoma

Function of latency genes
Genes expressed during latency are important for B cell growth transformation,
maintaining the viral episome, and preventing apoptosis. The specific functions of these genes
and their protein products are reviewed below.
EBNAs: EBNA-LP and EBNA2 are the first proteins expressed during latent EBV
infection.

EBNA2 is required for B cell transformation and is responsible for activating

transcription from various promoters, which results in the expression of additional EBNAs as well
as the LMPs

25, 26

. EBNA2 also activates transcription of several cellular genes including CD21

(EBV receptor), CD23 (B cell activation marker), c-myc and c-fgr (proto-oncogenes)

27-29

. EBNA-

LP enhances EBNA2-dependent transcription of viral and cellular genes and likely plays a role in
30

RNA processing . The EBNA3 proteins regulate the activity of EBNA2, and they also upregulate
cellular and viral gene expression, including CD21 and LMP1 (EBNA3C), CD40 and Bcl-2
31

32

(EBNA3B) . EBNAs 3A and 3C are required for B cell transformation .
EBNA1 is a DNA binding protein that functions to maintain the viral episome and is
therefore essential for EBV persistence.

EBNA1 ensures episomal segregation during cell

division by binding the origin of plasmid replication (oriP) on the viral genome and tethering it to
33

mitotic chromosomes . EBNA1 is also important for B cell transformation during latency and for
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10

activating the expression of additional EBV latent genes .

Transcription of EBNA1 is

autoregulated through its binding to the oriP and various upstream promoters. EBNA1 is the only
protein expressed in all of the patterns of latency associated with disease (I, II, III). The
importance of EBNA1 and its potential as a vaccine target will be discussed in a later section.
LMPs:

LMP1 is an important signaling molecule that is necessary for many of the
34

changes involved in B cell transformation . Structurally, it mimics proteins of the tumor necrosis
35

factor (TNF)-receptor superfamily by acting as a constitutively active CD40 homolog .
Downstream signaling stimulates two important families (nuclear factor κB (NF-κB) and c-jun
kinase) of transcriptional activators that are both involved in controlling cell growth

36, 37

.

Additional phenotypic effects include B cell aggregation, the upregulation of activation and
adhesion molecules, the activation of cytokine genes, and the induction of cell survival proteins
such as Bcl-2

10, 35

. LMP1 therefore functions as an oncogene for EBV, and the resulting effect is

constitutive B cell proliferation. Unlike LMP1, neither LMP2A nor LMP2B are essential for B cell
38

transformation . LMP2A co-localizes with LMP1 in the plasma membrane of the infected B
39

cell . Its cytoplasmic tail resembles that of the B cell receptor (BCR), and it competes for binding
to molecules involved in BCR downstream signaling.

The resulting inhibition of BCR signal

transduction allows EBV to prevent and therefore control normal B cell stimulation and activation.
40

This helps promote latency, as normal BCR signaling induces reactivation of the lytic cycle .
LMP2A also promotes B cell survival by deregulating transcription factors during B cell
development in order to bypass certain developmental checkpoints while driving B cell
41

differentiation to a long-lived memory phenotype .
Small RNA molecules: The EBERs are the most abundant EBV RNAs, present at about
10

50,000 copies per cell . Both EBER1 and EBER2 are small, nuclear, non-polyadenylated RNAs
whose function is not completely understood.
42

Neither 1 nor 2 are necessary for B cell

transformation , but their expression leads to the upregulation of Bcl-2

43

44

and IL-10 . The result

is increased resistance to apoptosis and enhanced B cell maturation, proliferation, and survival.
EBV also encodes a large group of micro RNAs (miRNAs) with a wide rande of functions. For
example, BamHI A transcripts are highly spliced RNAs that most likely influence latent infection
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through cell signaling or by regulating promoters, as the transcripts are antisense to many
45

important genes .
EBV gene expression during lytic infection
EBV in infected B cells can remain latent with varying levels of gene expression or it can
reactivate to lytic replication. The decision to enter the lytic cycle induces a classic regulatory
cascade where about 80 different genes are expressed.

Virally-encoded lytic proteins are

involved in cell entry, gene expression regulation, nucleotide metabolism, viral DNA synthesis,
10

and virion assembly as well as management of host defenses and cellular metabolism . Viral
gene expression during lytic infection is defined by the order of expression and the mechanisms
that drive it.

Gene expression is temporally regulated into three broad phases in which the

immediate-early, early, and late genes are sequentially expressed.
Immediate early (IE) gene expression: Viral transactivator proteins incorporated in the
viral tegument activate transcription of the IE genes, which encode additional transcriptional
transactivators important for early progression of the lytic cycle. IE proteins include BZLF1 and
BRLF1, which initiate the switch from latent to lytic infection and downregulate latent gene
10

expression .
Early (E) gene expression: Transcription of the E genes is independent of viral DNA
10

synthesis. E proteins such as BSMLF1 and BMRF1 are transactivators of other early genes ,
46

such as BHRF1 and BALF1, which are homologous to the anti-apoptotic molecule Bcl-2 .
Additional early genes encode proteins involved in viral DNA replication, such as the major DNA
binding protein (BALF2), DNA polymerase (BALF5), ribonucleotide reductases (BORF2 and
10

BaRF1), thymidine kinase (BXLF1), and alkaline exonuclease (BGLF5) .
Late (L) gene expression: Expression of the L genes is either augmented by or
completely dependent on the onset of viral DNA synthesis. The majority of these genes encode
structural proteins such as viral glycoproteins, nucleocapsid proteins, tegument proteins, and a
core protein; the majority of the L proteins are therefore required for proper assembly and
10

packaging of EBV virions .
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The life cycle of EBV
EBV’s replication cycle, similar to all herpesviruses, begins after viral fusion and entry in
the host cell. Nucleocapsid and tegument are then released into the cytoplasm, where they travel
to nuclear pores via the cellular cytoskeleton. Viral DNA is translocated, circularized, and partially
chromatinized in the nucleus. Chromatinization is a dynamic form of transcriptional regulation
that changes throughout the viral life cycle.

The nature of viral DNA chromatinization (and

therefore the viral genes accessible) as well as the presence and status of specific viral and
cellular regulators of transcription are important factors that influence whether EBV enters lytic
47

replication or establishes latent infection .
It was originally believed that oropharyngeal epithelial cells were the target for primary
and productive EBV infection, and that released virions would then latently infect resting naïve (or
9

occasionally memory) B cells that traffic through the oropharynx . However, it has also been
48

shown that viral infection can be entirely restricted to lymphoid cells . This indicates that primary
productive infection can occur in B cells, although the majority become latently infected
11

lymphoblasts that display a type III pattern of gene expression .
Latently infected B cells then typically undergo a phase of maturation and differentiation
that is associated with a downregulation of latent gene expression. One proposed pathway in
which this occurs is in the germinal centers of lymphoid follicles through similar mechanisms
49

exhibited during normal B cell activation . The latency III program of gene expression induces
proliferation of EBV-infected naïve B cells, which eventually migrate to lymphoid follicles to
differentiate. This is likely facilitated through a downregulation of gene expression to a type II
latency pattern, where LMPs mimic cellular and extracellular factors that may induce class switch
recombination, somatic hypermutation, and stimulate BCR signaling.

Additional lines of

evidence, however, suggest that EBV-infected B cells may not transmit and differentiate through
the germinal center

24, 50

51

, and not all EBV-infected B cells are isotype-switched . Regardless of

the mechanism, latently infected B cells differentiate into a resting memory phenotype, where
they express even fewer EBV antigens (type I or 0 pattern of latency) and establish a carrier state
that persists for life

19, 22, 24

.
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The exact details that lead to viral reactivation remain elusive; however, various
contributing factors have been shown to stimulate the transition to lytic replication. For example,
latently infected resting memory B cells may encounter their cognate antigen and undergo
52

differentiation into plasma cells .

This can trigger re-entry into the EBV lytic cycle, where

depending on the location of the B cell, released virions can infect naïve B cells in the periphery,
epithelial cells in the oropharynx, or can be shed directly in saliva. Additional factors that may
influence reactivation include times of weakened immunity as a result of trauma, infection, or
physiological stress associated with increased stress hormones

53-56

. The life cycle of EBV is

summarized in Figure 1-2.
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Figure 1-2: The EBV life cycle

Figure 1-2: Primary EBV infection occurs in epithelial cells and B cells. B cells are infected
either directly or with virus released from oral epithelial cells. The majority of EBV-infected B
cells undergo latent infection, where the type III program of gene expression induces B cell
proliferation and maturation. Some EBV-infected B cells also undergo lytic infection as well.
EBV-specific cytotoxic T cells control primary infection and subsequent reactivations, but the
virus persists in resting memory B cells. This figure was adapted from Odumade, et al.,
57
2011 .
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1.2 THE ADAPTIVE IMMUNE RESPONSE AGAINST EBV
The virus-specific immune response is crucial for maintaining a disease-free virus-host
equilibrium. The host immune system can easily detect and destroy virus-infected cells during
lytic replication, when the vast majority of EBV genes are expressed, but detection is difficult
during latency. EBV uses additional mechanisms to hinder or delay host immune responses,
which include blocking antigen presentation, mimicking the function of host immunomodulators,
and generating orthologs of cellular proteins that mislead infected cells to stimulate desired
10

functions . Despite these various mechanisms, healthy individuals mount an effective immune
response that regulates and controls infection, but does not completely eliminate the virus. This
balance between viral reactivation and host immune surveillance is maintained throughout the
lifetime of all healthy seropositive individuals. While components of the innate immune response
are certainly important in combating EBV (such as NK cells), the most crucial control comes from
58

the humoral and cell-mediated arms of the adaptive immune system .
The humoral immune response against EBV
The humoral immune response consists of antigen-specific antibodies which target and
59

destroy extracellular pathogens and prevent the spread of intracellular infections . Antibodies
can contribute to immunity by binding and therefore blocking infection of host cells
(neutralization); by coating pathogen and stimulating phagocyte removal; and by triggering
destruction through additional immune mechanisms such as NK cell-mediated killing of antibodyantigen coated cells (antibody-dependent cell-mediated cytotoxicity) or activating the complement
59

system . 	
   	
  
	
  

EBV elicits a strong humoral immune response. Most EBV-specific antibodies against lytic

antigens are generated during acute infection, while EBV-specific antibodies against latent
15

antigens tend to arise during convalescence . IgM antibodies against a variety of IE, E, and L
lytic antigens arise first, and responses against viral capsid antigen (VCA) are detected most
10

frequently . Anti-VCA IgM antibodies are usually present at the onset of symptoms, peak during
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the acute phase of infection, and decline to undetectable levels upon resolution of clinical
symptoms. VCA IgG arises about three months after the onset of infection, which is around the
15

same time as antibodies to EBNA1 begin to appear . IgG antibodies to VCA and EBNA1 persist
60

for life . Antibody responses against other EBV proteins are also detected, including those
against the envelope glycoprotein gp350, which can neutralize virus and are important for
61

convalescence and control of reactivation . Elevated titers of isotype-specific EBV antibodies
can also be used for diagnostic and prognostic characterization of certain EBV-associated
15

62

63

64

diseases, such as BL (VCA, EA) , HL (VCA, EA, EBNA2) , NPC (VCA) , and GC (VCA) .
EBV-induced polyclonal B cell activation also leads to the production of non-EBV-specific
heterophile antibodies, which are reactive against antigens expressed on red blood cells (RBCs)
7

of many animals such as sheep, cow, goat, horse, and ox . A standard means of diagnosing IM
is by testing the ability of sera from infected patients to agglutinate such cells.
The cell-mediated immune response against EBV
+

+

Cell-mediated immunity (CMI) includes CD8 and CD4 T lymphocytes, which interact with
peptide derived from viral antigen that is displayed on the surface of antigen presenting cells
(APCs) in the context of major histocompatibility (MHC) alleles (in humans these are the HLA
alleles). Individuals present different peptides depending on their HLA alleles. As a result of this
+

+

interaction with MHC molecules, CD8 and CD4 T lymphocytes can be stimulated to proliferate
59

and differentiate into either effector or memory cells . Effector T cells develop quickly, mediate
direct or indirect killing of infected cells, and have a more limited lifespan than memory cells,
65

which develop slowly, but confer long-term protection against reinfection .
The typical immune response to an acute infection involves the activation, expansion, and
contraction of antigen-specific T cells. Although the majority of expanded cells will die by
66

apoptosis, a minority survives and differentiates into the long-lived memory pool .

Upon

secondary exposure to cognate antigen, these memory T cells can undergo rapid recall
proliferation and can differentiate into secondary effector and memory populations. Memory T cell
subsets are quite heterogeneous, but can be broadly classified as either effector memory (TEM) or
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65

central memory (TCM) cells . TCM cells reside primarily in lymphatic tissues and may require
further differentiation to attain full effector function, but respond to secondary antigen stimulation
66

with rapid proliferation . In contrast, TEM cells reside primarily in the periphery and have more
rapid effector function upon secondary stimulation, but they do not proliferate as well as the TCM
66

compartment . Although both are long-lived, TEM cells have a shorter lifespan than TCM cells,
66

which are stably maintained through homeostatic self-renewal .
T cells are important for controlling acute EBV infection and for long-term control of EBV
67

+

reactivation . CD8 T cells recognize viral peptides that are 8 to 11 amino acids (aa) long and
68

are presented by epitope-specific MHC class I molecules on the surface of infected cells .
Almost all nucleated cells express MHC class I receptors. EBV-specific cytotoxic T lymphocytes
(CTLs) are generated against both lytic and latent antigens, display an effector phenotype during
69

IM, and mediate direct killing of cells infected with intracellular pathogen . CTLs against lytic
+

antigens arise first, while CD8 T cells against latent antigens arise slightly later during acute
infection and can continue to arise for 3 to 4 months following convalescence

70, 71

. EBV-specific

CTLs are generally positive for granzyme and perforin, which correlates with cytotoxic activity, as
demonstrated by cytotoxicity and cytokine secretion assays

71-76

. Most EBV-specific CTLs are

short-lived and undergo apoptosis once the level of EBV antigen drops. CTLs to IE antigens
decline rapidly after infection, while CTLs to latent antigens decline more slowly

67, 77

. Expression

+

of PD-1, a marker of lymphocyte exhaustion, is elevated on EBV-specific CD8 T cells during IM,
67

but returns to low levels during convalescence . After resolution of acute infection, lytic antigen
responses typically have a TEM cell phenotype, while latent antigen responses have either a TEM
or TCM cell phenotype

67, 70, 74

.
+

During IM there is a massive expansion of lytic EBV antigen-specific CD8 T cells. In
+

some individuals, up to 44% of the total CD8 T cell pool can be directed against a single epitope,
78

and responses are highly HLA type-dependent . IE lytic proteins such as BZLF1 and BRLF1 are
+

highly antigenic and are recognized by more CD8 T cells than E proteins, which are more
67

antigenic than L proteins . This hierarchy of antigenicity may be due to immune-evasion genes,
which are not expressed until later in the lytic cycle. In fact, there is a direct correlation between

	
  

17

lytic protein immunodominance and the efficiency to which those proteins are processed and
79

+

presented in lytically infected cells . In contrast, up to 5% of CD8 T cells are directed against
latent antigens during IM, and EBNA3-specific responses are most common

67, 80-82

. Other EBV

+

latency proteins that are targets for CD8 T cells include LMP2 followed by EBNAs 1 and 2

67, 82-84

.

In long-term healthy carriers, the frequency of CTLs directed against EBV antigens can reach 5%,
+

+

with about 0.2 to 2% of CD8 T cells directed against lytic proteins and 0.05 to 1% of CD8 T cells
67

+

specific for latent proteins . Thus, a significant proportion of the CD8 T cell pool is devoted to
controlling long-term EBV infection. Age-correlated expansion of EBV-specific T cells has also
+

been observed, and responses can constitute up to 14% of total CD8 T cells in healthy
85

individuals over age 60 .
+

+

In comparison to the CD8 T cell response, less is known about EBV-specific CD4 T cells.
+

CD4 T cells recognize 10 to 18 aa long peptide fragments that are presented by epitope-specific
MHC class II molecules after endocytosis rather than de novo synthesis. Only a limited group of
cells express MHC class II, including B cells and professional antigen presenting cells (APCs)
+

such as dendritic cells (DCs) and macrophages. CD4 T cells generally have a large repertoire of
potential effector activities, and the majority differentiate into various subsets with distinct
86

+

immunological ‘helper’ functions (helper T cells (TH)) . CD4 TH cells can promote the activation
+

of CD8 T cells during inflammatory responses against intracellular pathogens (TH1), promote B
cell activation for antibody secretion in response to extracellular pathogens (TH2), provide B cell
help in lymph node follicles for B cell differentiation (follicular helper, TFH), and help regulate TEFF
+

cells through silence or death signaling (regulatory T cells, Tregs). Additionally, CD4 TH cells can
function as CTLs and lyse MHC class II-positive cells that express their cognate antigen.
+

EBV-specific CD4 T cells produce the inflammatory cytokines interferon gamma (IFN-γ)
and tumor necrosis factor alpha (TNF-α), lower levels of interleukin 2 (IL-2), and some clones are
perforin positive, cytotoxic, and can inhibit the outgrowth of virus-transformed cells

67, 87, 88

. EBV-

+

specific CD4 T cell responses against lytic antigens are more evenly distributed across the IE, E,
+

and L proteins compared to CD8 responses

10, 89, 90

+

. This is probably because CD4 T cells

readily communicate with professional APCs, which process and display extracellular antigen. In
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contrast, antigen presented by MHC class I molecules on the surface of virus-infected cells is
more likely influenced by EBV immune evasion mechanisms.
+

During IM, there is large expansion of BZLF1-specific CD4 T cells; responses against
BMLF1 and EBNA3A are also commonly detected
than EBNAs 1 or 2

71, 90

71, 88, 90

+

. CD4 T cells recognize EBNA3C more
+

. After resolution of acute infection, EBV-specific CD4 T cells rapidly
10

decline to less than 1% total frequency after 1 year .

In healthy carriers, CD4

+

T cells

predominantly recognize EBNA1, with the majority of responses generated against its carboxyl
terminus
91, 93

.

91, 92

+

. CD4 T cells also recognize EBNAs 2 and 3C, but to a lesser extent than EBNA1

Other latency proteins (EBNA3A, 3B; LMP1, 2)

BMLF1, BHRF1, BNLF2b, BCRF1, gp110, gp350)

91, 93

87, 88, 94-96

67,

and many lytic proteins (BZLF1,
+

are also recognized by CD4 T cells in

healthy carriers.
+

The frequency of EBV-specific CD8 T cells is generally about 10-fold higher than the
+

frequency of EBV-specific memory CD4 T cells in healthy virus carriers

91, 93

. Studies using B

cells with inducible latent gene expression were used to demonstrate that newly infected B cells
+

are better recognized by CD8 T cells, while latently infected B cells are better recognized by
+

97

+

CD4 T cells . CD8 T cells recognized latency proteins quickly, but frequencies declined once
+

expression was halted. CD4 T cell recognition of latency proteins was initially delayed, but
persisted for several days after expression was suppressed.

1.3 EBV-ASSOCIATED DISEASES
EBV and humans have coevolved for millions of years, during which both virus and host
have developed intricate strategies to maintain coexistence in a disease-free setting; a
disturbance of the balance between EBV and host immune responses can manifest as a variety
of EBV-associated diseases.

In the absence of T cells, the oncogenic potential of EBV is

demonstrated in vitro by its capacity to immortalize B cells.

In vivo, the incidence of EBV-

associated diseases is significantly elevated in individuals with weak or suppressed immune
systems.

Despite the near ubiquity of EBV worldwide, EBV-associated malignancies are

	
  

19

relatively rare among individuals with intact immune systems.

However, there is great

geographical variation in incidence, and certain populations of otherwise healthy individuals are at
high risk of developing EBV-associated malignancies. This points to a crucial requirement for
genetic and environmental cofactors that contribute to the viral tropism and cellular transformation
of EBV-associated cancers, but the exact contributions of EBV to the various malignancies are
still not clearly understood.
The wide range of EBV-associated diseases can be divided into two broad categories:
malignancies of B cell origin (lymphoid) and malignancies of non-B cell/epithelial cell origin. EBVassociated malignant disorders of B cells include a range of immunoblastic lymphomas (that arise
during immunosuppression), BL, and a subset of HL. There are also a wide array of non-Hodgkin
10

lymphomas that are positive for EBV to varying degrees . Some malignancies of non-B cell
origin include NPC, GC, and T cell/NK cell lymphomas. A list of the various diseases and the
percent of cases associated with EBV can be found in Table 1-3. EBV has also been linked to a
98

99

number of autoimmune disorders including multiple sclerosis , dermatomyositis , rheumatoid
arthritis

100

, and systemic lupus erythematosus

101, 102

; elevated EBV DNA is often detected in the

blood of patients with these diseases, but the role of EBV in disease pathogenesis is still
unclear

102, 103

.

Table 1-3: Diseases and their approximate association with EBV
Cellular
origin

B cell

Non-B
cell

Disease

Association
with EBV

IM
B cell lymphoproliferative disease
Immunoblastic diffuse large B cell lymphoma (HIV)
Chronic active EBV
Burkitt’s lymphoma: Endemic
Sporadic
HIV-associated
Hodgkin’s lymphoma
HIV-associated
Centroblastic diffuse large B cell lymphoma (HIV)
Nasopharyngeal carcinoma
Gastric carcinoma
T/NK cell lymphomas

	
  

90%
>90%
100%
96%
10-70%
30-70%
40-60%
95%
30%
100%
10%
10-100%

latency
type
III
III
III
II
I
II
I
II
I
II

20

Infectious mononucleosis
IM is a self-limiting lymphoproliferative disease that can be caused by primary EBV
infection in adolescents and adults. It is largely a disease of developed countries, where higher
standards of hygiene and sanitation result in delayed virus acquisition.
adolescents or adults who become infected with EBV will develop IM

104

Around 50% of

, which is characterized by

a massive expansion of latently infected B cells in lymphoid tissue and blood, lytic replication of
virus in the oropharynx, and virion shedding into the saliva. Up to 25% of peripheral blood B cells
can become infected with EBV during IM, and this stimulates a robust T cell response that can
78

comprise up to 50% of the total T cell pool at its peak . Symptoms of IM are caused by this
massive T cell response. Treatment is only supportive, and infection generally resolves on its
own.
Malignancies of B cell origin
Immunoblastic lymphomas are a heterogeneous group of latency III-expressing B cell
tumors that arise in immune compromised individuals who cannot mount an effective CTL
response. Immune suppression can be a result of genetic defects (X-linked lymphoproliferative
disease, XLPD), medical treatment (post transplant lymphoproliferative disease, PTLD), or
immune-targeting infections (Human Immunodeficiency Virus; HIV)

105, 106

. XLPD is caused by a

mutation in a gene involved in the regulation of T cell activation and homeostasis, which results in
an inability to control EBV-driven B cell proliferation

107

. PTLD is a heterogeneous group of

diseases associated with organ transplant; its development is largely dependent on the degree
and duration of immune suppression as well as the type of organ transplanted. Lesions that
occur within the first year after transplant are almost always EBV positive

108

.

HIV-infected individuals have a 60- to 200-fold increased risk of developing various
lymphomas

109

.

About 10% of all AIDS patients develop B cell malignancies, and EBV is

associated with about 60% of cases overall.

A small portion of these are considered

immunoblastic latency III-expressing tumors, which tend to accompany T cell impairment
observed during late stage AIDS.

Immunoblastic diffuse large B cell lymphomas (DLBCLs)

	
  

21

10

comprise 15% of all HIV lymphomas, and >90% are EBV positive . Other immunoblastic
lymphomas such as primary central nervous system (CNS) lymphomas also occur during the late
stages of AIDS and are usually EBV positive. EBV is also associated with cancers that express
type I or type II patterns of latency during co-infection with HIV. The most common are BL (35%),
10

HL (5%), and centroblastic DLBCL (25-30%) . EBV is present between 30 to 70% (BL), >95%
10

(HL), and in 30% (DLBCL) of cases . BL and HL arise early during the course of HIV infection,
when immune function is still relatively intact. HIV-infected individuals are also at increased risk
for developing Non-Hodgkin lymphomas (NHL) and a variety of lymphomas that involve tissues
within the gastrointestinal tract, lungs, liver, and bone marrow

109

. NHL during HIV is EBV positive

10

in 50% of cases .
The two most common B cell malignancies that occur among immune-competent
individuals are BL and HL. BL cells express a type I latency program. Endemic BL is the most
common childhood tumor in equatorial Africa and New Guinea, and occurs at an astounding 5 to
20 cases per 100,000 children anually
equatorial Africa

111

110

. This accounts for 74% of all childhood malignancies in

. Non-endemic (sporadic) BL occurs equally across all age groups at a much

lower incidence of 0.2 to 3 cases per 100,000 annually throughout the United States and
Europe

112

10

. While between 20 to 85% of sporadic BL tumors are EBV positive , endemic BL is

nearly universally positive for EBV

112

. It is probably not a coincidence that endemic BL is highly

prevalent in areas where malaria infection is common, as malaria induces B cell proliferation and
may impair EBV-specific CTL activity

113

. One indication of a causative role for EBV in BL is that

children in endemic regions with the highest antibody titers against VCA are the most at risk for
subsequent BL tumor development

114

. A defining feature of BL is dysregulation of the c-myc

oncogene caused by a chromosomal translocation into an immunoglobulin locus

115

. Constitutive

expression of the c-MYC protein drives continuous proliferation and inhibits differentiation. EBV
may expand the population of B cells at risk for this translocation, or EBV infection may aid in the
survival of mutated cells that would have normally undergone apoptosis. Malaria-induced B cell
activation would further expand the population of B cells at risk for malignant transformation.
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HL is arguably the most common EBV-associated lymphoma worldwide, with about 40%
11

of EBV-positive cases in the western hemisphere and 80% of cases in the developing world .
One indication of EBV’s contribution to HL is the 2- to 5-fold increased risk of disease following
IM. Risk is highest within the first year after resolution of IM

116

, and increased antibody titers

against EBV antigens have been found prior to the development of HL

117

.

EBV genomes in HL

cells are monoclonal, which implies that infection may be a prerequisite for the development of
disease

118

. About 90% of EBV-positive HLs have mutated immunoglobulin genes that cause a
10

loss of function . Genes expressed during the type II pattern of EBV latency observed in HL
cells may provide the proliferative and anti-apoptotic signals needed for oncogenesis.
Malignancies of non-B cell/epithelial cell origin
NPC and GC are both malignancies of epithelial cell origin that occur in immune
competent individuals. NPC occurs worldwide, but it is 10 times more common in Southern
China, where it is the most common malignancy in men and the second most common among
women

119

; prevalence is also increased among the Inuit population in the Arctic

15, 120

. EBV-

associated GCs are most prevalent in Central and Eastern Europe as well as some countries in
North and South America

64, 121

. Such geographic variations of incidence imply that both genetic

and environmental cofactors have important roles in the etiology of these two diseases.

EBV-

infected NPC cells typically exhibit a latency II pattern of gene expression, and EBV is more
strongly associated with NPC than GC

122

. This is especially true among the undifferentiated

subtype that is highly prevalent in China (20-30 cases per 100,000), where nearly all cases are
EBV positive

120

. About 10% of all GC cases are associated with EBV

123

, which may be the most

common EBV-associated non-lymphoid malignancy on a global scale, diagnosed in over 90,000
new patients each year

124

.

GC tumors express a type I pattern of latency with variable

13

expression of LMP2A . NPC arises from the mucosal epithelium of the nasopharynx, while GC
arises from epithelial cells within the gastrointestinal tract.

In both malignancies, the

accumulation of genetic and epigenetic alterations results in the inactivation of tumor suppressor
genes and overexpression of oncogenes, which in the presence of proliferative and anti-apoptotic
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signals, leads to tumorigenesis

64, 125

. EBV also contributes to a variety of other tumors, including

carcinomas of the salivary glands, thymomas and thymic carcinomas derived from thymic
10

epithelia cells, laryngeal carcinomas, and lymphoepithelial tumors of the respiratory tract .
Atypical EBV infection of cells that are neither B lymphocytes nor epithelial cells is most
often observed during immunodeficiency. Individuals with congenital immunodeficiencies, AIDS,
or who have undergone transplant surgery occasionally develop leiomyosarcomas with EBVpositive smooth muscle cells expressing various iterations of latency I or II genes

15, 126

. EBV is

also present in virtually all T/NK cell lymphomas, which typically express a type II pattern of
latency

109

.

Additionally, T and NK cells are infected with EBV during chronic active EBV

(CAEBV), which is a rare lymphoproliferative disorder of childhood that usually presents after
10

primary EBV infection . The etiology of CAEBV is not known, but patients with various genetic
mutations have been described, and EBV latency II proteins can be detected in the peripheral
blood

10, 123

.

EBNA1 and EBV-associated disease
One common thread between all EBV-associated diseases is the expression of the EBV
latency protein EBNA1, which is the only protein expressed in all types of latency and in all EBVassociated malignancies. EBNA1 is important for initial B cell immortalization. It facilitates EBV
genome persistence in latently infected cells, and it initiates the expression of additional latency
genes such as the EBERs and small microRNAs, which are involved in cell transformation. The
inhibition of EBNA1’s DNA-binding ability results in decreased proliferation, loss of episomes, and
even apoptosis in certain cell lines

127, 128

. Conversely, the expression of EBNA1 in EBV-negative

cells has been linked to less differentiated, more rapidly growing tumors with increased
metastases

129, 130

. EBNA1 also has several potentially transformative cellular effects that are

independent of DNA binding and seem to be essential for EBV-associated carcinogenesis

11, 131

.

In support of the importance of EBNA1, immune responses directed against the protein
are decreased or absent in many EBV-associated malignancies. Furthermore, the loss of such T
cells has been linked to the progression of various diseases, including HL, BL, NPC, and NHL
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132-134

. This implies a loss of such responses could contribute to an inability to control infection.
+

HL patients with EBV-positive tumors have a selective loss of EBNA1-specific CD4 T cells
62

compared to patients with EBV-negative tumors and healthy seropositive donors . In one study,
0 of 10 EBV positive, but 9 of 11 EBV negative HL patients had detectable EBNA1-specific CD4

+

62

T cells by IFN-γ production or by proliferation asssays . Interestingly, the same patients all had
detectable EBNA1-specific antibodies. The presence of EBNA1 IgG in the absence of specific
+

CD4 T cell help suggests those T cells were not always absent, but were lost at some point prior
to or during tumorigenesis. Similar findings have been described in BL

134

. A selective loss of

EBV-specific T cells has also been detected in some HIV-positive individuals, including those
+

under antiretroviral therapy with recovered total CD4 T cell counts
+

133

. Additionally, the loss of

+

EBNA1-specific CD4 and CD8 T cells has been associated with the development of NHL

133

,

+

and a decrease in EBNA1-specific CD8 T cells has been described among patients with EBVpositive NPC

132

.

While it is unclear exactly what causes a loss of EBNA1-specific T cells,

vaccines that aim to enhance or restore such responses could be a valuable therapeutic
approach, as supported by the success of adoptive immune therapies discussed below.

1.4 TREATMENT OF EBV-ASSOCIATED DISEASES
Therapies for immunoblastic lymphomas have a range of effectiveness that is influenced
by the source, degree, and duration of immune suppression. Common therapies include those
that target viral replication (chemotherapy, radiation, antiviral agents), eliminate B cells
nonspecifically (anti-B cell antibodies), or reconstitute EBV-specific immune responses (adoptive
transfer).

Treatment for PTLD highlights the importance of EBV-specific CTL immunity and

function, as reconstitution of EBV-specific immune cells is often an effective therapeutic
approach. In fact, between 25 to 63% of adults with early lesions respond well to a reduction of
immunosuppression

109

. EBV-specific T cells can also be reconstituted through adoptive transfer,

where specific T cells are first expanded in vitro (using autologous LCLs) and then re-infused into
PTLD patients. Activated EBV CTLs are polyclonal, long-lived, have broad reactivity to a range of
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latency epitopes, and are able to eradicate tumors upon transfer in vivo

135

.

EBV-specific CTLs

can be expanded from either donor or recipient cells, depending on what cells the PTLD lesions
arise from. Both types have successfully been used as prophylaxis in patients with high viral
loads after transplant or as treatment for patients with established PTLD
HLA-matched donor T cells have demonstrated positive results

138

136, 137

. Even partially

. The best responses were

+

generated when individuals also received high numbers of CD4 T cells, which have been shown
to directly target and kill EBV-transformed B cells in addition to providing helper functions

109

.

The success of adoptive therapy for the treatment of PTLD has provoked interest in
adapting a similar approach to treat other EBV-related diseases including NPC and HL. This
approach has had more limited success due to the restricted expression of latent viral antigens
and the various immune suppression/evasion techniques elicited by tumor cells

109

. As a result,

current strategies aim to target antigen recognition and augment CTL function by altering
stimulation protocols, genetically modifying effector cells to render them resistant to certain types
+

of immune suppression, and generating EBV-specific CD4 T cell immunity in conjunction to
+

CD8 CTLs. Additional treatment options are generally the same for EBV positive and negative
cancers, and include various combinations of chemotherapy, antiviral drugs, and other
compounds that serve to activate viral gene expression in order to sensitize EBV-infected cells,
inhibit the growth of cancer cells, or induce apoptosis

139

.

Although adoptive transfer has resulted in sustained clinical responses in some patients,
CTL generation is costly, time consuming, and requires access to highly specialized health care
facilities. It is therefore an impractical solution for the thousands of patients diagnosed annually
with EBV-associated diseases. Further development of strategies that exploit various aspects of
EBV biology is warranted; vaccination would be the most cost-effective approach to reach the
largest number of people, but there is currently no licensed preventative or therapeutic EBV
vaccine.
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1.5 VACCINE STRATEGIES
Vaccines have had a substantial impact on disease prevention since Edward Jenner first
introduced the concept over 200 years ago. Vaccination has saved more than 700 million cases
of disease and more than 150 million deaths

140

. Vaccines are responsible for the eradication of

smallpox, and diseases that once plagued the world such as poliomyelitis, measles, mumps, and
rubella are now practically nonexistent.

Vaccines induce protection by stimulating adaptive

immune responses and generating functional memory cells that can be rapidly reactivated upon
encounter with cognate antigen. The major component of protection for most of these highly
successful vaccines is high affinity neutralizing antibodies, which can be generated by many
types of vaccines including live attenuated, inactivated, or subunit vaccines

141

. Most vaccines are

given prophylactically to prevent infection, but vaccines can also be used in a therapeutic context
after infection has already occurred. Vaccines can limit the spread of a pathogen within infected
cells, they can reduce transfer between individuals, and they have even been used to treat or
prevent certain cancers.
Conventional vaccines
There are over 70 licensed vaccines that utilize different strategies to induce an immune
response

142

. Conventional vaccines include live attenuated and inactivated vaccines, purified

protein vaccines, peptide/subunit vaccines, DNA vaccines, and recombinant-vectored vaccines.
Live attenuated vaccines are most commonly generated through prolonged passage of pathogen
in a non-human host so that it can no longer replicate in human cells. Because of their capacity
to infect host cells, live attenuated vaccines can induce B and T cell responses; however, the
possibility of reversion to virulence is cause for concern.

An alternative to live, attenuated

vaccines are inactivated (killed) vaccines, which are generated by exposing pathogen to heat,
chemicals, or irradiation. Inactivated vaccines do not pose the threat of reversion to virulence,
but in exchange they are not as immunogenic and may require multiple exposures to generate
long-term immunity. Despite their capacity to elicit broad-ranging potent responses, live
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attenuated or killed EBV vaccines are generally not considered a viable option due to the
carcinogenic potential of EBV and the capacity for a number of EBV genes to independently
transform cells

143

. Protein/subunit vaccines are generated against an immunogenic fragment of

the pathogen (typically a protein), either through isolation or using recombinant DNA technology.
Immune responses are typically weak, require multiple boosts, and are primarily humoral;
synthetic peptides can be used for vaccination in a similar manner. Alone, synthetic peptide
vaccines are even less immunogenic than protein/subunit vaccines; however, they can also be
incorporated into immune-stimulating complexes with both B and T cell epitopes that induce both
humoral and CMI responses. DNA vaccines carry the gene sequence of a specific antigen that is
produced inside host cells after vaccination.

As a result, DNA vaccines typically favor CMI.

Despite the low cost and relative safety of DNA vaccines, delivery and immunogenicity remain a
challenge. Recombinant DNA technology can also be used to generate recombinant-vectored
vaccines. In this approach, genetically modified viruses such as vaccinia virus and adenovirus
serve as vectors for delivering antigen, which is then produced at high levels within the
immunized host. Recombinant viral vector vaccines- especially those that infect APCs- have the
potential to elicit strong B and T cell responses, and the delivery system itself can even act as a
potential adjuvant.

Pre-existing immunity and additional safety concerns are challenges for

recombinant virus vaccines, but vector modifications, use of viruses that do not commonly infect
humans, and development of replication-defective vectors can overcome many of these
obstacles

144

.

Adenovirus as a vaccine carrier
There are over 50 known human Adenovirus (AdHu) serotypes, which commonly infect
humans at a young age.

Although relatively non-pathogenic, infection can cause acute

respiratory or gastrointestinal illness

145

. Adenoviruses (Ad) contain a linear, double stranded

DNA genome that is encapsidated in an icosahedral protein shell. The Ad genome can range
10

between 26 to 45 kb pairs long, and contains two inverted terminal repeats (ITRs) at either end .
10

Genes are grouped by early, intermediate, and late transcription units . The early E1A gene is
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expressed first and acts as a transactivator for expression of the remaining early genes. It is
therefore necessary for viral replication.
Recombinant Ad-based vectors are an ideal system to deliver antigen for many reasons.
First, Ad can be rendered replication-defective by deleting the essential early E1 gene (which is
provided in trans during production)

146

. Large amounts of foreign DNA can then be incorporated

into the deleted E1-domain and expressed off exogenous promoters to ensure high levels of
transgene expression

147

. Second, Ad vectors express high levels of transgene product in a wide

range of cell types, including DCs and macrophages

148

. As a result, vectors induce potent and

+

protective transgene product-specific CD8 T cell responses

149

. Finally, recombinant Ad vectors

are safe, easy to manipulate, and relatively inexpensive to manufacture.
Ad was initially studied as a delivery vehicle for gene transfer, but potent immune
responses to both the vector itself as well as the transgene product rapidly cleared Ad-transduced
cells and caused serious side effects in some individuals

150, 151

. The induction of robust T cell

responses raised concern for the use of Ad vectors in gene therapy, but was beneficial for the
use of Ad vectors as vaccine carriers. The inherent immunogenicity of Ad acts as an adjuvant for
stimulating cellular and humoral immune responses, and transgene product-specific responses
are sustained over time

152, 153

. While Ad-transduced cells at the site of vaccination are rapidly

cleared by the immune system, very low levels of transcriptionally active vector have been shown
to persist in activated T cells and may act as an internal ‘boost’ for the specific responses

153

.

Several Ad serotypes have been developed for use as vaccine vectors. Early studies
focused on AdHu5, which along with AdHu2, are the most prevalent serotypes that infect
humans. Mice vaccinated with AdHu5 vectors that expressed rabies glycoprotein (rab.gp) quickly
developed protective titers of rab.gp-specific neutralizing antibodies along with antigen-specific
+

+

CD8 and CD4 T cells

154

. Ad vaccine vectors have since been tested with a variety of viral

antigen-based transgenes, and they all elicited very high transgene product-specific B and T cell
responses

155

.

Furthermore, the magnitude of transgene-specific T cells is often higher in

comparison to responses elicited by other recombinant viral vectors and by DNA vaccines
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One potential problem for the use of AdHu5 vaccine vectors is pre-existing immunity.
Between 45 to 80% of adults have high titers of neutralizing antibodies specific to AdHu5, which
varies depending on geographic region

157

.

Pre-existing neutralizing antibodies and vector-

specific T cells can inhibit adaptive immune responses either by restricting the amount of viral
vector that can enter APCs and express transgene (antibodies) or by quickly eliminating vectortransduced cells (CMI)

158

. This has been demonstrated in animals that were pre-exposed to
+

AdHu5 prior to immunization with AdHu5 vectors. Transgene product-specific CD8 T cell and B
cell responses were reduced in comparison to responses of animals that were not first exposed to
AdHu5

158

.

Numerous approaches can be used to circumvent the issue of pre-existing immunity.
One approach is to increase the vector dosage; however, extremely high doses of Ad vector can
induce serious side effects. Alternatively, transgene product-specific responses can be enhanced
through prime-boost vaccine strategies that utilize heterologous Ad vectors or additional delivery
vehicles

159

. Another approach that avoids pre-existing immunity is the use of serologically distinct

uncommon human Ads

160, 161

or Ads that naturally infect non-human species

157, 162

. Recombinant

vectors derived from simian Ad (SAdV, hereon referred to as AdC) are similar to human Ad in
terms of genetic organization, structure and cell tropism

162

. AdCs have been found to induce

strong transgene product-specific T and B cell responses in a similar magnitude as human Ads
following systemic vaccination

163

. This has been shown repeatedly in both mice and non-human

primates (NHPs) using a variety of transgene products

159, 164-166

. As a result, several recombinant

AdC vectors have been developed as vaccine carriers, including serotypes C68 (AdC68), C6
(AdC6), and C7 (AdC7)

167

.

Needs and challenges of an EBV vaccine
Despite their vast impact on public health, current vaccines have their limitations.
Vaccines are not yet protective against pathogens with antigenic hypervariation or intracellular
pathogens that require T cells for control. Persistent infections with long periods of latency face a
unique set of challenges, as the development of -or protection against- clinical disease may not

	
  

30

be feasible endpoints for measuring vaccine efficacy, and traditional correlates of protection may
not be sufficient or even desirable outcomes. Neutralizing antibodies are not suited to clear cells
that harbor virus. Instead, potent, CTLs are typically responsible for clearing latently infected
cells. A thorough understanding of the nature of such antigen-specific T cell responses and
appropriate methods of quantification is therefore important for vaccine development. Additional
surrogates of protection and biomarkers of disease are also needed, but this information is
typically not known until efficacy has been demonstrated in large-scale clinical trials.
A successful EBV vaccine could have numerous applications. The first, and perhaps
most obvious use would be to prevent primary EBV infection.

However, designing an EBV

vaccine that provides sterilizing immunity has been quite challenging—mostly because it is
unclear what type of immunity would provide protection from repeated mucosal infections.
Furthermore, the natural immune response to EBV may not be sufficient in protecting healthy
seropositive individuals from recurrent infections, as repeated infections with different strains of
EBV have been described in otherwise healthy individuals

10, 168

.

A second application for a

preventative EBV vaccine would be to reduce the incidence of IM, even if the rate of acquisition
does not change. The massive expansion of EBV-specific T cells during IM has been described
as an “abnormal” immune response that subsequently impairs the immune system
increases the risk of acquiring certain EBV-associated diseases such as HL

170

serum EBV DNA levels are elevated before the onset of PTLD as well as NPC

169

and

. Furthermore,

104

. Therefore, a

vaccine that prevents IM or facilitates better control of viral DNA in the blood may ultimately
decrease the incidence of EBV-associated malignancies. Vaccination to prevent EBV infection or
disease would benefit a variety of populations including transplant recipients, individuals in areas
with high incidences of NPC and BL, and western societies where there is a high incidence of IM.
EBV vaccines can also be administered to EBV seropositive individuals in the context of
therapeutic vaccination to treat or prevent certain malignancies.

Currently, the majority of

therapies to treat EBV-associated diseases involve an ex vivo component, where T cells are
stimulated, expanded, and then re-infused. A therapeutic vaccine that is capable of expanding
specific immune responses in vivo could reach far more individuals than the current adaptive
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immune strategies, although adaptive techniques would still be important for individuals where
vaccination is not an option. The goal of a therapeutic EBV vaccine would be to restore cellular
immunity in diseases where important responses are lacking, such as NPC, HL, and BL. In the
presence of disease, vaccination could be administered to elicit or boost T cell responses that
limit progression or cause remission.

Vaccination could also be used to prevent disease

occurrence among high-risk seropositive individuals. Additional groups that would potentially
benefit from such a vaccine include those at high risk of acquiring HIV infection as well as HIV+

positive individuals with relatively stable CD4 T cells and low HIV loads.
An important factor to consider when designing an EBV vaccine is that of target antigens;
but because the immune correlates of protection against EBV infection, IM, and EBV-associated
malignancies are not well understood, optimal target antigens are still unclear. The decision of
which viral antigens to target through vaccination largely depends on the desired
outcome/vaccine application.

A preventative EBV vaccine would probably need to elicit

neutralizing antibodies; most antigens that elicit neutralizing antibodies are expressed during lytic
replication. An effective therapeutic vaccine would need to target the smaller range of proteins
expressed during latency, when virus is not replicating. Furthermore, therapeutic EBV vaccine
strategies should aim to elicit or boost cellular immune responses against specific EBV antigens
that are expressed in the various malignancies. Since different malignancies express different
EBV antigens, this is another factor that must be appropriately considered. The work described
here focuses on EBNA1 because it is the only latent antigen that is expressed in all EBVassociated malignancies. It is therefore a very promising target for a therapeutic vaccine.
EBV vaccine studies
Most vaccine efforts to date have focused on EBV’s gp350, which is the most abundant
of the surface antigens, is the main target of virus-neutralizing antibodies, and is also a target for
CTLs

104

. The potency of gp350 antibodies was demonstrated in immunodeficient mice

reconstituted with PBMCs from EBV seronegative individuals

171

prevented the development of lymphoma after EBV challenge

	
  

. Monoclonal antibodies to gp350

172

. Recently, two tetrameric gp350
32

vaccines (a subunit vaccine and a DNA vaccine) were found to be more immunogenic than their
monomeric equivalents

173

, however the significance of these results is unknown, as mice were

not challenged with tumor after vaccination. Recombinant gp350 in combination with adjuvants
or expressed by adenoviral or vaccinia viral vectors also protected cotton-top tamarins and
common marmosets from developing EBV-induced lymphomas

174-176

. Interestingly, vaccination

with the gp350-expressing viral vectors as well as with certain preparations of soluble gp350 did
not induce neutralizing antibodies, which suggests a role for CMI

174, 175, 177

. EBV acquisition in the

absence of lymphoma was not a quantified endpoint because these animals do not develop
persistent EBV infection.
Vaccines designed to elicit neutralizing antibodies have also been tested in humans, with
variable results. A gp350-expressing vaccinia virus induced neutralizing antibodies to EBV when
tested in seronegative children in China

178

. All 10 children that received the placebo vaccine

seroconverted 1.25 years after immunization, while only 3 of 9 vaccinated children became
infected in the same time span. In a phase I trial of children with chronic kidney disease, only
33% developed neutralizing antibodies after receiving three doses of soluble gp350, and immune
responses declined rapidly

179

. Authors concluded that the dosage and adjuvant were likely not

optimal. In the only phase II trial of a prophylactic EBV vaccine, vaccination of EBV seronegative
adults with three doses of soluble gp350 reduced the rate of EBV IM by 78%, but it did not reduce
the rate of EBV acquisition

180

. Despite promising results, it is still not clear if a reduction in the

rate of IM will reduce the risk of certain malignancies.
Vaccines designed to elicit cellular-based responses have also been studied.

The

majority of these cell-based therapies have required some sort of ex vivo expansion or stimulation
phase, but more traditional vaccine designs are under development. In a phase I clinical trial of
HLA-matched, EBV seronegative adults, vaccination with an epitope-specific EBNA3A peptide
vaccine induced epitope-specific T cells in eight of nine recipients

181

. Four of those vaccine

recipients later became infected with EBV, but none developed IM. In comparison, one of the two
placebo recipients who acquired EBV developed IM. Importantly, this study demonstrated that
vaccine-driven induction of EBNA3-specific cellular immune responses did not significantly
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influence the development of a normal repertoire of EBV-specific T cell responses following
seroconversion.

This indicates that vaccination will likely not introduce additional risks upon

primary exposure to EBV. It also demonstrates the capacity of cell-mediated immunity to protect
against IM. Although EBNA3 is highly immunogenic, its expression is limited to lymphoblastic
diseases. The challenge now is to devise novel strategies that target other EBV latent antigens
expressed during the more restricted phases of latency that are associated with cancers such as
NPC, BL, and HL.
Additional vaccine candidates that have induced antibody and/or T cell responses in mice
or in human cell lines include an LMP2A-derived peptide-based vaccine, which prolonged survival
after tumor challenge and inhibited tumor growth therapeutically

182

; a virus-like particle vaccine

expressing EBNA1, LMP2, and nearly all of the EBV lytic genes except BZLF1, which induced
neutralizing antibodies and T cell responses in mice and reactivated human T cells lines

183

; and

Ad-based vaccines expressing various combinations of EBNA1, LMP1, and LMP2 epitopes,
which in one study stimulated T cell responses in healthy EBV seropositive and NPC patient cell
lines that inhibited LCL outgrowth

184

. This wide array of vaccine candidates serves to explore a

variety of options in order to determine the most effective methods for eliciting the most
successful responses in the absence of known correlates of protection.

1.6 AN ANIMAL MODEL FOR EBV: RHESUS LYMPHOCRYPTOVIRUS
Because EBV only infects humans, vaccine development has been largely impeded by
the lack of an appropriate animal model for EBV research. Humanized mouse models are an
alternative system, but the reconstituted immune systems in mice are not identical to those of
healthy humans.

Despite recent improvements, it is likely that some features of the human

immune response will not be accounted for

185

. Cotton-top tamarin monkeys can become infected

with very high titers of EBV and subsequently develop EBV-induced B cell lymphomas, but the
high doses and non-physiologic route of infection (intraperitoneal injection) make it challenging to
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translate results to humans. More importantly, these animals are now an endangered species
and are therefore not practical as pre-clinical models for vaccine development.
An alternative approach for studying EBV is to use a related virus, rhesus
lymphocryptovirus (rhLCV), which naturally infects rhesus macaques (Macaca mulatta).

The

animal model based on rhLCV is a particularly powerful tool for studying various aspects of EBV
due to its unusually high degree of biologic, genetic, and pathogenic similarity to EBV and the
similarity of the immune responses between humans and non-human primates
non-human primates strongly resembles EBV infection of humans

187

186-189

. Infection of

. Most animals are infected

during infancy through the oral route, and a majority of the target population is naturally infected
by adulthood

187, 190

. The virus, which can be detected in blood or upon activation in saliva,

persists for life as a latent infection in B cells. As seen with humans, rhLCV infection induces
transient lymphoproliferation in vivo and immortalizes B cells in tissue culture

187

. Animals can

develop virus-associated malignancies, and the incidence of these malignancies is increased
during immunosuppression

190, 191

. Furthermore, rhLCV has a high degree of sequence homology

to EBV, molecular organization is well conserved between the two viruses, and they have an
identical repertoire of latent and lytic genes (Figure 1-3)

190, 192, 193

. In fact, rhLCV is the only fully

sequenced gamma-1 herpesvirus with a homolog for every EBV gene, and the functions of the
genes are complementary. Thus, the biology, molecular virology, and immunology of rhLCV
infection in rhesus macaques are very similar to EBV infection in humans, making this model
appropriate for studying EBV immunology as well as for pre-clinical testing of EBV therapeutics.

	
  

35

Figure 1-3: EBV and rhLCV ORF homology

Figure 1-3: Small boxes representing the open reading frames (ORFs) of EBV and rhLCV
are aligned in positional order within each genome. EBV and rhLCV share an identical
repertoire of ORFs, and genomic arrangements are the same. The degree of amino acid
similarity between homologous EBV and rhLCV ORFs ranges between 28% to 98% and is
represented by the various shading and patterns within each box. Average homology
between all EBV and LCV ORFs is 75.6%. EBNA1 sequence homology falls within the
light grey box, at about 46%. BZLF1 sequence homology falls within the medium grey box,
186
at about 71%. Figure was adapted from Wang F., 2013 .
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1.7 OBJECTIVES AND SIGNIFICANCE
Since its discovery over 60 years ago, great strides have been made towards
understanding the virology and pathogenesis of EBV. However, translating this information into
an effective prophylactic or therapeutic EBV vaccine has proven challenging, and progress
towards an EBV vaccine has been slow. Most EBV vaccine efforts to date have focused on
decreasing acquisition or reducing the burden of IM.

A therapeutic EBV vaccine could also

significantly improve public health, but there are still many questions that need to be answered
before such a vaccine can reach fruition.
Work described here focuses on EBNA1 as a potential target for a therapeutic EBV
vaccine.

EBNA1 is an attractive target for vaccination because it is the only EBV protein

consistently expressed in all forms of latency and in all EBV associated malignancies. Despite
this, EBNA1 has only recently begun to be viewed as an appropriate vaccine antigen. It was
originally believed that EBNA1-specific CTL responses were either non-existent or non-functional
due to an internal glycine-alanine rich repeat domain (GAr) that had been shown to interfere with
antigen presentation by MHC class I molecules

194-196

. However, it has since been demonstrated

that functional EBNA1-specific T cells are frequently detected in EBV-infected humans
+

197-199

, and

+

a loss of EBNA1-specific CD4 and/or CD8 T cells has been correlated with numerous EBVassociated diseases, including HL, NPC, and BL

62, 132-134

. These findings suggest that EBNA1

plays an important role in controlling EBV infection.
The overarching goal throughout this dissertation was to determine if EBNA1 is a suitable
target for vaccine development. This was addressed with the following aims:
I. Characterize the T cell response to the latent antigen rhEBNA1.
An improved understanding of important immune responses benefits the preclinical
development of potential EBV vaccines. Therefore, using the EBV homolog rhLCV as an animal
model for EBV, we aimed to characterize the magnitude, phenotype, and functionality of rhesus
EBNA1 (rhEBNA1)-specific T cell responses in naturally infected animals. This was done using
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some of the most advanced flow cytometry techniques that allow us to precisely characterize
responses using a multitude of biological and immunological markers. We hypothesized that
most animals would have detectable responses that exhibited a variety of functions.

By

comparing our findings to the human EBNA1 response, these studies also serve to validate the
rhLCV animal model and to establish baseline responses so that we can use this model to
develop and test potential vaccines.
II. Develop novel recombinant adenoviral-based vaccine vectors that express rhEBNA1.
EBNA1-specific T cell responses are reduced in a variety of EBV-positive cancers, and a
loss of these responses is associated with disease progression. Thus, the primary goal of a
therapeutic EBV vaccine would be to restore or enhance EBNA1-specific T cell-mediated
immunity directly in vivo. Such a vaccine would need to elicit both protective CTL responses as
well as a strong central memory component. With that in mind, we developed recombinant Adbased vaccine vectors that express rhEBNA1 as potential therapeutic prototype vaccines. Ad
vectors have been shown to induce potent, multi-specific, and sustained transgene productspecific T cell responses, which is important for targeting cells that are already infected with virus.
To further enhance transgene-specific responses, we also included herpes simplex virus
glycoprotein D (HSV-gD), which is a known inhibitor of the herpes virus entry mediator - B and T
lymphocyte attenuator (HVEM-BTLA) immune inhibitory signaling pathway.

Our lab has

consistently shown that vaccines that express antigen as fusion protein with HSV-gD elicit more
potent T cell responses compared to vaccines that express the antigen alone. These results are
independent of antigen or of vaccine carrier. We therefore expected vaccines containing HSV-gD
to induce larger transgene-specific responses compared to appropriate controls. Replicationdefective Ad vector vaccines expressing rhEBNA1 within functional or non-functional versions of
HSV-gD were generated and subsequently tested in a series of in vitro and small animal studies
for quality control purposes.

The main goals of these studies were to demonstrate that all

vaccines expressed equal levels of transgene and were capable of inducing EBNA1-specific T
cell responses.
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III.

Vaccinate naturally rhLCV-infected rhesus macaques and evaluate the effect of

vaccination on rhEBNA1-specific cellular immunity.
The rhLCV animal model is an excellent tool for the preclinical development of EBV
vaccines. Using this system, we sought to evaluate whether vaccination could expand functional
rhEBNA1-specific T cells in rhesus macaques with persistent rhLCV infection. Fifteen healthy
rhLCV seropositive rhesus macaques were enrolled in the study, and animals were vaccinated in
a prime-boost regimen with two serologically distinct replication-defective adenoviral vectors that
expressed our chimeric rhEBNA1 constructs. To better understand the effect of vaccination on T
cell phenotype and function, we once again conducted in-depth analyses of rhEBNA1-specific T
cells using flow cytometry. It has been shown that suboptimal latent EBV T cell responses from
both healthy and EBV-positive tumor bearing individuals can be recovered ex vivo

200, 201

.

Therefore, our goal was to determine if the induction or expansion of rhEBNA1-specific
responses is possible in vivo through vaccination. We hypothesized that vaccination with Adbased rhEBNA1 vectors would lead to the expansion of functional rhEBNA1-specific T cells in the
majority of vaccinated animals. This study serves as an important proof-of-principle analysis of a
therapeutic rhEBNA1-based vaccine regimen and provides insight into appropriate strategies for
therapeutic EBV vaccination.

Most importantly, our findings address the critical question of

whether EBNA1 is a viable target for vaccination.
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CHAPTER 2:

T CELL RESPONSES TO LATENT ANTIGEN EBNA1 AND
LYTIC ANTIGEN BZLF1 DURING PERSISTENT RHLCV
INFECTION OF RHESUS MACAQUES

ABSTRACT
Epstein Barr virus (EBV) infection leads to life-long viral persistence through its latency in
B cells. EBV-specific T cells control reactivations and prevent the development of EBVassociated malignancies in most healthy carriers, but infection can sometimes cause chronic
disease and malignant transformation. Epstein-Barr Nuclear Antigen 1 (EBNA1) is the only viral
protein consistently expressed during all forms of latency and in all EBV-associated malignancies,
and is a promising target for a therapeutic vaccine. Here we studied the EBNA1-specific immune
response using the EBV-homologous rhesus lymphocryptovirus (rhLCV) infection in rhesus
macaques. We screened 40 animals for rhLCV EBNA1 (rhEBNA1)-specific T cell responses by
intracellular cytokine staining (ICS) and flow cytometry.

We then assessed the frequency,

phenotype, and cytokine production profiles of rhEBNA1-specific T cells in 15 rhesus macaques
and compared to the lytic antigen of rhLCV, BZLF1 (rhBZLF1). We were able to detect rhEBNA1+

+

specific CD8 and/or CD4 T cells in 14 of the 15 animals screened. In comparison, all 15
+

animals had detectable rhBZLF1 responses.

Peptide-specific CD8 T cells showed a more
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activated phenotype, belonging mainly to the effector cell subset, while most peptide-specific
+

CD4 T cells exhibited a resting phenotype of central memory (TCM). By comparing our results to
the human EBV immune response, we demonstrate that the rhLCV model is a valid system for
studying chronic EBV infection and for the pre-clinical development of therapeutic vaccines.

Portions of this chapter were adapted from:
Leskowitz RM, Zhou XY, Villinger F, Fogg MH, Kaur A, Lieberman PM, Wang F, and Ertl HC.
+
+
CD4 and CD8 T cell responses to latent antigen EBNA1 and lytic antigen BZLF1 during persistent
lymphocryptovirus infection of rhesus macaques. Journal of Virology 2013; 87(15):8351-8362.
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INTRODUCTION
The Epstein-Barr Nuclear Antigen 1 is a particularly important target for vaccination, as it
is the only protein present during all stages of viral infection including every form of latency, lytic
infection, and all EBV-associated cancers

202

. EBNA1 is a 76 kilo Dalton (kDA) viral-encoded

DNA binding phosphoprotein that is essential for the maintenance and replication of viral DNA
during latency

203

33

. EBNA1 is therefore tightly linked to EBV persistence , and the elimination of

EBNA1 from the EBV genome results in a rapid loss of stability

33, 204

. Furthermore, dominant

negative forms of EBNA1 or siRNA depletion of EBNA1 inhibits EBV-dependent B cell
proliferation, thus indicating that EBNA1 is also important for B cell transformation during
latency

205, 206

.

EBNA1 is separated into C and N terminal domains, which are linked by an

internal glycine-alanine rich repeat domain (GAr). The repeat domain stabilizes the protein and
inhibits EBNA1’s degradation by cellular proteasomes

194, 195

. As a result, both the generation of

peptide sequences for association with MHC class I molecules and the induction of EBNA1+

specific CD8 T cells are impaired

195

. Furthermore, the mRNA that encodes the GAr is enriched

for purines, which causes a lack of secondary structure and reduces the translation efficiency and
antigen presentation of EBNA1

196, 207

. Consequently, despite its obvious importance, EBNA1 was

not originally considered a viable target for vaccination, as it was believed to escape immune
detection by CTLs.
Nevertheless, recent studies have demonstrated that most EBV-infected humans develop
+

CD8 T cells in response to EBNA1

197, 198

. The primary source of epitopes is most likely newly

synthesized EBNA1 as a result of proteasome-dependent degradation of defective ribosomal
products (DRiPs) during translation

197, 198, 208

. Long-lived, stable EBNA1 has a half life greater

than 20 hours in B cells and is therefore not a likely source of epitopes

195

. Upon expansion,

EBNA1-specific CTLs have been shown to prevent the outgrowth of infected B cells in vitro and to
secrete IFN-γ in response to stimulation, thus suggesting they play a role in controlling infections
in vivo

199

+

. Additionally, EBNA1 is an immunodominant target of EBV-specific CD4 T cells that

are capable of inhibiting virus-induced B cell proliferation in vitro

	
  

92, 209

.

In support of the
42

+

+

importance of EBNA1-specific T cell responses, loss of EBNA1-specific CD4 or CD8 T cells has
been correlated with numerous diseases, including non-Hodgkin’s lymphoma, nasopharyngeal
carcinoma, and Burkitt’s lymphoma

62, 132-134

.
+

+

While we know that EBNA1-specific CD4 and CD8 T cells develop in response to EBV
infection

203

, little is known on how persistent, low-level antigen exposure influences the

phenotype and functionality of this response in vivo. Generally, if antigen is not cleared following
primary infection, CD4
exhaustion

210

.

+

and CD8

+

T cells can develop various degrees of functional

Each pathogen and host establish their own unique relationship that varies

depending on the duration, magnitude, and location of antigen exposure

211

. Chronic viremia and

continuous high antigen exposure leads to constant T cell receptor triggering that causes
progressive T cell dysfunction and interferes with differentiation into the TCM cell pool

212

. In the

most severe situations, this may ultimately result in physical deletion of the responding cells;
however, a hierarchical loss of effector functions is more frequently observed

212

. The ability of

cytolysis, robust proliferation, and IL-2 production are lost at early stages of exhaustion. This is
followed by the loss of TNF-α and then IFN-γ production

212

. In contrast, T cells responding to

persistent infection with low antigen exposure are not as severely impaired

212

. Studies examining

the effect of gammaherpesvirus persistence on the T cell response in mice demonstrate more
limited proliferative potential in response to antigen, but the antiviral T cell response is vigorous
and exhibits immediate cytotoxic function

213

.

Exhausted T cells also upregulate various cell

surface markers, and the number and level of expression appears to be associated with the
severity of infection and degree of exhaustion

214

.

A detailed understanding of the immune response to EBNA1 benefits the preclinical
development of EBV vaccines. The most common methods for studying EBV-specific T cell
responses utilize EBV-specific T cell lines expanded in vitro after repetitive antigenic stimulation,
which can change T cell function and lead to selective proliferation of specific clones. Instead, we
aim to characterize EBNA1-specific T cell responses directly ex vivo using intracellular cytokine
staining, which offers the ability to both quantitate these responses and to analyze their functional
nature directly without expansion.
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Using the rhLCV model, we have characterized the magnitude, phenotype, and function
of latent rhEBNA1-specific immune responses in healthy rhLCV-infected rhesus macaques.
Although some studies have been conducted to assess immune responses to rhLCV

188, 215

, the

scope of such studies has been more limited. Here we screened 40 captivity-kept rhesus
macaques for rhEBNA1-specific T cells using ICS followed by multicolor flow cytometry. We then
characterized peptide-specific T cell responses in blood from a cohort of 15 captivity-kept rhesus
+

+

macaques, which allowed us to define dominant CD4 and CD8 T cell subsets and cytokine
production profiles. We compared this to responses directed against the highly immunogenic,
immediate-early lytic rhBZLF1 protein, which has been studied extensively in humans and to
some degree in rhesus macaques. Our results show that most rhLCV seropositive animals carry
both rhEBNA1- and rhBZLF1-specific T cells.

+

RhEBNA1-specific CD4 T cells were highly

functional, with both TCM and TEM cell subsets and a wide range of cytokine responses, while
+

specific CD8 T cells were composed primarily of more activated IFN-γ-producing effector cells.
+

In contrast, rhBZLF1-specific CD4 T cells maintained a resting phenotype of TCM cells and
+

primarily produced single-cytokine responses.

As with rhEBNA1, the CD8 T cell response
+

against rhBZLF1 was more activated than the CD4 T cell response, but contained a large
proportion of memory cells as well. The similarities between our findings and the human immune
response against these two very important proteins serve to further validate the rhLCV model as
a useful and highly relevant animal model for studying various aspects of EBV. Our studies are
also fundamentally important for establishing baseline responses so that the rhesus macaque
model can be used for exploring potential EBV vaccines.
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RESULTS PART I
Characteristics of NHPs
Forty Indian-origin rhesus macaques were enrolled in this study at the Yerkes National
Primate Center (YNPC). All animals were female adults ranging from 5-19 years of age at the
start of the study. Animals were either housed at a field station or at the main station, and all
except ID# 442, PH1019, and PWW were born at YNPC. All animals were SIV negative and all
but two animals (RNg7, Rje8) had antibodies to rhLCV. Thus, 95% (38/40) of the rhesus
macaques enrolled in our study were rhLCV seropositive. Animals were tested for Mamu-A*01,
A*02, A*08, B*01, B*04, B*08, B*17 (YNPC). Table 2-1 shows housing arrangements, age,
rhLCV serology, genotype, and blood collection time points for each animal.
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Table 2-1: List of rhesus macaques used in this study
NHP ID # Housing Age at rhLCV
MHC Alleles
start of serology
study
RUu6
MS
10
Y
442
11
Y
B.01
RDn6
11
Y
RLz5
12
Y
RCv5
13
Y
RTn5
15
Y
A.01, A.08
RQm7
9
Y
RBm7
9
Y
A.01
RAt7
9
Y
A.01, A.02
RZl7
9
Y
A.01, B.17
RCj7
9
Y
RFu7
10
Y
A.01
RVw6
10
Y
A.01, A.08, B.01
RCa6
12
Y
B.17
RQf7
10
Y
A.01
PH1019
10
Y
A.08, B.17
RMr6
11
Y
A.01, B.01
RJy5
12
Y
B.17
RQf6
12
Y
A.02
RYa6
12
Y
B.01, B.17
PWw
13
Y
A.02, A.08
RKc5
14
Y
B.01
Rje8
8
N
A.01
RNg7
10
N
A.01, B.17(?)
RBo10
FS
5
Y
A.01, B.08
RLy9
6
Y
Ref8
8
Y
RDc8
8
Y
A.02
RYr9
6
Y
A.01
RRi9
7
Y
B.01
RQb8
8
Y
A.01
RNm8
8
Y
RBt7
9
Y
A.01, B.01
RQt5
13
Y
RTp4
15
Y
RJm10
5
Y
B.17
RNw9
6
Y
A.08
RTf9
7
Y
A.01, B.01
RCs7
9
Y
RYc3
19
Y
A.01

Blood collection
0, 2M
0
0
0, 4-6M, 11-13M
0, 4-6M, 11-13M
0, 2M, 4-6M, 11-13M
0
0
0
0, 4-6M, 11-13M
0, 4-6M, 11-13M
0
0, 2M, 4-6M, 11-13M
0, 2M
0
0, 2M, 4-6M, 11-13M
0
0
0	
  
0, 4-6M, 11-13M
0, 2M, 4-6M, 11-13M
0
0
0	
  
0
0, 4-6M, 11-13M
0
0
0	
  
0, 4-6M, 11-13M	
  
0
0
0
0, 4-6M, 11-13M
0, 4-6M, 11-13M	
  
0
0, 4-6M, 11-13M	
  
0	
  
0
0, 4-6M, 11-13M

rhEBNA1
+
+
CD4
CD8
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
N
N
N
N
N
N
N
N/A
N/A
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
N
N
N
N

Y
Y
Y
Y
Y
Y
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N/A
N/A
Y
Y
Y
Y
N
N
N
N
N
N
N
N
N
N
N
N

Abbreviations: NHP, non-human primate; DOB, date of birth; FS, field station; MS, main station.
Blood from all 40 animals was collected over a period of two months (time point 0). Additional
samples from smaller cohorts were collected at 2 months (6 animals), 4-6 months (15 animals), and
11-13 (15 animals) months after initial bleeds. The two most right-hand columns reflect presence or
+
+
absence of rhEBNA1-specific CD4 (left) or CD8 (right) T cells detected by ICS at time point 0.
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RhEBNA1 responses can be quantitated and characterized directly from the peripheral
blood of rhesus macaques
The ability to detect rhEBNA1-specific T cells directly ex vivo is important for analyzing
intricacies of the immune response and is critical for experiments such as vaccine testing, where
the direct effect of vaccination and potential correlates of protection can be assessed. Therefore,
our first goal was to determine if rhEBNA1-specfic T cells in the peripheral blood of naturally
rhLCV infected rhesus macaques can be detected directly ex vivo using ICS. To accomplish this,
we enrolled a large cohort of 40 animals for testing. The two animals with negative rhLCV
serology were excluded from these analyses. To measure rhEBNA1-specific T cell responses,
+

+

PBMCs were isolated and tested for CD4 and CD8 T cells producing IFN-γ, IL-2, and/or TNF-α
in response to a short in vitro stimulation with overlapping rhEBNA1 peptide pools. Background
activity was measured by culturing cells in medium containing DMSO for the same length of time.
6

+

Results are expressed as absolute number of cells per 10 live CD3 T cells. To calculate the
sum of the peptide-specific response, we subtracted normalized background activity and then
summed the seven possible different combinations of functions. We define a positive response as
+

6

+

anything greater than the mean plus two standard deviations of total CD4 (183 per 10 CD3 T
+

6

+

cells) or CD8 (216 per 10 CD3 T cells) cytokine responses from 5 seronegative animals from
the New England Primate Research Center (Figure 2-1A). To determine differentiation status,
+

+

samples were stained for CD95, CD28, and CCR7, where TCM cells are CD95 CD28 CCR7
+

+

lo

+

-

TEM cells are CD95 CD28 CCR7 , and TEFF cells are CD95 CD28 CCR7
+

lo

high

,

.

+

We were able to detect rhEBNA1-specific CD4 and/or CD8 T cells in 25 of the 38 (66%)
rhLCV-seropositive rhesus macaques (Table 2-1, right-hand columns).

All 25 of the animals

+

had rhEBNA1-specific CD4 T cell responses, while only 10 animals had rhEBNA1-specific CD8

+

+

T cell responses (26%). Interestingly, all of the animals with rhEBNA1-specific CD8 T cells also
+

+

had rhEBNA1-specific CD4 T cells. This could reflect a need for CD4 T helper cells or it could
simply be a result of the larger number of MHC class II epitopes within rhEBNA1.

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  

	
  Refer to page 141 for comment on staining panel.	
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+

+

The magnitude of rhEBNA1-specific CD4 and CD8 T cells was quite variable and
+

+

seemed to fall within three distinct groups based on the number of total CD4 or CD8 specific
6

+

cells per 10 CD3 T cells. Responses were either (1) less than 1,000, (2) between 1,000-10,000,
or (3) greater than 10,000, as seen in Figure 2-1B and corresponding shading in Table 2-2. The
+

6

+

magnitude of CD4 T cell responses ranged between 186 and 42,830 cells per 10 CD3 T cells,
6

+

but the majority of those responses (19 of 25 animals) were less than 1,000 cells per 10 CD3 T
6

+

cells. Thus, the median response was 417 cells per 10 CD3 T cells. Subset analyses revealed
+

6

+

that rhEBNA1-specific CD4 T cell responses composed of fewer than 1,000 cells per 10 CD3 T
cells were evenly distributed between TEM and TCM cell phenotypes (TCM versus TEFF, P = 0.007;
TEM versus TEFF, P = 0.005 by Kruskal-Wallis test), while the majority of rhEBNA1-specific T cell
6

+

responses composed of greater than 1,000 cells per 10 CD3 T cells were primarily TEM cells
(TEM versus TEFF, P = 0.03; TEM versus TCM, P = 0.027 by Kruskal-Wallis test). Such a large
proportion of TEM cells could be reflective of ongoing or recent rhLCV reactivation, which would be
expected to increase the proportion of TEM and TEFF cells. This observation is further supported
+

by results for rhEBNA1-specific CD8 T cell responses, which were similarly large in magnitude
6

+

+

(258 to 25,264 cells per 10 CD3 T cells). However, in contrast to CD4 T cell responses, only
+

6

+

about half of rhEBNA1-specific CD8 T cell responses fell below 1,000 cells per 10 CD3 T cells.
+

The median rhEBNA1-specific CD8 T cell response was therefore significantly larger than the
+

6

+

rhEBNA1-specific CD4 T cell response, at 3,213 cells per 10 CD3 T cells (P = 0.023, two-sided
Mann-Whitney test).

+

This is again suggestive of recent reactivation, as CD8 CTLs rapidly
+

proliferate in order to clear infection, and the observed rhEBNA1-specfic CD8 T cells were
primarily of an effector phenotype for all animals (TEFF versus TCM, P = 0.021; TEFF versus TEM, P
= 0.035 by Kruskal-Wallis test).

Animals with the highest numbers of total rhEBNA1-specific

+

CD8 T cells had the largest proportion effector cells.
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+

+

Figure 2-1: Number of rhEBNA1-specific CD4 and CD8 T cell responses
A.

B.

CD4+ vs. CD8+

CD4+ vs. CD8+

seronegative

43000

# peptide-specific live CD3+/106

CD4

CD8

RDn6
RFu7
RTn5
RZi7
442
RLz5
RUu6
RYa6
RJy5
RCa6
PH1019
RMr6
RAt7
RQm7
RQf6
RKc5
RCv5
RQf7
PWw

13000
10000
7000
4000
1000
750
625
500
375
250
125

33000
23000

# peptide-specific live CD3+/106

84-05
93-04
172-97
218-05
336-03

23000

CD4
CD8

26%
(10/38)

43000

33000

0

66%
(25/38)

13000
10000
7000
4000
1000
750
625
500
375
250
125

CD4

Mean
61
82

0

CD8

Median SD
34
61
90
67

N
5
5

CD4
CD8

Mean
3026
6533

Median SD
417
8851
3213
8315

RCj7
RBm7
RVw6
RTf9
RRi9
RCs7
RQb8
RYr9
RNm8
RBt7
RLy9
RQt5
RTp4
RYc3
RDc8
RBo10
REf8
RJm10
RNw9

N
25
10

Figure 2-1: PBMCs from rhLCV seronegative (A) and rhLCV seropositive (B) animals were tested by ICS
+
+
for rhEBNA1-specific CD4 and CD8 T cells producing IFN-γ, IL-2, or TNF-α. Graphs display the total of all
6
+
cytokine-producing cells per 10 live CD3 T cells after subtraction of normalized background values. (A)
Horizontal bars reflect the median response for all rhLCV seronegative samples. The limit of detection is
+
6
+
+
defined as the mean + 2 standard deviations (SD) for total CD4 (183 cells/10 CD3 T cells) and total CD8
6
+
(216 cells/10 CD3 T cells) responses from rhLCV seronegative animals. (B) Detection limit cutoffs are
th
th
represented as shaded bars, and positive responses are displayed as floating bars (5 to 95 percentiles)
with lines at the median. The frequency of responding animals is presented above each bar.
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+

+

Table 2-2: Numbers of rhEBNA1-specific CD4 and CD8 T cells
CD4
TOTAL
42830
15353
308

TCM
89
70
208

TEM
32544
11984
101

EFF
2374
399
11

CD8
TOTAL
25264
9546
15488

TCM
0
17
1109

TEM
2245
901
104

EFF
22661
8198
13145

1,00010,000

RLz5
RTn5
RCj7
RFu7
RBo10

5074
2406
1865
1012
344

567
146
65
13
138

3464
1509
1130
792
84

574
0
26
0
84

6752
258
−
−
5721

404
46
−
−
458

414
13
−
−
147

5427
100
−
−
4456

RLy9
RUu6
RCv5
REf8
RZi7
RQt5
RYr9
RBt7
RCa6
RRi9
RNm8
RTp4
RVw6
RQb8
RQm7
RAt7
RBm7

675
657
514
281
654
490
425
417
358
341
316
272
234
225
214
206
186

266
96
355
201
0
358
238
272
30
104
234
114
85
68
11
56
136

138
458
359
81
459
95
224
43
340
28
65
38
131
30
228
159
57

208
50
0
40
42
3
86
75
19
37
0
96
38
44
4
24
35

567
598
430
704
−
−
−
−
−
−
−
−
−
−
−
−
−

21
32
239
182
−
−
−
−
−
−
−
−
−
−
−
−
−

118
53
215
61
−
−
−
−
−
−
−
−
−
−
−
−
−

431
441
120
280
−
−
−
−
−
−
−
−
−
−
−
−
−

> 10

4

Subject
RDn6
442
RDc8

<1,000

	
  

+

+

Table 2-2: RhEBNA1-specific CD4 (left) and CD8 (right) T cell responses are
6
+
displayed as counts per 10 live CD3 cells after subtraction of background values.
+
+
Responses are separated into three groups based on the number of total CD4 or CD8
T cells: light grey, less than 1000 cells; medium grey, between 1,000-10,000 cells; dark
grey, greater than 10,000 cells. The number of responses within central memory,
effector memory, and effector T cell subsets are listed to the left of the total responses for
each animal. Within subsets, all values greater than 100 are in bold, and the largest
subset response is highlighted in red; subset responses with 10 or fewer cells difference
between them were considered equal.
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RhEBNA1-specific T cells decreased and stabilized over time
An outbreak of Human Metapneumovirus at YNPC a few months prior to the onset of
these studies may have induced rhLCV reactivation and could therefore be responsible for the
large responses observed. Once reactivation was controlled, the magnitude of specific T cell
responses would be expected to decline and stabilize. To study this in the context of rhEBNA1,
we measured rhEBNA1-specific T cell responses over time in 17 of the 40 rhesus macaques and
determined the frequency, magnitude, and phenotype by ICS. Animals included in these studies
exhibited a wide range of magnitudes in order to determine if differences were somehow related
to response stability. Animals were bled an additional one to three times over a 13-month period
in intervals of 2, 4, and 7 months as listed in Table 2-1.
+

+

The number of animals with rhEBNA1-specific CD4 and/or CD8 T cell responses
+

+

declined with time. RhEBNA1-specific T cells were initially present in 12 (CD4 ) and 5 (CD8 ) of
+

+

17 animals at month 0, which decreased to 8 (CD4 ) and 4 (CD8 ) of 15 animals by the end of
the study (11 to 13 months later). This change could reflect the natural contraction of T cells
following re-activation and expansion, or it could simply be a reflection of the small number of
animals tested at each time point. Nevertheless, our sample size was too small to conduct
powerful statistical analyses, although some important changes did seem to occur. First, the
+

majority of responses tended to decline and stabilize with time, including all CD4 and CD8
6

+

responses that were initially greater than 1,000 cells per 10 CD3 T cells (Figure 2-2).

+

This

+

reached significance at the 4 to 6 month time point for rhEBNA1-specific total CD4 T cell
responses, where the distribution of responses was significantly smaller compared to month 0 (P
= 0.046, Kolmogorov-Smirnov test) (Figure 2-2A). Two animals with responses that did not
follow this trend were PH1019 and PWw. In these animals, responses were not detectable at
baseline, sharply increased at the second time point, and later decreased.

Additionally, the

+

rhEBNA1-specific CD4 T cell responses of RTp4 and RWv6 were relatively stable across all time
+

points, while corresponding CD8 T cell responses were virtually absent. In terms of subsets,
+

+

CD4 TCM cell responses remained relatively stable (Figure 2-2B), while the large CD4 TEM cell
responses decreased significantly by 4 to 6 months (P = 0.041) and remained stable through

	
  

51

months 11 to 13 (P = 0.031, two-sided Mann-Whitney test), as would be expected after resolution
+

or control of reactivation (Figure 2-2C). A similar trend was observed within the CD8 TEFF cell
responses, and this was most pronounced for animals with the largest magnitudes at the first time
point (Figure 2-2D).
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+

+

Figure 2-2: RhEBNA1-specific CD4 and CD8 T cells over time
n=

12
17
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15
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15
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Figure 2-2: RhEBNA1-specific CD4+ (left column) and CD8+ (right column) T cells detected by ICS at month
0 and then in 2-, 4-, and 7-month intervals are shown using a subcohort of animals from YNPC. Graphs
6
+
display the total of all cytokine-producing cells per 10 live CD3 T cells after subtraction of normalized
background values for (A) total, (B) central memory, (C) effector memory, and (D) effector T cell subsets.
Values below the limit of detection are graphed as 0. The number of subjects with positive responses / the
total number of subjects tested at each time point is displayed at the top of each column. Responses from
RTn5, PH1019, PWw, and RVw6 were measured all four times; RUu-6 and RCa-6 were measured at 0 and
+2 MOS; and all remaining animals were measured at 0, +4/6 MOS, and +11/13 MOS.
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DISCUSSION
In this study, we assessed the natural immune response to rhEBNA1, which is a highly
attractive target for vaccine development.

We screened 40 rhesus macaques for rhEBNA1-

specific T cells in peripheral blood, and we demonstrate that responses can be detected directly
ex vivo based on the production IFN-γ, IL-2, and TNF-α by ICS. The number of animals with
+

+

rhEBNA1-specific CD4 T cells was larger than CD8 T cells, and the range in magnitude for both
subsets was extremely variable.

We suspect the largest of those responses is indicative of

recent rhLCV reactivation. Animals with fewer than 1,000 rhEBNA1-specific T cells tended to
+

+

have equal proportions of specific CD4 TCM and CD4 TEM cell responses, with little to no
+

rhEBNA1-specific CD8 TEFF cells. In contrast, animals with more than 1,000 rhEBNA1-specific T
+

+

cells tended to have mostly rhEBNA1-specific CD4 TEM and CD8 TEFF cells. Chronic infection
promotes the differentiation of TEM and TEFF cells, and low-level expression of rhEBNA1 during
latent rhLCV infection could therefore be responsible for maintaining relatively equal proportions
+

of rhEBNA1-specific CD4 TCM and TEM cells rather than mostly TCM cells. However, it is also
possible that TEM responses in some of these are animals still contracting after recent lytic
+

+

reactivation. Similarly, the large CD4 TEM and CD8 TEFF cell populations could be indicative of
reactivation, or they could be a result of low-level antigen during latent infection.
To determine if rhEBNA1-specific T cells are maintained in this highly activated state, we
followed responses over time in a smaller cohort of animals to assess their stability. Our findings
provide further evidence of recent rhLCV reactivation, as rhEBNA1-specific T cells tended to
decrease and stabilize among those animals with initially high responses. This was especially
true within TEFF and TEM cell populations. The presence of rhEBNA1-specific TCM cells and the
capacity for expansion and contraction of more activated subsets indicate the potential to
successfully target and expand of rhEBNA1-specific T cells by vaccination. Our theory of rhLCV
reactivation is based on the magnitude and phenotype of rhEBNA1-specific T cell responses, but
unfortunately these studies are limited by our lack of data on viral loads. Therefore, we chose not
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to characterize the rhEBNA1-specific immune response using these data, as unconfirmed
reactivation introduces additional factors that make interpretation quite difficult.

RESULTS PART II
Frequency and magnitude of rhEBNA1- and rhBZLF1-specific T cell responses
The initial goal of these studies was to characterize the frequency, magnitude,
phenotype, and function of rhEBNA1-specific T cells in healthy, naturally infected rhesus
macaques. However, our original time points may have been influenced by viral infection and
possible rhLCV reactivation, as indicated by the magnitude and phenotype of rhEBNA1-specific T
cell responses at the first time point. Regardless of the cause of such large responses, our
follow-up studies demonstrated that results from month 0 seemed to be atypical, and responses
tended to decrease and stabilize with time. We therefore decided to characterize rhEBNA1specific responses from 15 animals using two additional time points that were collected after
responses had stabilized. Furthermore, because it is difficult to characterize immune responses
based on such a small sample size, we aimed to increase the number of subjects with detectable
rhEBNA1-specific T cells by increasing the degree of overlap within our rhEBNA1 peptide pool
from 5 to 10 amino acids.

This could potentially increase the number of epitopes that are

recognized by T cells. However, increasing the size of the peptide pool creates competition for
binding to MHC molecules and could therefore reduce the likelihood of binding a specific peptide
during stimulation. This could cause a reduction in T cell responses if there are very few T cell
epitopes within the pool. For this reason, PBMCs were stimulated with two different pools that
each contained half of the rhEBNA1 peptides from our new larger library, and responses were
measured by ICS.

For comparison, we also measured T cell responses to the highly

immunogenic immediate-early antigen rhBZLF1, which regulates the switch from latent infection
to lytic replication and is not expressed during latency

216, 217

. This also serves as an internal

control, as changes caused by reactivation would be detected among rhBZLF1-specific T cells as
well. Peptide-specific responses were measured at two time points spaced two months apart,
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and analyses were based on the average response of each subject. RhEBNA1- and rhBZLF1specific total cytokine responses for each time point can be seen in Tables 2-3A and 2-3B,
respectively.
The number of subjects with detectable rhEBNA1-specific T cells increased after
stimulation with the modified rhEBNA1 peptide pools. We were able to detect rhEBNA1-specific
+

+

CD4 and/or CD8 T cells in 14 of the 15 rhesus macaques (93%) from YNPC (Figure 2-3A).
+

Twelve of the 15 animals (80%) had rhEBNA1-specific CD4 T cell responses above the detection
6

+

limit, with a magnitude that ranged between 238 and 2,190 responding cells per 10 CD3 T cells.
+

Slightly fewer animals had detectable rhEBNA1-specific CD8 T cell responses (10 of the 15, or
6

+

67%) with a lower magnitude that ranged from 233 to 693 cells per 10 CD3 T cells. The mean
+

6

+

rhEBNA1-specific CD4 T cell response of 638 cells/10 CD3 T cells was significantly higher
+

6

+

than the mean CD8 T cell response of 387 cells/10 CD3 T cells (P = 0.0391). One subject,
+

+

RZi7, had neither CD4 nor CD8 rhEBNA1-specific T cells above the detection limit. Eight of the
+

+

remaining 14 animals had both CD4 and CD8 rhEBNA1-specific T cells; in seven of these
+

+

animals the CD4 response was higher. We were unable to detect a peptide-specific CD8 T cell
+

response in four animals, and two animals did not have detectable CD4 T cell responses.
+

+

In contrast to results for rhEBNA1, we detected rhBZLF1-specific CD4 and/or CD8 T
cells in all 15 of the screened animals (Figure 2-3B). Fourteen of these macaques (93%) had
+

rhBZLF1-specific CD4 T cell responses above the detection limit, and the magnitude ranged
6

+

from 226 to 1206 rhBZLF1-specific cells per 10 CD3 T cells. RZi7 was the only animal with no
+

+

detectable CD4 T cells to rhBZLF1. We were also able to detect rhBZLF1-specific CD8 T cell
responses in 14 animals (93%), and the magnitude of the response was larger than the rhBZLF1
+

+

6

+

CD4 T cell response, ranging from 285 to 2184 rhBZLF1-specific CD8 T cells per 10 CD3 T
cells.

+

The one subject with undetectable rhBZLF1 CD8 T cell responses had undetectable
+

+

6

rhEBNA1 CD8 T cells as well. While the difference between the mean CD4 (550 cells/10 CD3
+

6

+

+

T cells) and CD8 (687 cells/10 CD3 T cells) T cell responses was not significant, there seemed
+

+

to be a trend towards higher CD8 responses, as noted in 7 of the 13 animals with both CD4 and
+

+

+

CD8 peptide-specific T cells. Of the remaining six animals, four had larger CD4 than CD8 T
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+

+

cell responses, and two had similar levels of both CD4 and CD8 rhBZLF1-specific T cells (a
6

+

difference of fewer than 10 cells per 10 CD3 T cells).
+

+

Numbers of rhEBNA1- and rhBZLF1-specific CD4 and CD8 T cells varied between
individual animals; some rhesus macaques had over 500 rhEBNA1- or rhBZLF1-specific
+

+

6

+

circulating CD4 or CD8 T cells per 10 CD3 T cells, while the majority of animals had lower
numbers averaging 200 to 400 cells. Animals with high rhEBNA1 responses did not necessarily
have high rhBZLF1 responses and vice versa. In contrast, those with high responses against one
peptide pool tended to have lower responses against the other.
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+

Table 2-3: Total cytokine-secreting rhEBNA1- (A) and rhBZLF1- (B) specific CD4 and CD8
T cells for each animal at both collection points
A.

+

B.
Number of T cells by cell population
+
+
CD4
CD8
Subject
RNw9
RQt5
RYc3
RRi9
RLy9
RTp4
RCj7
RTn5
RZi7
RLz5
PH1019
PWw
RVw6
RCv5
RYa6

Bleed 1
461
562
63
146
103
739
351
268
67
1380
71
158
1666
469
378

Bleed 2
498
294
1334
538
394
159
744
208
91
760
122
150
2713
714
368

Bleed 1
284
393
238
342
44
725
764
0
89
450
451
545
267
130
457

Number of T cells by cell population
+
+
CD4
CD8

Bleed 2
235
74
410
21
62
34
623
60
14
465
458
149
603
200
111

Subject
RNw9
RQt5
RYc3
RRi9
RLy9
RTp4
RCj7
RTn5
RZi7
RLz5
PH1019
PWw
RVw6
RCv5
RYa6

Bleed 1
260
323
32
698
1566
152
342
255
137
438
144
211
133
1337
1007

Bleed 2
191
427
1893
579
845
255
254
327
40
178
405
730
605
957
851

Bleed 1
2395
324
434
1331
0
937
464
352
336
465
1756
498
411
190
583

Bleed 2
1973
246
556
614
364
610
361
779
294
163
1190
425
768
535
234
6

Peptide-specific responses at both collection points (bleed 1, bleed 2) are displayed as counts per 10
+
live CD3 cells after subtraction of background values.
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Figure 2-3: Numbers of rhEBNA1- and rhBZLF1-specific T cells in PBMCs
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Figure 2-3: We determined the frequency and magnitude of rhEBNA1- and rhBZLF1-specific T cell
responses in 15 rhesus macaques by ICS. All values are represented as peptide-specific T cell
6
+
counts per 10 live CD3 T cells. The average sum of total cytokine secreting rhEBNA1- (A) or
+
+
rhBZLF1- (B) specific CD4 and CD8 T cells after subtraction of background values is shown. Data
for each animal reflect the mean of two time points spaced two months apart; values for each time
point can be seen in table 2-3. Bars indicate the mean value of all positive animals within each
group. Standard deviations are as follows: rhEBNA1 CD4, 538; rhEBNA1 CD8 134; rhBZLF1 CD4,
+
+
358; rhBZLF1 CD8, 538. There was a significant difference between total rhEBNA1 CD4 and CD8 T
cell cytokine responses (P = 0.0391). P-values were calculated using a two-sided Wilcoxon’s
matched-pairs signed-rank test, with a P-value <0.05 considered significant. All multiple comparisons
were Bonferroni-adjusted to control for a type I error rate.
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+

+

Peptide-specific CD4 and CD8 T cell responses differ in phenotypes and types of
cytokine production
We next assessed rhEBNA1- and rhBZLF1-specific subset phenotypes (TEFF, TCM, and
TEM) and their corresponding functionalities based on the production of IFN-γ, IL-2, and/or TNF-α.
+

The average CD4 T cell response to rhEBNA1 was composed largely of TCM cells (mean, 426
6

+

cells per 10 CD3 T cells); TEM cells were detectable at about one-third lower frequency (mean,
6

+

+

138 cells per 10 CD3 T cells), and TEFF CD4 T cells were virtually absent (mean, 28 cells per
6

+

10 CD3 T cells) (Figure 2-4A). Differences between each subset were significant (TCM versus
TEFF cells, P = 0.0015; TCM versus TEM cells, P = 0.003; TEFF versus TEM cells, P = 0.0015).
+

Both CD4 TCM and TEM cell populations produced all three cytokines (Figure 2-4B).
There were subtle differences in the profiles of each. On average, TCM cells produced IL-2 with
the highest frequency (IL-2 versus TNF-α, P = 0.0102), followed by IFN-γ, and then TNF-α. In
contrast, TEM cells most often produced IFN-γ (46%; IFN-γ versus IL-2, P = 0.006; IFN-γ versus
TNF-α, P = 0.0117), followed by IL-2 and TNF-α, which were about the same.
+

+

The rhEBNA1 CD8 T cell response differed from the CD4 T cell response in terms of
+

both phenotype and function. In contrast to the large CD4 TCM response, 60% of rhEBNA1+

6

+

specific CD8 T cells had an effector phenotype with a mean of 237 cells per 10 CD3 T cells
(Figure 2-4C). T cells with a central memory phenotype were detected at about one-half the
6

+

frequency of the effector response, with a mean of 104 cells per 10 CD3 T cells. The TEM cell
+

response was significantly smaller, contributing only 12.5% to the total CD8 response with a
6

+

mean of 49 cells per 10 CD3 T cells (TEM versus TEFF cells, P = 0.0177; TEM versus TCM cells, P
+

= 0.0294). RhEBNA1-specific CD8 TEFF cells mainly produced IFN-γ (74%; IFN-γ versus TNF-α,
P = 0.006) (Figure 2-4D). Cytokine production within the TCM and TEM cell subsets was low, but
+

the profile of the average response was similar to the rhEBNA1 CD4 T cell response; TNF-α was
produced by the fewest TCM cells (TNF-α versus IFN-γ, P = 0.0411; TNF-α versus IL-2, P =
0.0117), and IFN-γ was produced by the most TEM cells (IFN-γ versus TNF-α, P = 0.0294).
+

The CD4 T cell response to rhBZLF1 was nearly exclusively composed of TCM cells
6

+

(mean, 467 cells per 10 CD3 T cells) (Figure 2-5A). The TCM cell response contributed to 88%
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+

of the total rhBZLF1 CD4 T cell response, while TEM and TEFF cell subsets represented only 9%
and 3% of the total response, respectively. Differences between each subset were significant
(TCM versus TEFF cells, P = 0.0003; TCM versus TEM cells, P = 0.0003; TEFF versus TEM cells, P =
0.0018).

+

The dominant functions of the rhBZLF1 CD4 TCM response differed from that of

rhEBNA1. While all three cytokines were still detected, IFN-γ production was significantly lower
than both IL-2 (51%) and TNF-α production (37%), comprising only 12% of the total response
(IFN-γ versus IL-2, P = 0.0018) (Figure 2-5B).
+

+

The rhBZLF1 CD8 T cell response was larger than the rhEBNA1 CD8 T cell response.
6

+

6

+

It was composed of more equal proportions of TEFF (mean, 226 cells per 10 CD3 T cells), TCM
6

+

(mean, 214 cells per 10 CD3 T cells), and TEM (mean, 147 cells per 10 CD3 T cells) cell
subsets (Figure 2-5C).

Although there were no significant differences between the average

magnitudes of each response, the TEM cell subset contributed only 25% of the total rhBZLF1
+

CD8 T cell response, while the TEFF and TCM cell subsets were each 38.5% and 36.5%
respectively. In terms of cytokine production, all three subsets produced IFN-γ most frequently
(in TEFF cells [84%], IFN-γ versus IL-2 and TNF-α, P = 0.0054 and 0.0036, respectively; in TCM
cells [58%], IFN-γ versus IL-2 and TNF-α, P = 0.0006 and 0.0018, respectively; in TEM cells
[59%], IFN-γ versus IL-2 and TNF-α, P = 0.003 and 0.0006, respectively) (Figure 2-5D). IL-2
was produced with a frequency of about 30% within each memory subset, while only 10% of
memory responses were positive for TNF-α.
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Figure 2-4: Subset analysis of rhEBNA1-specific T cell responses

rhEBNA1-specific CD4+ T cell
subset phenotype
2500

# peptide-specific CD3+/106

1750

***

***

B.

***

1000

# peptide-specific CD3+/106

A.

600
500
400
300
200
100
0

C.

**

**
RTn5
RLz5
RVw6
RCv5
RYa6

350

RCj7
RTp4
RLy9
RRi9
RYc3
RQt5
RNw9
mean

300
250
200
150
100

0

EFF

2500

TCM

**

1750

TEM

**

1000
600
500
400
300
200
100

IFNg IL2 TNFa

IFNg IL2 TNFa

IFNg IL2 TNFa

EFFECTOR

TCM

TEM

D.

# peptide-specific CD3+/106

# peptide-specific CD3+/106

**

1250
1050
850
650
450

50

rhEBNA1-specific CD8+ T cell
subset phenotype

0

rhEBNA1-specific CD4+ T cell
cytokine production

rhEBNA1-specific CD8+ T cell
cytokine production
1250
1050
850
650
450
350

**

*

**

**
RLz5
PH1019
PWw
RVw6
RYa6

300
250

RCj7
RTp4
RYc3
RQt5
RNw9
mean

200
150
100
50
0

EFF

TCM

TEM

IFNg IL2 TNFa

IFNg IL2 TNFa

IFNg IL2 TNFa

EFFECTOR

TCM

TEM

+

+

Figure 2-4: The average total counts of rhEBNA1-specific cytokine-producing CD4 (A) and CD8 (C) T
+
+
+
hi
cells within the effector (EFF; CD28 CD95 ), central memory (TCM; CD28 CD95 , CCR7 ), and effector
+
+
lo
memory (TEM; CD28 CD95 , CCR7 ) cell populations of all positive animals are shown. The numbers of
+
+
rhEBNA1-specific CD4 (B) and CD8 (D) effector, TCM, and TEM cells producing IFN-γ, IL-2, and TNF-α
were determined. Bars indicate the averages. Significant differences were calculated using a two-sided
Wilcoxon’s matched-pairs signed-rank test, with a P-value <0.05 considered significant (indicated by
asterisks). All multiple comparisons were Bonferroni-adjusted to control for type I error rate.
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Figure 2-5: Subset analysis of rhBZLF1-specific T cell responses
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Figure 2-5: The average total counts of rhBZLF1-specific cytokine-producing CD4 (A) and CD8 (C) T cells
lo
hi
hi
hi
hi
within the effector (EFF; CD28 CD95 ), central memory (TCM; CD28 CD95 , CCR7 ), and effector
hi
hi
lo
memory (TEM; CD28 CD95 , CCR7 ) cell populations of all positive animals are shown. The numbers of
+
+
rhBZLF1-specific CD4 (B) and CD8 (D) effector, TCM, and TEM cells producing IFN-γ, IL-2, and TNF-α
were determined. Bars indicate the averages. Significant differences were calculated using a two-sided
Wilcoxon’s matched-pairs signed-rank test, with a P-value <0.05 considered significant (indicated by
asterisks). All multiple comparisons were Bonferroni-adjusted to control for type I error rate.
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Polyfunctional analyses reveal distinct cytokine combinations within each subpopulation
Because increased polyfunctionality has been associated with increased protection and
therefore better control of viral replication in some chronic viral infections

218, 219

, we further

assessed peptide-specific T cell functionality using Boolean gating to analyze the seven possible
combinations of IFN-γ, IL-2, and TNF-α production. Comparing the cytokine profiles of the most
common rhLCV-specific T cell subsets, rhEBNA1-specific CD4

+

TCM cells were highly

polyfunctional and exhibited an array of different cytokine profiles. While we detected substantial
+

responses within every combination, CD4 TCM cells most often produced either all 3 cytokines or
+

IL-2 alone (Figure 2-6A). The rhEBNA1-specific CD4 TEM cell responses were quite similar,
producing either all 3 cytokines or IFN-γ alone most often, but the frequency of IL-2 and TNF-α
+

production (either alone or together) was substantially reduced in CD4 TEM cells. In contrast, the
+

majority of rhEBNA1-specific CD8 TEFF cells produced IFN-γ only (Figure 2-6B). There was also
a small population of IL-2 producing TEFF cells.

Based on the degree of double- and triple

cytokine-producing cells, the percentage of polyfunctional rhEBNA1-specific CD4

+

TCM cell

+

responses was significantly larger than the percentage of polyfunctional CD8 TCM cell responses
+

+

(P = 0.0021) (Figure 2-6C). A similar trend was observed between CD4 and CD8 TEM cell
+

responses (P = 0.0519). Furthermore, CD4 TCM and TEM cell responses were significantly more
+

polyfunctional than CD4 TEFF cell responses (TEFF versus TCM, P = 0.0366; TEFF versus TEM, P =
+

0.0279). We observed a similar trend within the rhEBNA1-specific CD8 T cell response as well
(TEFF versus TCM, P = 0.0177).
In contrast to the high degree of polyfunctionality within the rhEBNA1-specific CD4

+

+

memory T cell response, rhBZLF1-specific CD4 TCM cells were largely monofunctional, most
+

often producing only IL-2 or TNF-α (Figure 2-7A). RhBZLF1-specific CD8 TEFF cells were
+

strongly dominated by cells producing IFN-γ only (Figure 2-7B). While CD8 TEFF cell responses
to rhEBNA1 and rhBZLF1 exhibited similar functions, we also detected rhBZLF1-specific CD8

+

TCM and TEM cells that produced either IFN-γ only, IFN-γ in combination with IL-2, or IL-2 alone.
+

+

The rhBZLF1 CD8 TCM cell response was significantly more polyfunctional than the CD4 T cell
+

+

response (P = 0.0081), but the majority of both CD4 and CD8 T cell responses were composed
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of single-cytokine producing cells and therefore exhibited only a low degree of polyfunctionality
(Figure 2-7C).
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Figure 2-6: Multi-function analysis of rhEBNA1-specific T cell responses

Figure 2-6: Fifteen rhesus macaques were assessed for polyfunctional rhEBNA1-specific T cell responses.
6
+
Graphs show responses as counts per 10 live CD3 cells after subtraction of background values for all
positive animals. (A and B) All possible combinations of IFN-γ, IL-2, and TNF-α production by rhEBNA1+
+
specific CD4 and CD8 effector, TCM, and TEM cells. Black circles represent the average number of T cells
comprising each cytokine combination in a single animal. Bars represent the mean value +/- the standard
deviation of each group. Each combination of cytokine responses is represented by plus (+) and minus (-)
signs below the x-axis, which is also associated with a pie slice color. The same colors are reflected in the
pie charts, which display the average ratio of the various cytokine combinations within each subset. (C) Pie
+
charts display the proportion of triple (red), double (green), and single (blue) cytokine-producing CD4 (top)
+
and CD8 (bottom) peptide-specific responses based on average production of IFN-γ, IL-2, and/or TNF-α.
+
+
Percentages of polyfunctional CD4 TCM and TEM cells were significantly larger than CD4 effector
+
responses (TCM vs. EFF, P = 0.0366; TEM vs. EFF, P = 0.0279). The percentage of polyfunctional CD8
+
+
TCM cells was significantly larger than CD8 effector responses (P = 0.0177). CD4 TCM cells also
+
exhibited a larger degree of polyfunctionality than CD8 TCM cells (P = 0.0021). P-values within groups or
+
+
between CD4 and CD8 responses were calculated using a two-sided Wilcoxon’s matched-pairs signedrank test or two-sided Mann-Whitney test, respectively. A P-value <0.05 was considered significant. All
multiple comparisons were Bonferroni-adjusted to control for type I error rate. Graphs were generated using
SPICE software (exon.niaid.nih.gov/spice/).
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Figure 2-7: Multi-function analysis of rhBZLF1-specific T cell responses

Figure 2-7: Fifteen rhesus macaques were assessed for polyfunctional rhBZLF1-specific T cell responses.
6
+
Graphs show responses as counts per 10 live CD3 cells after subtraction of background values for all
positive animals. (A and B) All possible combinations of IFN-γ, IL-2, and TNF-α production by rhBZLF1+
+
specific CD4 and CD8 effector, TCM, and TEM cells. Black circles represent the average number of T cells
comprising each cytokine combination in a single animal. Bars represent the mean value +/- the standard
deviation of each group. Each combination of cytokine responses is represented by plus (+) and minus (-)
signs below the x-axis, which is also associated with a pie slice color. The same colors are reflected in the
pie charts, which display the average ratio of the various cytokine combinations within each subset. (C) Pie
+
charts display the proportion of triple (red), double (green), and single (blue) cytokine-producing CD4 (top)
+
and CD8 (bottom) peptide-specific responses based on average production of IFN-γ, IL-2, and/or TNF-α.
+
+
CD8 TCM cells exhibited a larger degree of polyfunctionality than CD4 TCM cells (P = 0.0081). P-values
were calculated using a two-sided Mann-Whitney test, with a P-value <0.05 was considered significant. All
multiple comparisons were Bonferroni-adjusted to control for type I error rate. Graphs were generated using
SPICE software (exon.niaid.nih.gov/spice/).
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Expression of programmed death receptor 1 (PD-1) does not indicate exhaustion
One of the hallmarks of chronic infection is the upregulation of various inhibitory
receptors on the cell surface, which can be used to gauge the degree of T cell exhaustion. While
the effector-like function and multi-cytokine production by rhEBNA1-specific T cells is not
+

consistent with an exhausted phenotype, the increased proportion of rhEBNA1-specific CD4 TEM
+

cells and IFN-γ production by CD8 TEFF cells could be caused by constant low-level antigen
stimulation. Therefore, to determine the activation status of rhEBNA1- and rhBZLF1-specific T
cells, we measured cell surface expression of the inhibitory receptor PD-1 by staining cells with a
PD-1 antibody prior to stimulation with overlapping peptide pools and ICS. PD-1 is an activation
+

+

marker of CD4 and CD8 T cells that is upregulated as a negative feedback mechanism to limit
immune pathology during infection

220

. Upon ligand binding, PD-1 delivers inhibitory signals that

downregulate T cell receptor signaling and suppress effector cell functions.

During chronic

infection, high levels of PD-1 expression have been associated with T cell dysfunction and failure
to control infection

221

. Thus, PD-1 is typically used as a marker of T cell exhaustion.

The percentage of rhEBNA1-specific memory CD4

+

T cells expressing PD-1 was
+

increased (mean: 55%; range: 23% to 90%) compared to rhBZLF1-specific memory CD4 T cells
+

(mean: 41%; range: 20% to 77%; P = 0.0186) and total CD4 memory cells (mean: 35%; range:
+

+

28% to 41%) (Figure 2-8A; P = 0.0068). While the percentage of PD-1 CD4 memory T cells
+

+

was lower than PD-1 CD8 memory T cells (mean: 54%; range: 41%-66%) (P = 0.0005),
rhEBNA1-specific T cells did not follow this trend, and there was no significant difference between
the two memory subsets. Peptide-specific memory responses were broad, which suggests a
range of activation that is highly variable between animals. In contrast, the percentages of both
rhEBNA1- (mean: 21%; range: 9% to 49%) and rhBZLF1- (mean: 33%; range: 7% to 68%)
+

+

+

specific PD-1 CD8 TEFF cells were significantly lower than total CD8 TEFF cells (mean: 62%;
range: 36% to 83%) (P = 0.0039, 0.0007, respectively), and the same was true for rhEBNA1+

+

specific PD-1 CD8 effector versus memory cells (P = 0.039) (Figure 2-8B).

There was no

correlation between the magnitude of rhEBNA1-specific responses and percentages of PD-1
+

+

expression. However, two animals with the highest frequencies of PD-1 CD4 memory cells
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+

+

(RVw-6) and PD-1 CD8 memory cells (RCj-7) also had some of the largest magnitudes of
matching responses. Interestingly, there was a negative correlation for rhBZLF1-specific memory
+

CD4 T cell responses (r = -0.6; P = 0.02) and a trend towards a positive correlation for rhBZLF1+

specific memory CD8 T cell responses (r = 0.5; P = 0.054), which may encounter antgen more
often. As expected, the percentage of PD-1-expressing naïve T cells was significantly lower than
all other populations, since PD-1 is expressed upon activation. Similar trends were also observed
for the intensity of PD-1 expression (data not shown because inter-experimental values cannot be
compared).
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Figure 2-8: PD-1 surface expression on rhEBNA1- and rhBZLF1-specific T cells
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Figure 2-8: The percentages of total, rhEBNA1-, and rhBZLF1-specific CD4 (A) and CD8 (B) T cells
expressing PD-1 are shown for memory and effector cell subsets from 14 rhLCV-seropositive rhesus
macaques. PBMCs were stained for PD-1 prior to stimulation with overlapping rhEBNA1 or rhBZLF1
peptide pools. The percent of peptide-specific PD-1+ T cells was obtained by creating a single Boolean
gate that included every combination of cytokines. Animals with peptide-specific responses below the limit
of detection were excluded from peptide-specific subsets. Floating bars reflect the interquartile range of
responses, with whiskers extending to the minimum and maximum values. Horizontal bars reflect the
median response, with a + symbol designating the mean. Significant differences (designated by *) are as
+
+
+
follows: total CD4 memory versus total CD8 memory, P = 0.0005 (designated by ^) ; rhEBNA1 CD4
+
+
+
memory versus rhBZLF1 CD4 memory, P = 0.0186, and total CD4 memory, P = 0.0068; rhEBNA1 CD8
+
+
memory versus rhEBNA1 CD8 effector, P = 0.0391 (designated by #); total CD8 effector versus rhEBNA1
+
+
CD8 effector, P = 0.0039, and rhBZLF1 CD8 effector, P = 0.0007. Additionally, all naïve responses were
significantly smaller than every other group. Significance was calculated using Wilcoxon matched-pairs
signed rank test, with a P-value <0.05 considered significant. All multiple comparisons were Bonferroniadjusted to control for type I error rate.

	
  

70

DISCUSSION
The striking similarities between EBV and rhLCV favor the use of rhLCV infection of
rhesus macaques as an ideal system for pre-clinical studies aimed at preventing or treating EBV
associated malignancies, but a more detailed understanding of rhLCV-specific T cell responses is
needed to firmly establish this model. We characterized rhEBNA1-specific T cell responses in 15
rhLCV-seropositive healthy rhesus macaques and compared these responses to rhBZLF1+

specific T cells within the same population of animals by ICS. RhEBNA1-specific CD4 T cells
+

+

were detected at a slightly higher frequency than CD8 T cells, while rhBZLF1-specific CD4 and
+

CD8 T cells were both present in 93% of the animals.

Unlike responses in humans

222

,

responses to rhEBNA1 in macaques did not appear to be influenced by the Mamu-genotype,
although additional studies with larger cohorts and more extensive genotyping as well peptide
mapping would be required to firmly establish the effects of MHC class I restricting elements on T
cell responses.
In addition to frequencies, we also examined subset phenotypes and cytokine production
of rhEBNA1- and rhBZLF1-specific T cells. These studies served to determine the effect of
persistent low-level antigen on specific T cell responses and to evaluate the capacity of such T
cells to respond to vaccination. T cells affected by persistent antigen exposure may be difficult to
expand, as TCM cell pools are often depleted and TEFF/TEM cells do not function optimally. We
+

found that rhEBNA1-specific CD4 T cells were composed of both TCM and TEM cell subsets that
+

produced IFN-γ, IL-2, and TNF-α, while rhEBNA1-specific CD8 T cells were primarily IFN-γproducing TEFF cells. This may suggest that repeated in situ reactivation of rhLCV or the
persistent presence of latently infected cells expressing rhEBNA1 primarily maintains activation of
+

+

CD8 rather than CD4 T cells. An alternative explanation could be that rhEBNA1-specific CD8

+

T cells are exposed to antigen more regularly and are beginning to lose function, but low
expression of the inhibitory molecule PD-1 indicates this is most likely not the case. In fact, PD-1
+

expression was higher on rhEBNA1-specific CD4 memory T cells, which indicates that these T
cells probably see antigen more often.

+

In comparison, rhBZLF1-specific CD4 T cells were
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primarily of the TCM subset, produced IL-2 and TNF-α, and exhibited significantly lower PD-1
+

surface expression compared to rhEBNA1-specific memory CD4 T cells. In contrast, rhBZLF1+

specific CD8 T cells were composed of both effector and memory cell subsets that mainly
produced IFN-γ, followed by IL-2. The presence of rhEBNA1-specific TCM cells that produce
multiple cytokines in response to stimulation indicates that vaccination could be a feasible
approach for expanding this response.
Both rhEBNA1 and rhBZLF1 T cell responses have previously been studied in
macaques. Using IFN-γ enzyme-linked immunosorbent spot (ELISpot) assays, Fogg et al.

215

measured antigen-specific responses to latent rhLCV proteins directly ex vivo by culturing
PBMCs with recombinant vaccinia viruses. While responses were detected against all latent
+

proteins tested, rhEBNA1-specific CD8 T cells were identified most frequently in nearly half of
the animals (11 of 23) and with the highest mean responses of the latent proteins tested. The
+

same group detected ex vivo rhBZLF1-specific CD8 T cell responses at a frequency of 63% (36
of 57)

217

.

Orlova et al.

188

showed by IFN-γ ELISpot assays of T cell lines from healthy

seropositive rhesus macaques that rhBZLF1-specific T cells were present in 53% (8 of 15) of the
+

animals tested, 40% of which had specific CD8 T cells. Using a more sensitive method that
allows for simultaneous screening of several T cell cytokines, we show that every rhLCVseropositive rhesus macaque carries rhBZLF1-specific T cells, while the majority (14 of 15) have
circulating rhEBNA1-specific T cells. Such T cells could not be detected at significant frequencies
in rhLCV-seronegative animals.
EBNA1- and BZLF1-specific T cells have been studied in more depth in the human
system and with a variety of techniques and functional readouts in diverse cohorts. Early studies
based on ELISpot assays for IFN-γ revealed EBNA1-specific T cell responses in less than 20% (2
of 13) of healthy human adults, while responses to another latent antigen, EBNA3, were detected
in nearly 80% of this cohort

223

. In contrast, Fogg et al.

132

detected EBNA1-specific T cells ex vivo

in over 90% (12 of 13) of human adults and about 50% of those responses included EBNA1+

specific CD8 T cells. Bickham et al.

224

+

studied the EBNA1 CD4 T cell response and found

detectable responses in only 37% (7 of 19) of the tested individuals directly ex vivo; upon in vitro
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+

expansion EBNA1-specific CD4 T cells became detectable in 95% of those individuals.
Similarly, Munz et al.

92

+

detected EBNA1-specific CD4 T cell responses in all human adults (10 of

10) upon initial in vitro expansion of specific cells.
BZLF1 is considered an immunodominant target of the EBV-specific T cell response

1, 225

.

Prevalence of T cells in response to this antigen within human populations is commonly studied
using specific HLA backgrounds and immunodominant epitopes, and so their presence and
characteristics in a truly diverse population are not well documented. Houssaint et al.

225

detected

+

BZLF1-specific CD8 T cells in 60% of polyclonal T cell lines from human subjects, but epitopespecific responses have been detected at a much higher rate when cells are tested with the
appropriate HLA background. For example, Tan et al.

226

and Woodbury et al.

71

both reported

BZLF1-specific responses in all individuals of their HLA-specific cohorts. Less is known about
+

BZLF1-specific CD4 T cells, but Long et al.

89

used IFN-γ ELISpot assays to detect responses in

79% of EBV-seropositive individuals. The various techniques and corresponding results have
been reviewed elsewhere

1, 89, 217

+

, but in general, BZLF1 is known to induce a stronger CD8 than

+

CD4 T cell response, which is similar to what we observed in the current study.
Other studies have examined subset phenotypes and cytokine production of human EBVspecific T cells by flow cytometry. Heller et al.

227

reported the presence of proliferation-competent

+

IFN-γ-producing EBNA1-specific CD4 T cells in 90% (18 of 20) of individuals; slightly more than
half belonged to the TCM cell subset and the remaining belonged to the TEM cell subset. Both the
frequency and subset distribution are quite similar to our findings in rhesus macaques. Guerreiro
et al.

228

described responses in eight EBV-seropositive individuals and found the majority of
+

+

+

directly ex vivo-tested EBNA1-specific CD4 and CD8 T cells and BZLF1-specific CD4 T cells
+

belonged to the TCM cell subset and produced IL-2 and/or TNF-α, while BZLF1-specific CD8 T
cells were more activated and produced mainly IFN-γ and TNF-α. While we describe similar
+

subset distributions, we found that rhesus EBNA1 CD4 T cells were more polyfunctional and
more commonly produced IFN-γ either alone or in combination with other cytokines. We also
+

detected more activated rhEBNA1 CD8 T cells based on the large effector populations. It is
possible that some of these differences are due to the fact that Guerreiro et al. analyzed the
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cytokine profiles of only two of the highest responders. Not only may the small sample size sway
81

the response, but also the profile of high responders may naturally differ. Finally, Ning et al.

compared BZLF1 polyfunctional responses to a combination of latent EBV antigens, adding
MIP1-α and CD107a to the staining panel. Although they did not analyze subset distributions,
+

+

they found polyfunctional responses within both human CD4 and CD8 T cell populations similar
to results of our studies in rhesus macaques. These findings indicate that latent infection has
only minor impact on the function of EBNA1-specific T cells.
An additional approach to gauge the degree of T cell exhaustion is to measure the
expression of inhibitory receptors on the cell surface. Expression of the inhibitory receptor PD-1
increases after T cell activation, and overexpression of PD-1 has been linked to T cell exhaustion
and decreased functional capacity. We had originally planned on measuring PD-1 expression
using MHC class I tetramer staining, but the Mamu A*08 specific tetramer developed by our
collaborators was not sensitive enough to consistently detect responses directly ex vivo. Instead,
we stained PBMCs for PD-1 prior to stimulation with peptide pools for ICS. It would have been
ideal to stain for multiple inhibitory receptors, but there are only a small number of suitable human
antibodies that cross-react with rhesus proteins.

Because PD-1 can reflect normal T cell

activation as well as T cell dysfunction, our data were interpreted in the context of the phenotypic
and functional readouts.
+

+

We detected a significantly larger frequency of rhEBNA1-specific PD-1 CD4 memory T
cells compared to total and rhBZLF1-specific CD4

+

memory cells.

However, the average

+

percentage of rhEBNA1-specific PD-1 T cells was just above 50%, which is not indicative of
exhaustion

229

.

Salisch et al.

230

used flow cytometry to characterize the distribution of PD-1

expression among T cell subsets in healthy rhesus macaques and found that PD-1 was primarily
+

restricted to memory T cells: between 30% to 45% of CD4 memory T cells expressed PD-1. The
+

+

increase we observed in PD-1 rhEBNA1-specific CD4 memory T cells relative to total CD4

+

memory cells could be a result of recent activation or could be caused by low-level rhEBNA1
+

expression during latency. However, because the frequency of PD-1 rhBZLF1-specific T cells
was not elevated in any subset, reactivation is unlikely. Memory responses were broad, which
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suggests a range of activation that is highly variable between animals. This could reflect different
rates of rhLCV reactivation or the ability of different Mamu genotypes to detect different epitopes.
We were surprised to find consistently low percentages of rhEBNA1- and rhBZLF1+

+

+

specific PD-1 CD8 TEFF cells compared to total CD8 TEFF cell responses, as effector cells are
typically highly activated and are often associated with increased expression of PD-1
However, Hokey et al.

231

231

.

+

found higher PD-1 expression on total CD8 TCM cells compared to TEM

and TEFF cells. Similarly, Salisch et al.

230

+

+

found that the majority of PD-1 CD8 T cells (between

20-30%) exhibited a memory phenotype. In comparison, we found larger percentages of total
PD-1

+

+

CD8 memory (54%) and effector cells (62%).
+

Petrovas et al.

232

report a similar

+

percentage of PD-1 CD8 memory T cells in healthy rhesus macaques using an approach similar
to ours, however, they stained for PD-1 after stimulating cells for 6 hours, whereas we stained
+

+

prior to stimulation. The large percentage of total PD-1 CD8 TEFF cells we detected could signify
a high degree of general immune activation.
Groups have also studied PD-1 expression on EBV-specific T cells. Day et al.
Petrovas et al.

234

233

and
+

used a BMLF1 tetramer to detect the percentage of PD1-expressing CD8 T

cells, which was about 75% (range: about 50% to 100%). We expected to find a similarly large
+

+

percentage of rhBZLF1-specific PD-1 CD8 TEFF cells, but instead found the opposite. One
+

explanation is that neither rhEBNA1- nor rhBZLF1-specific CD8 T cells frequently encounter
antigen- either due to the rhEBNA1 GAr domain or to a lack of recent reactivation, respectively.
Differences in methods of detection and markers used to define various subsets could also be
responsible for these discrepancies. Differences could also be a reflection of epitope specificity,
as supported by Greenough et al.

221

+

, who studied PD-1 expression on EBV-specific CD8 T cells

during AIM, convalescence, and chronic infection using tetramers against immediate-early
+

(BRLF1) and early (BMLF1) lytic antigens. They report a percentage of total BRLF1 CD8 T cells
expressing PD-1 during convalescence (median: 35.1%; range: 10.3% to 80%) that is quite
+

+

similar to the percentage of total PD-1 CD8 rhBZLF1 responses in our studies (data not shown,
median: 29.8%; range: 12.2% to 70%). They also describe very similar percentages of BMLF1
+

CD8 T cells as Day et al. and Petrovas et al. Furthermore, they note that PD-1 expression was
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highest within the TEM cell compartment, which would be represented within our memory subset
(which was also the largest). To our knowledge, we are the first group to study the expression
PD-1 on rhLCV-specific T cells. Our results clearly demonstrate that PD-1 is not over-expressed
on rhEBNA1- or rhBZLF1-specific T cells, both of which produce multiple cytokines in response to
stimulation. Therefore, while antigens may be continually present and could influence the cell
phenotypes we observed, they do not appear to cause functional exhaustion.
Trends observed in our studies regarding the immunodominance of lytic and latent
+

proteins parallel responses observed in humans; EBNA1-specific CD4 T cell responses are
+

more dominant than CD8 T cell responses, and the opposite is observed for BZLF1.

In

+

concordance with this, we found that rhEBNA1-specific CD4 T cells were more polyfunctional
than rhEBNA1-specific CD8

+

T cells and rhBZLF1-specific CD4

+

T cells.

RhEBNA1- and

+

rhBZLF1-specific CD8 TEFF cells had similar functional properties, but the magnitude of rhBZLF1+

specific responses was larger, and rhBZLF1-specific CD8 TCM cells were more polyfunctional.
+

Upon primary infection and subsequent reactivations, BZLF1-specific CD8 T cells are probably
seeing more antigen and have a more direct role in controlling reactivations than the CD4

+

+

response, which is mostly central memory. On the other hand, EBNA1-specific CD8 T cells may
be less sensitive in detecting antigen due to the glycine-alanine repeat domain, and this may
+

somehow trigger a larger and more functional CD4 T cell response.
All of the studies in humans as well as rhesus macaques demonstrate that a natural
+

+

infection with EBV or rhLCV induces detectable CD4 and CD8 T cell responses to both EBNA1
and BZLF1. Differences in subset distribution or functionality of EBNA1-specific T cell responses
in different studies may in part reflect differences in the employed assays. We have chosen to
assess antigen-specific responses with overlapping peptide pools and a short 6-hour stimulation
because we feel that this method provides the most accurate reflection of the response in vivo.
Prolonged stimulation of T cells by their ex vivo expansion not only changes T cell functions but
also leads to selective proliferation of some T cells and concomitant loss of others. Furthermore,
studies that use only IFN-γ as an output of response specificity are likely minimizing the actual
frequencies of the responses. Variances may also reflect different study populations from diverse
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geographic regions, different age ranges, or different underlying diseases. While humans are
more frequently exposed to infectious agents and more commonly encounter perturbations of
their immune systems that may support EBV reactivation, such as infections
or stress

237, 238

235

, autoimmunity

236

,

, the non-human primates of our study were housed in a relatively controlled

environment. Furthermore, it is important to note that most primates become naturally infected
with rhLCV during the first few years of life. Exposure of humans in developed countries is more
sporadic and can be delayed until adolescence or even adulthood although infections occur
earlier in less developed countries such as Africa

239

.

Some studies suggest that responses

against lytic and latent antigen in healthy seropositive individuals are influenced by the length of
time since primary exposure

71, 240

, and this is much more variable in the human response.

Nonetheless, other data failed to demonstrate a correlation between age and magnitude of T cell
responses to antigens of EBV using cohorts from Africa

241

.

The immunological responses to EBV are complex yet critical for understanding their role
in human carcinogenesis and related diseases. Although primary infection is in general benign,
the persistence of this oncogenic virus can lead to multiple cancer types, typically exacerbated by
immunological dysfunction or immunosuppression associated with human immunodeficiency
virus type 1 (HIV-1) infection or solid-organ transplants. Recent evidence also supports a role for
EBV infection in several autoimmune disorders, suggesting that EBV has a complex interaction
with the host immune system. The natural rhLCV infection of rhesus macaques provides an ideal
animal model to study host immunological responses to EBV-like viruses and is also the system
of choice for pre-clinical evaluation of EBV vaccines. Therefore, the importance of this study is
twofold: first, by comparing rhesus macaque EBNA1 and BZLF1 T cell responses to human
EBNA1 and BZLF1 T cell responses, we have further validated the rhLCV model as an
appropriate and useful system for studying EBV. Second, an improved understanding of the
rhEBNA1 immune response will benefit the pre-clinical development of vaccines that could
potentially prevent or control EBV-associated malignancies.
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Our study provides a baseline for future studies of therapeutic interventions in the rhLCV
model. We have shown that rhEBNA1-specific T cell responses are present and functional. Next,
we will determine if they can be expanded through vaccination.
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CHAPTER 3:

ADENOVIRUS-BASED VACCINES TO RHESUS
LYMPHOCRYPTOVIRUS EBNA1: VECTOR DESIGN,
MOUSE STUDIES, IN VITRO TESTING

ABSTRACT
The impact of EBV on human health is substantial, but vaccines that prevent primary
EBV infections or treat EBV-associated diseases are not yet available. EBNA1 is an important
target for vaccination because it is the only protein expressed in all EBV-associated
malignancies. We designed two therapeutic EBV vaccines that express a GAr-deleted rhLCV
EBNA1. Vaccines were based on two serotypes of E1-deleted simian adenovirus.

To further

modulate the response, rhEBNA1 was fused to herpes simplex virus glycoprotein D (gD), which
acts to block an inhibitory signaling pathway during T cell activation. Although we were unable to
detect rhEBNA1-specific T cell responses in mice, vaccines stimulated IFN-γ production by
autologous rhEBNA1-specific T cells in vitro.

These experiments confirm the specificity and

functionality of our novel prototype vaccines.

Portions of this chapter were adapted from:
Leskowitz R, Fogg MH, Zhou XY, Kaur A, Silveira ELV, Villinger F, Lieberman PM, Wang F, and Ertl HC.
+
Adenovirus-based vaccines to rhesus lymphocryptovirus EBNA1 induce expansion of specific CD8 and
+
CD4 T cells in persistently infected rhesus macaques. Journal of Virology 2014; 88(9): 4721-4735.
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INTRODUCTION
EBV is associated with about 200,000 new cases of cancer annually and around 1% of
all human cancers worldwide

104

. Although primary infections are in general benign, EBV

establishes a persistent infection through its latency in B cells, where it occasionally reactivates.
52

This can lead to EBV-associated malignancies in certain populations . For example, when the
immune system becomes compromised, as it does during infection with HIV or immune
suppression following organ transplant, its ability to control EBV declines, and EBV-associated
52

malignancies can arise . In Southern China, EBV-associated nasopharyngeal carcinoma afflicts
0.05% of all males over the age of 50

242

. EBV-associated gastric carcinomas are highly prevalent

in Eastern Asia, Eastern Europe and Africa
Burkitt’s lymphoma in Central Africa

243

104

, and EBV is tightly linked to endemic forms of

. EBV has also been linked to autoimmune disorders

102

.

The impact of EBV on human health is thus substantial, but vaccines to prevent primary EBV
infections or treat EBV-associated diseases are not yet available.
An effective therapeutic EBV vaccine would need to target antigens produced during
latency, when most viral protein expression is down-regulated

244

. Epstein-Barr nuclear antigen 1

functions to maintain the viral episome and is essential for viral DNA replication during latency. It
is the only antigen expressed during all forms of latency
malignancies

246

245

and in all EBV-associated

. EBNA1 is thus a primary target for a therapeutic EBV vaccine. However, like

many antigens of herpesviruses, EBNA1 subverts CD8

+

T cell responses, thus potentially

enhancing EBVs’ ability to persist and escape immune surveillance. EBNA1 mRNA contains a
purine-rich domain that encodes a large GAr sequence, which can interfere with EBNA1-specific
CD8

+

T cell responses, either by direct inhibition of GAr-containing protein synthesis or

proteasome-mediated degradation, thus leading to reduced antigen presentation

194-196

. As a

+

result, induction and effector functions of EBNA1-specific CD8 T cell responses are impaired.
Nevertheless, EBNA1-specific CD8

+ 197, 198

and CD4

+ 92

T cells are frequently detected in EBV-

infected humans. These T cells are capable of controlling EBV-infected cells in vitro

199, 209

, and

the loss of EBNA1-specific T cells has been correlated with numerous EBV-associated

	
  

80

diseases

62, 132-134

; this suggests that EBNA1-specific T cells play an important role in controlling

infections in vivo.
Studies described in the following two chapters explore the use of EBNA1 as a potential
vaccine target. In the previous chapter, we demonstrated that like humans, rhesus macaques
+

+

develop EBNA1-specific CD8 and CD4 T cells during persistent rhLCV infection. Here, using
the rhLCV model, we developed and tested two prototype vaccines expressing rhesus EBNA1.
To facilitate rhEBNA1 processing and antigen presentation, the GAr domain was removed from
the coding sequence. To further modulate the response, rhEBNA1 was genetically fused into the
C-terminal domain of a modified herpes simplex virus (HSV-1) glycoprotein D (gD), which is a
structural envelope protein that is essential for HSV-1 entry into host cells

247

. HSV-1 gD contains

an immunoglobulin fold flanked by an N-terminal hairpin loop, C-terminal extension, and
hydrophobic transmembrane region (TMR)
herpes virus entry mediator (HVEM)
during T cell activation
subsequently blocked

247, 250

250

.

249

248

. The N-terminal loop of HSV-gD binds the bimodal

and prevents inhibitory molecules from binding HVEM

Downstream HVEM immunoinhibitory signaling pathways are

. As we have previously shown, HSV-1 gD thereby enhances T cell

responses to antigens fused into its C-terminus

247

. For example, mice vaccinated with DNA or

Ad-based vaccines expressing antigen fused to HSV-1 gD develop significantly larger
+

+

frequencies of IFN-γ CD8 T cells (Figure 3-1).
HSV-1 gD-rhEBNA1 chimeric antigens were expressed by E1-deleted Ad vectors of
simian serotype 25 (SAdV-25) for priming and serotype 23 (SAdV-23) for booster immunizations.
Vectors based on these serotypes are from here on referred to as AdC68 (SAdV-25) and AdC6
(SAdV-23) vectors. We have previously shown that chimpanzee-based Ad vectors induce potent
and sustained transgene product-specific T cell responses in rodents
primates

159, 251

163, 164

and non-human

. Because humans are our eventual target population, we chose simian-derived

Ad vectors rather than Ad vectors based on human serotypes in order to prevent neutralization of
the vaccine construct by antibodies to the vaccine carrier

167

. Heterologous prime-boost vaccine

regimens have been shown to elicit high transgene product-specific T cell responses, as they
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overcome blocking immunity induced by the first vaccine and allow successful boosting of the
memory immune response by the second vaccine

251, 252

.

This chapter focuses on vaccine production, small animal studies, and in vitro
experiments designed to test rhEBNA1 transgene expression and the ability of our vaccines to
stimulate transgene product-specific T cell responses. Western blotting and cell surface staining
experiments confirmed similar levels of transgene expression when rhEBNA1 was fused to
various forms of HSV-1 gD.

We were unable to detect rhEBNA1-specific T cell responses in

mice regardless of the strain of mouse, vaccine dose, or the presence of mutations that
destabilized rhEBNA1. However, vaccines stimulated IFN-γ production by autologous rhEBNA1specific T cells in vitro, thus confirming their functionality and specificity.
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Figure 3-1: Enhanced T cell responses to antigens expressed as fusion proteins with
HSV-gD

+

Figure 3-1: (A) PBMCs were stimulated and stained for CD8 surface expression and intracellular IFN-γ 10
days after mice were immunized i.m. with AdC68 vectors (bottom) or DNA vaccines (top) expressing various
+
antigens either alone or fused to gD. Numbers reflect the frequencies of CD8 T cells that produce IFN-γ.
+
(B) A comparison of IFN-γ-specific CD8 T cell responses to DNA vaccines expressing antigen fused to wild
type gD (center bar), super gD (SgD; black bar), or non-binding gD (NBEFgD) shows enhanced and
diminished T cell responses from splenocytes 14 days after immunization. Figure was adapted from Lasaro
247
et al., 2008 .
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RESULTS
Vector construction and in vitro transgene expression
We developed several Ad-based vaccines expressing rhEBNA1 in which the GAr domain
was removed from the coding sequence and a flag tag was inserted. The truncated rhEBNA1
protein was genetically fused into the C-terminal domain of various forms of HSV-1 gD. The GArdeleted rhEBNA1 was also expressed without a fusion partner (rhEBNA1). Finally, to control for
any non-specific effects of vaccination, we used a vaccine that expressed gD fused to an
irrelevant antigen, i.e., the nucleoprotein of influenza A virus (gD-NP).

Vaccines based on

recombinant E1-deleted AdC68 and AdC6 viral vectors were used to deliver the antigens.
The truncated rhEBNA1 was inserted into a mutated version of gD with enhanced HVEM
binding (termed super (S)gD; SgD-rhEBNA1). Enhanced binding to HVEM by SgD is the effect of
a single amino acid mutation that opens up the HVEM binding domain and results in more potent
T cell responses against antigens fused into it’s C-terminus as compared to wild-type HSV-1
gD

248

. To control for this effect, we generated a vaccine that expressed the truncated rhEBNA1

within a version of SgD with strongly reduced binding to HVEM (NBEFSgD-rhEBNA1)

247, 248

. We

confirmed rhEBNA1 protein functionality with a DNA binding assay using protein lysates from
infected cells (data not shown). Schematic representations of the chimeric proteins are shown in
Figure 3-2A.
To compare vaccine immunogenicity, it was essential that all vaccines expressed similar
amounts of rhEBNA1. We therefore quantified rhEBNA1 expression levels by immunoblotting
and cell surface staining of infected CHO-CAR cells. Immunoblots of protein lysates from AdC
vector-infected cells confirmed that SgD-rhEBNA1 and NBEFSgD-rhEBNA1 were expressed at
similar levels (Figure 3-2B).

The rhEBNA1 transgene product was detected with antibodies

against the flag epitope (Figure 3-2B; top), HSV-1 gD (Figure 3-2B; center), and rhesus serum
reactive to rhEBNA1 (data not shown).

As expected, both SgD-rhEBNA1 and NBEFSgD-

rhEBNA1 achieved similar levels of expression at the expected size of 90-kDA. The 55-kDA
band detected only by the gD antibody is unrelated to rhEBNA1, since it was also expressed by
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vectors encoding gD only and therefore reflects either a gD degradation product, an alternative
splicing event, or cross-reactivity with an Ad vector-derived protein. It is also possible that gD has
been cleaved from the chimeric SgD-rhEBNA1 protein, although full length SgD-rhEBNA1 is still
expressed at comparable levels compared to NBEFSgD-rhEBNA1.

Cell surface staining of

infected CHO-CAR cells for SgD-rhEBNA1 and NBEFSgD-rhEBNA1 with an antibody to flag also
revealed similar levels of transgene expression (Figure 3-2C).

This indicates that the gD

transmembrane domain redirected rhEBNA1 from the nucleus to the cell surface at similar levels
regardless of the version of gD.
While vectors expressed gD-rhEBNA1 chimeric proteins at similar levels, the AdCrhEBNA1 vector expressed markedly higher levels of rhEBNA1 (Figure 3-3A), which would have
made it difficult to determine whether differences in vaccinated animals were due to blockade of
the HVEM pathway or to levels of rhEBNA1 expression. We therefore chose the two vectors with
similar levels of rhEBNA1 expression but different abilities to block the HVEM pathway (SgDrhEBNA1, NBEFSgD-rhEBNA1) for in vivo comparisons in rhesus macaques.
The chimeric proteins were also tested in an HVEM binding assay to confirm enhanced
and reduced binding to SgD and NBEFSgD, respectively. Normalized protein extracts from cells
infected with AdC68 vectors encoding SgD-rhEBNA1, NBEFSgD-rhEBNA1 or rhEBNA1 were
added to plates coated with HVEM. Figure 3-2D shows the enhanced binding of SgD-rhEBNA1
compared to NBEFSgD-rhEBNA1 and rhEBNA1 without gD, both of which failed to bind HVEM at
the tested concentrations of protein, as expected.

	
  

85

Figure 3-2: In vitro testing of AdC-SgD-rhEBNA1 and AdC-NBEFSgD-rhEBNA1 vaccines

A.

B.

C.

D.

Figure 3-2: (A) Schematic representations of HVEM-binding (top) and non-binding (bottom) gD-rhEBNA1
fusion proteins expressed by AdC-based vaccines. Super (S) gD contains a mutation at position 294 of
248
HSV-1 gD, in which a tryptophan was changed to an alanine (light grey band) . The result is increased
HVEM binding. The non-binding effect (NBEF) gD was generated by replacing seven amino acids at the N248
terminus of HSV-1 gD with alanine (dark grey bands) . These mutations block HVEM binding. (B)
10
9
8
Western blot analyses of protein lysates harvested from CHO-CAR cells infected with 10 , 10 , or 10 vps
of AdC-based vaccines expressing SgD-rhEBNA1 (left), NBEFSgD-rhEBNA1 (center), or gD alone (right).
Transgene products were detected with antibodies against the flag epitope (top row) or HSV-1 gD (center
row). Anti β-actin was used as an internal control (bottom row). (C) Cell surface staining of infected CHO10
9
CAR cells for SgD-rhEBNA1 and NBEFSgD-rhEBNA1. Cells were infected for 48 hours with 10 or 10 vp of
10
AdC68-SgD-rhEBNA1 or AdC68-NBEFSgD-rhEBNA1 or 10 vp of AdC68-gD, stained with mouse anti-flag
antibody, and probed with goat anti-mouse IgG-Alexa700. (D) An HVEM binding assay was used to test the
ability of the chimeric proteins to bind their receptor. Normalized protein extracts from CHO-CAR cells
infected with AdC68 encoding SgD-rhEBNA1 show enhanced HVEM binding (vs. AdC68-NBEFSgDrhEBNA1, p = 0.0036; vs. AdC68-rhEBNA1, p = 0.0035; Comparing AUC by one-way Anova). A p-value
<0.05 was considered significant. All multiple comparisons were Bonferroni-adjusted to control for type I
errors.
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Vaccination does not induce rhEBNA1-specific T cells in mice
We tested the ability of our Ad-based rhEBNA1 vaccines to induce rhEBNA1-specific T
cell responses in mice.

Rhesus LCV does not naturally infect mice, and we were unable to find

any reports of rhLCV-specific vaccines tested within the murine immune system. Because mouse
epitopes were unknown, we began with a dose escalation study in a small group of BALB/c mice.
We used AdC vectors expressing either truncated rhEBNA1 alone or fused to HSV-1 gD from
9

which the transmembrane domain had been deleted. Four animals per group received either 10 ,
10

10 , or 10

11

vps per mouse of AdC68-rhEBNA1 or AdC68-gD-rhEBNA1 administered intra-

muscularly (i.m.). As a control, four animals were vaccinated with 10

11

vps per mouse of AdC68-

HIV-gag. T cells were tested for IFN-γ production by ICS after PBMCs were stimulated with an
overlapping rhEBNA1 peptide pool at 2 and 4 weeks after vaccination. As shown in Figure 3-3,
+

+

frequencies and numbers of rhEBNA1-specific IFN-γ CD8 T cells were all low, but looked most
promising at the 10

11

dosage. All rhEBNA1-specific T cell responses were significantly lower than

HIV-gag-specific T cell responses (p < 0.05), as shown at week 4. Using the highest dose of 10

11

vps per mouse, we repeated the same study through week 12 and compared responses to
vaccine-naïve animals, which were not significantly different than animals vaccinated with either
+

Ad-rhEBNA1-expressing vaccine (Figure 3-4). Peptide-specific CD4 T cell responses were also
undetectable (data not shown).

These results indicate that BALB/c mice do not recognize

epitopes within rhEBNA1.
A similar series of experiments using C57/Bl6 (n = 5) and ICR (n = 10) mice produced the
same results despite staining for three different cytokines in order to broaden our detection of
vaccine-induced responses (Figure 3-5). Mice were vaccinated with 10

11

vp of AdC68-rhEBNA1

or AdC68-gD-rhEBNA1, and PMBCs were stained for IFN-γ, IL-2, and TNF-α.

The lack of

substantial responses led us to conclude that mice are not capable of recognizing epitopes within
rhEBNA1, even when they are outbred (such as ICR mice).
Alternatively, the lack of rhEBNA1-specific T cell responses in mice could be a result of
the high degree of stability of rhEBNA1, which is a DNA-binding protein that is not very well
degraded. To address this, we destabilized rhEBNA1 by introducing various mutations within the
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protease-resistant DNA binding domain (rhEBNA1-M and gD-rhEBNA1-M) to interfere with
protein folding and increase degradation and antigen presentation of rhEBNA1. Thus, if mice are
capable of responding to rhEBNA1, then immunization with AdC vaccines expressing rhEBNA1M or gD-rhEBNA1-M would induce larger rhEBNA1-specific T cell responses. However, we were
still unable to detect rhEBNA1-specific T cells after vaccination with mutated rhEBNA1 vaccines
(data not shown).
To confirm that the lack of rhEBNA1-specific T cell responses was not caused by
experimental error, we tested for the induction of gD-specific antibodies by serum ELISA. All
animals that received gD-expressing vaccines developed antibodies against gD, which confirms
that mice appropriately responded to vaccination (data not shown).
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+

+

Figure 3-3: Frequency and number of IFN-γ CD8 T cells following dose-escalation study
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Figure 3-3: The frequency (A) and number (B) of IFN-γ CD8 T cells following a dose-escalation study of
9
10
11
BALB/c mice (n = 4 per group) that received 10 , 10 , or 10 vp of AdC68 vectors expressing either
11
rhEBNA1 or gD-rhEBNA1. As a control, animals were vaccinated with 10 vp of AdC68 expressing HIVgag. Responses were measured by production of IFN-γ after PBMCs were stimulated with overlapping
rhEBNA1 or gag peptide pools. Representative data is shown here at week 4. Responses are shown after
subtraction of background values. Bars indicate the mean.
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+

Figure 3-4: Kinetics of peptide-specific CD8 T cells after vaccination
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Figure 3-4: BALB/c mice (n = 5) were immunized with 10 vp of AdC68-expressing rhEBNA1
(red circle) or gD-rhEBNA1 (blue square) to study the kinetics of peptide-specific T cells.
PMBCs were collected every other week after vaccination and were stimulated with
overlapping rhEBNA1 (left column) or HIV-gag (right column) peptide pools (labeled here as
negative control). Responses are reported as the frequency (top row) or number (bottom row)
+
+
of IFN-γ CD8 T cells after a five hour incubation. Vaccine-naïve mice (black triangle) were
included as an additional control starting at week 4 in order to measure general immune
fluctuation. 	
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+

Figure 3-5: Peptide-specific CD8 T cells after vaccination of C57/Bl6 and ICR mice
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Figure 3-5: C57/Bl6 (left; n = 5) and ICR (right; n = 10) mice were immunized with 10 vp of AdC68expressing rhEBNA1 (red circle) or gD-rhEBNA1 (blue square). PMBCs were collected at weeks 2, 4, 10,
and 12 after vaccination and were stimulated with overlapping rhEBNA1 or HIV-gag (labeled here as
+
+
negative control) peptide pools. Responses are reported as the frequency of IFN-γ (A), IL-2 (B), or TNF+
+
α (C) CD8 T cells after a five-hour incubation.
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Vaccination induces rhEBNA1-specific T cells in vitro
To test if our vaccines could stimulate rhEBNA1-specific effector T cells in vitro, rhesus
macaque DCs were infected with the AdC68-rhEBNA1 or AdC68-gD-rhEBNA1 viral vectors and
+

cultured with autologous rhEBNA1-specific CD8 T cells. T cell responses were measured by an
IFN-γ ELISPOT assay.

As shown in Figure 3-6, the rhEBNA1 antigen could be efficiently
+

processed and presented to rhEBNA1-specific CD8 T cells. DCs infected with the AdC68-gDrhEBNA1 vector were able to induce IFN-γ secretion by rhEBNA1-specific T cells, and responses
were comparable to those elicited by an AdC68-rhEBNA1 vector, which lacked gD. Empty vector
or non-infected DCs did not induce responses. IFN-γ was produced by responding T cells, since
cultures containing only infected DCs failed to produce IFN-γ.
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Figure 3-6: In vitro stimulation of rhEBNA1-specific T cells
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  

	
  
	
  

	
  

Figure 3-6: Mature DCs from an rhLCV-seropositive rhesus macaque were infected with
the indicated Ad vectors or pulsed with rhEBNA1 peptide and then co-cultured with
+
+
autologous rhEBNA1-specific CD4 -depleted CD8 T cells. rhEBNA1-specific responses
were measured by an IFN-γ ELISPOT assay after 16 hours and results are shown as
6
+
average spots per 10 CD8 T cells based on quadruple experiments of the DC + T cells
and triplicate experiments of the other samples. Asterisk denotes significant differences:
all p-values < 0.0001 except for peptide vs. AdC68-rhEBNA1 (p = 0.0009) and AdC68-gDrhEBNA1 (p = 0.0036). P-values were calculated using one-way ANOVA, with a p-value
<0.05 considered significant. All multiple comparisons were Bonferroni-adjusted to control
for type I errors.
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DISCUSSION
EBV infection causes a significant amount of morbidity and mortality within both immune
competent and immune compromised populations throughout the world, but there is currently no
approved prophylactic or therapeutic EBV vaccine.

Using the rhLCV animal model of EBV

infection, we constructed AdC-based vaccines that target rhEBNA1, the only antigen of rhLCV
(and EBV) expressed during lytic and latent infection and in all associated malignancies. Ad
vectors derived from chimpanzee serotypes are highly immunogenic
prevalence rates in human cohorts

254

159, 251, 253

, and are well suited for clinical development

, have low

255

. Vaccines

expressed a GAr-deleted form of rhEBNA1 that was fused to the HVEM-binding HSV-1 gD to
further promote T cell responses. We had originally planned to use AdC vaccines expressing
rhEBNA1 without HSV-1 gD as a control, but rhEBNA1 protein expression as detected via
western blot was at least 100-fold higher than gD-rhEBNA1. This likely reflects either differences
in protein stability caused by fusion to HSV-1 gD or differences in the rates of
transcription/translation between shorter versus longer sequences. Therefore, to better control for
the adjuvant effect of HSV-1 gD, rhEBNA1 was fused to an HVEM-non-binding form of gD. In
vitro studies confirmed that vaccines expressed similar levels of gD-rhEBNA1 fusion products so
that potential differences after vaccination could be attributed to HVEM binding of gD rather than
to differences in antigenic load. Additional in vitro studies confirmed that the two forms of gD
exhibited the expected HVEM binding patterns.
We initially attempted to confirm vaccine immunogenicity by testing their ability to induce
rhEBNA1-specific T cell responses in several different strains of mice, including BALB/c, C57/Bl6,
and ICR mice, which are outbred.

Mice were vaccinated with AdC68-rhEBNA1 or AdC68-gD-

rhEBNA1. We were unable to detect rhEBNA1-specific T cells regardless of the strain of mouse,
vaccine received, or dose of vaccination. A dose-escalation study followed by a kinetic analysis
of rhEBNA1-specific responses after immunization at the highest dose (10
elicit any clear rhEBNA1-specific T cell responses.

11

vps/mouse) did not

While we later learned that levels of

transgene expression by AdC-rhEBNA1 and AdC-gD-rhEBNA1 vaccines differed, this was
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inconsequential since neither vaccine elicited responses. This is perhaps because there are no
rhEBNA1-specific mouse epitopes. An alternative explanation is that rhEBNA1 is an extremely
stable protein that is not very well degraded. To address this question, we generated additional
vaccines with mutated rhEBNA1 DNA-binding domains to destablize rhEBNA1 and increase its
degradation. However, we were still unable to detect responses in mice upon vaccination with
modified vaccines. We assume this reflects a lack of suitable epitopes within rhEBNA1 that can
bind to mouse MHC molecules.
While mice were vaccinated with a TMR-deleted vaccine, it is not likely that inclusion of
the TMR would have significantly altered the results given that we were unable to detect
responses against rhEBNA1 alone, which was expressed at a much higher rate than gDrhEBNA1. Furthermore, all gD-rhEBNA1 transgene products were expressed at similar levels
regardless of the version of HSV-1 gD (data not shown). Thus, mouse studies were not repeated
with our TMR-containing vaccines. It is possible that without the TMR, the gD-rhEBNA1 fusion
protein was redirected to the nucleus, which would have minimized the adjuvant effect of HSV-1
gD. However, if this were the case, then the magnitude of rhEBNA1-specific T cells would have
increased after vaccination with rhEBNA1 (-M) and gD-rhEBNA1 (-M) vaccines.
We confirmed the immunogenicity of our rhEBNA1-expressing vaccines by an in vitro
assay in which rhesus macaque DCs were co-cultured with autologous peptide-induced
+

rhEBNA1-specific CD8 T cells. Vaccines stimulated IFN-γ production, which demonstrates their
ability to induce transgene product-specific T cell responses. These experiments do not exhibit a
clear adjuvant effect of HSV-1 gD, which could be due to the high level of rhEBNA1 expression
(compared to gD-rhEBNA1) as detected by western blots.

A dose titration would have been

useful for testing the difference between AdC-rhEBNA1 and AdC-gD-rhEBNA1 vectors and also
for confirming the adjuvant effect of HSV-1 gD. Nevertheless, these experiments confirm vector
immunogenicity and specificity, which was necessary in order to begin testing in rhesus
macaques.
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CHAPTER 4:

ADENOVIRUS-BASED VACCINES TO RHESUS
LYMPHOCRYPTOVIRUS EBNA1 INDUCE EXPANSION OF
CD8+ AND CD4+ T CELLS IN PERSISTENTLY INFECTED
RHESUS MACAQUES

ABSTRACT
Latent EBNA1 is a promising target for a therapeutic vaccine, as it is the only antigen
expressed in all EBV-associated malignancies. We have designed and tested two therapeutic
EBV vaccines that target the rhesus LCV EBNA1 to determine if ongoing T cell responses during
persistent rhLCV infection in rhesus macaques can be expanded upon vaccination. Vaccines
were based on two serotypes of E1-deleted simian adenovirus and were administered in a primeboost regimen. We found that vaccines expressing rhEBNA1 induced expansion of rhEBNA1+

+

specific CD8 and CD4 T cells in 33% and 83% of the vaccinated animals, respectively.
Additional animals developed significant changes within T cell subsets without changes in total
numbers. Vaccination did not increase T cell responses to rhBZLF1, an immediate early lytic
phase antigen of rhLCV, thus indicating that increases of rhEBNA1-specific responses were a
direct result of vaccination. Vaccine-induced rhEBNA1-specific T cells were highly functional and
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produced various combinations of cytokines as well as the cytolytic molecule granzyme B. These
results serve as an important proof-of-principle that functional EBNA1-specific T cells can be
expanded by vaccination.

Portions of this chapter were adapted from:
Leskowitz R, Fogg MH, Zhou XY, Kaur A, Silveira ELV, Villinger F, Lieberman PM, Wang F, and Ertl HC.
+
Adenovirus-based vaccines to rhesus lymphocryptovirus EBNA1 induce expansion of specific CD8 and
+
CD4 T cells in persistently infected rhesus macaques. Journal of Virology 2014; 88(9): 4721-4735.
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INTRODUCTION
EBV is a common human pathogen that establishes a persistent infection through latency
in B cells, where it occasionally reactivates. EBV infection is typically benign and is well controlled
by the host adaptive immune system; however, it is considered carcinogenic due to its strong
association with lymphoid and epithelial cell malignancies.

The EBV protein EBNA1 is a

promising target for a therapeutic vaccine, as it is the only antigen expressed in all types of
latency and in EBV-associated malignancies.
We designed and tested vaccines that target the rhLCV EBNA1 (described in detail in
Chapter 3). Rhesus macaques are naturally infected with rhLCV, a gamma-1 herpesvirus that is
closely related to EBV

191, 256

. Most rhesus macaques become infected during infancy, and rhLCV

persists for life in a latent form in B cells. Like EBV, rhLCV has been associated with viruspositive B cell lymphomas upon immunosuppression

191

. EBV and rhLCV share a high degree of

sequence homology, they have identical repertoires of lytic and latent genes
similar immune responses

257

189

, and they elicit

. We characterized rhEBNA1-specific T cell responses in a cohort of
+

seropositive rhesus macaques and found that most animals have rhEBNA1-specific CD4 and
+

CD8 T cells that resemble human T cell responses in many aspects (Chapter 2). The rhLCV
model is therefore ideal for preclinical testing of EBV vaccines.
The goal of this study was to test if prototype vaccines expressing rhEBNA1 could
+

+

expand ongoing rhEBNA1-specific CD8 and CD4 T cell responses in adult rhesus macaques
with persistent rhLCV infections. We developed and tested two vaccine regimens based on
replication-defective adenovirus (Ad) vectors derived from chimpanzee serotypes (AdC).
Vaccines expressed a GAr-deleted form of rhEBNA1. To further modulate the response,
rhEBNA1 was fused to herpes simplex virus glycoprotein D (gD), which binds the herpes virus
entry mediator (HVEM) and blocks its interaction with the immunoinhibitory B and T lymphocyte
attenuator (BTLA) during T cell activation. HVEM-binding and -non-binding versions of HSV-gD
+

were tested. Vaccination increased the number of circulating rhEBNA1-specific CD8 and CD4

+

T cells in rhesus macaques with persistent rhLCV infections regardless of gD binding ability.
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Responses were highly functional, and T cells produced various combinations of the cytokines
IFN-γ, IL-2, and TNF-α. T cells also produced granzyme B, which indicates that vaccination
increased the cytolytic potential of rhEBNA1-specific T cells. These preliminary studies confirm
that rhEBNA1 is a suitable target for therapeutic rhLCV and presumably EBV vaccines.
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RESULTS
Characteristics of NHPs
Fifteen female adult, healthy, and SIV-uninfected rhesus macaques aged 6 to 20 years
were enrolled in this study at the Yerkes National Primate Research Center (YNPRC). Animals
were negative for neutralizing antibodies to AdC68 and AdC6 and positive for antibodies to
rhLCV. Table 4-3 shows the basic characteristics of animals enrolled in this study.
	
  
Vaccination increases the frequency of rhEBNA1-specific T cell responses
To test if our vaccines could induce or expand rhEBNA1-specific T cell responses in vivo,
animals were injected i.m. with 10

11

vp of AdC68 vectors expressing SgD-rhEBNA1 (group 1, n =

6), NBEFSgD-rhEBNA1 (group 2, n = 6), or gD-NP (group 3, n = 3). They were boosted 15 weeks
later with the same doses of AdC6 vectors expressing the same inserts. Vaccines are described
in detail in the previous chapter. Responses were measured from blood collected two months
prior to and on the day of vaccination to determine baseline responses and at 2, 4, and 8 weeks
after priming and 2, 4, and 6 weeks after boosting (weeks 17, 19, and 21) to test for vaccineinduced changes (Figure 4-1). RhEBNA1-specific CD8
measured by ICS for IFN-γ, IL-2, and TNF-α

198

+

and CD4

+

T cell responses were

. We also analyzed the effects of vaccination on T

cell subsets, i.e., effector (TEFF), effector memory (TEM) and central memory (TCM) cells identified
by additional stains for CD95, CD28, and CCR7. Results obtained by ICS were normalized to
6

+

numbers of responding cells per 10 live CD3 cells, and background data were subtracted. We
used two criteria to define vaccine-induced increases of rhLCV-specific T cell responses. First,
average normalized numbers of specific T cells from 5 rhLCV seronegative animals were used to
determine the detection limit of the assay; numbers of total cytokine-producing T cells (after
background subtraction) had to be two standard deviations (SDs) above this limit. Second,
animals were classified as vaccine responders if rhEBNA1-specific cytokine responses increased
2 SDs or more above mean baseline responses for at least 3 time points after vaccination.
Animals that met these criteria only within T cell subsets were also viewed as responders, as the
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additional stains used to identify TEFF, TEM, and TCM cells increase staining sensitivity by reducing
+

background noise. Details on individual immune responses can be found in Table 4-1 (CD8 T
+

cell responses) and Table 4-2 (CD4 T cell responses).
Based on these criteria, 50% (6/12) of the animals were identified as vaccine responders
+

for rhEBNA1-specific CD8 T cells, and 92% (11/12) were vaccine responders for rhEBNA1+

specific CD4 T cells (summarized in Table 4-3; primary data are provided in Table 4-1 and
Table 4-2). The one vaccine non-responder was from group 1. Increases in rhEBNA1-specific T
cell responses were driven by the rhEBNA1 vaccines, as none of the group 3 animals who
received the control vectors qualified as vaccine responders. Additionally, none of the animals
qualified as responders when T cells were tested against an irrelevant rhLCV antigen, i.e., no
animals in any group developed sustained T cell increases against rhBZLF1, a highly
immunogenic immediate-early antigen of rhLCV (Table 4-1 and Table 4-2).
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Figure 4-1: Schedule of vaccinations and blood collection

AdC68
vaccines
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Figure 4-1 shows the vaccination (black arrows) and blood collection (red arrows) schedule.
Numbers along the axis display the timing in weeks after the first vaccination (at week 0).
Baseline responses for each animal reflect the average between week 0 and 2 months prior to
vaccination. BL, baseline; mos, months.
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+

6

+

Table 4-1: RhEBNA1-specific (top) and rhBZLF1-specific (bottom) CD8+ T cell responses are shown at all pre- and post-vaccination time points. Responses are normalized to 106 live
CD3+ T cells after subtraction of background data for individual animals. −, values below the detection limit (based on rhLCV-seronegative rhesus macaques); data for time points at which
the parental CD8+ T cell response was below the detection limit are not shown in the table (and were also omitted from the graphs). Peptide-specific vaccine responses greater than 2SDs
from the mean baseline are highlighted in grey. BL, baseline; NT, not tested; NHP, non-human primate; ID, identification number. 	
  

Table 4-1: Number of CD8 T cells/10 live CD3 cells 	
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+

6

+

Table 4-2: RhEBNA1-specific (top) and rhBZLF1-specific (bottom) CD4+ T cell responses are shown at all pre- and post-vaccination time points. Responses are normalized to 106 live CD3+
T cells after subtraction of background data for individual animals. −, values below the detection limit (based on rhLCV-seronegative rhesus macaques); data for time points at which the
parental CD4+ T cell response was below the detection limit are not shown in the table (and were also omitted from the graphs). Peptide-specific vaccine responses greater than 2SDs from
the mean baseline are highlighted in grey. BL, baseline; NT, not tested; NHP, non-human primate; ID, identification number. 	
  

Table 4-2: Number of CD4 T cells/10 live CD3 cells 	
  

Table 4-3: Characteristics and responsiveness of rhesus macaques enrolled in this study

Group

Group 1:
SgD-rhEBNA1

Group 2:
NBEFSgD-rhEBNA1

Group 3:
gD-NP

NHP ID

Age (yr)

MHC alleles

RYa6

12

PH1019

10

RTn5

15

RQt5

13

RRi9

7

RLy9

6

A.04, A.25
B.01, B.17
A.08, A.18b
B.17, B.83
A.01, A.08
B.12b, B.47
A.04, A.12
B.43a
A.03, A.04
B.01, B.12b
A.04
B.28b, B.47

RNw9

6

RZi7

9

RVw6

10

RTp4

15

PWw

13

RCv5

13

RYc3

19

RCj7

9

RLz5

12

Response to
vaccination
+
+
CD8
CD4
R
R
R

R

NR

R

NR

R

NR

R

NR

NR

A.04, A.08
B.12b, B.15a
A.01, A.07/19
B.17, B.55, B.69a
A.01, A.08
B.01, B.02
A.04
B.12b, B.28b
A.02, A.08
B.12b, B.28b
A.04
B.02, B.12b

R

R

R

R

R

R

R

R

NR

R

NR

R

A.01, A.03
B.12b, B.47
A.07, A.224
B.15a, B.23
A.04
B.12b, B.69a

NR

NR

NR

NR

NR

NR

Abbreviations: NHP, non-human primate; ID, identification number; MHC, major histocompatibility complex;
R, responders; NR, non-responders.
.
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+

Magnitude and differentiation status of rhLCV-specific CD8 T cells after vaccination
+

Numbers of rhEBNA1-specific CD8 T cells increased after vaccination. Increases were
+

most pronounced and sustained within the CD8 TEM cell subset, while numbers of rhEBNA1+

+

specific CD8 TCM and CD8 TEFF cells increased only transiently (Figure 4-2A). Increases of
rhEBNA1-specific T cells as measured by area under the curve (AUC) were significantly larger
+

than the corresponding rhBZLF1-specific responses for overall CD8 T (P = 0.048 by Mann+

Whitney) and CD8 TEM (P = 0.039) cells (Figure 4-2B). Increases of rhEBNA1-specific T cells
were also significantly larger than those of controls (for overall and TEM cells, P = 0.048, 0.024,
+

respectively). For all vaccine responders, rhEBNA1-specific CD8 T cells increased about 4-fold
from baseline, with an average increase of 474 total T cells and 277 TEM cells (6.5-fold change)
per 10

6

live CD3

+

cells after vaccination. Corresponding rhBZLF1-specific responses and

rhEBNA1-specific responses within the control group remained stable or contracted, which
+

indicates that increases in rhEBNA1-specific CD8 T cells were a result of vaccination.
There were no significant differences in rhEBNA1-specific CD8

+

T cell responses

+

between groups 1 and 2. However, the number of rhEBNA1-specific CD8 TEM cell responses of
group 1, but not group 2, increased significantly more after vaccination than the corresponding
rhBZLF1 responses (P = 0.0081) or rhEBNA1 responses of control animals (P = 0.012).
The selective increases of rhEBNA1-specific CD8

+

TEM cells caused shifts in the

+

proportions of the three CD8 T cell subsets (Figure 4-3A), while the proportions of rhBZLF1specific subsets did not change following vaccination (not shown). At baseline, most rhEBNA1+

specific CD8 responses were TCM or TEFF cells. After vaccination, the proportion of rhEBNA1+

specific CD8 TEM cells increased to nearly double the proportion at baseline for every time point
(Figure 4-3A, white bars). This shift, which clearly indicates that vaccination preferentially
+

induced or expanded CD8 TEM cells, became significant by week 8 (P = 0.035).
+

Magnitude and differentiation status of rhLCV-specific CD4 T cells after vaccination
+

RhEBNA1-specific CD4 T cell responses increased after vaccination. These increases
+

+

were pronounced within both CD4 TCM and TEM cell subsets, while CD4 effector responses
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remained stable (Figure 4-4A). Increases of rhEBNA1-specific T cells as measured by AUC
+

were significantly larger than the corresponding rhBZLF1-specific responses for overall CD4 T (P
+

+

= 0.0003), CD4 TCM (P = 0.0019), and CD4 TEM (P = 0.02) cells (Figure 4-4B). Increases of
rhEBNA1-specific T cells were also significantly larger than the same responses among animals
that received the control vaccine (for overall and TCM cells, P = 0.02, 0.039, respectively).
+

Numbers of rhEBNA1-specific CD4 T cells increased about 3-fold from baseline, with an average
increase of 424 total T cells, 212 TCM cells, and 191 TEM cells per 10

6

live CD3

+

cells.

Corresponding rhBZLF1-specific responses and rhEBNA1-specific responses within the control
group remained stable or contracted, therefore indicating that increases in rhEBNA1-specific
+

CD4 T cells were a result of vaccination.
+

RhEBNA1-specific overall CD4 T cell responses were significantly larger for group 2
responders than for group 1 (P = 0.0173, AUC, by the Mann-Whitney test); however, subset
responses between the same groups were not significantly different. The number of rhEBNA1specific T cells within group 2 but not group 1 also increased significantly more after vaccination
than corresponding rhBZLF1 responses (for overall, TCM, and TEM cells, P = 0.002, 0.0009, 0.021,
respectively) or rhEBNA1 responses of control animals (for overall, TCM, and TEM cells, P = 0.024,
0.047, 0.038, respectively). This may suggest that vaccines expressing rhEBNA1 with a non+

HVEM-binding version of gD induced more potent CD4 T cell responses than did the SgDrhEBNA1 vaccines.
The distribution of rhEBNA1-specific CD4

+

TCM and TEM cell subsets shifted after
+

vaccination (Figure 4-3B), while rhBZLF1-specific CD4 T cell subsets remained stable (not
shown). The shift in rhEBNA1-specific subset proportions, which was significant at week 2 (P =
+

0.045), was caused by pronounced increases of CD4 TEM cells, which resulted in a relative
+

reduction in the percentage of CD4 TCM cells.
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+

Figure 4-2: Magnitude of peptide-specific CD8 T cell responses upon vaccination

Figure 4-2: PBMCs were stimulated with specific peptide pools and ICS was used to measure production of
IFN-γ, IL-2, and TNF-α. Mean counts of rhEBNA1-specific (A) and rhBZLF1-specific (B) total cytokine+
producing CD8 T cells ± SD are plotted as a change from baseline (BL) for all vaccine responders of
groups 1 (X, black line) and 2 (, grey line) and all animals of group 3 (+, dashed line). Peptide-specific
+
CD8 T cell responses are shown for overall, TCM, TEM, and TEFF subsets (left to right). Raw data were used
to calculate changes from baseline, and any values below the limit of detection were excluded from the
6
+
calculation of the mean. All values are presented as numbers of responding cells per 10 live CD3 cells.
To calculate the sum of the peptide-specific response, we subtracted normalized background activity and
then summed the 7 possible different combinations of functions. Significant differences were determined by
comparing areas under the curve (AUC) and are as follows. For rhEBNA1 versus rhBZLF1 for all vaccine
+
responders, CD8 overall, P = 0.048, and TEM, P = 0.039. For rhEBNA1 for all vaccine responders versus
+
+
controls, CD8 overall, P = 0.048; TEM, P = 0.024. RhEBNA1 CD8 TEM responses were also significant for
vaccine responders within group 1 (rhEBNA1 versus rhBZLF1, P = 0.0081; rhEBNA1 responders versus
controls, P = 0.012). P values were calculated using two-sided Mann-Whitney tests (all responders grouped)
or ANOVA (comparisons between all three groups), with a P value of <0.05 considered significant.
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+

+

Figure 4-3: Proportions of peptide-specific CD8 and CD4 T cell subsets upon vaccination
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Figure 4-3: The proportions of rhEBNA1-specific CD8 (A) and CD4 (B) TEFF (dark gray), TCM (light gray),
and TEM (white) subsets are shown as a percentage of the total response at baseline and weeks 2, 8, and 17
after vaccination. For each subset, normalized counts were divided by the sum of all three subsets to
determine the relative proportions. Results for individual animals are shown as filled circles, and responses
th
th
for all vaccine responders are displayed as floating bars (5 to 95 percentiles) with lines at the median.
Significant differences were determined by comparing the percentage of a given subset after vaccination to
+
+
the percentage at baseline and are as follows: rhEBNA1-specific CD8 TEM and CD4 TEM cells at week 2, P
= 0.035 and 0.045, respectively. P values were calculated using the two-sided Mann-Whitney test, with a P
value of <0.05 considered significant.
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+

Figure 4-4: Magnitude of peptide-specific CD4 T cell responses upon vaccination

+

Figure 4-4: Mean counts of rhEBNA1-specific (A) and rhBZLF1-specific (B) total cytokine-producing CD4 T
cells ± SD are plotted as a change from baseline (BL). This figure is organized in the same fashion as
Figure 4-2. Significant differences are as follows. For rhEBNA1 versus rhBZLF1 for all vaccine responders,
+
CD4 overall, P = 0.0003; TCM, P = 0.0019; TEM, P = 0.02. For rhEBNA1 for all vaccine responders versus
+
controls, CD4 overall, P = 0.02; TCM, P = 0.039. RhEBNA1 responses were also significant for vaccine
+
responders within group 2 (for group 2 versus group 1, CD4 overall, P = 0.0173; for group 2 rhEBNA1
+
versus group 2 rhBZLF1, CD4 overall, P = 0.002; TCM, P = 0.0009; TEM, P = 0.021; for group 2 rhEBNA1
+
versus control rhEBNA1, CD4 overall, P = 0.024; TCM, P = 0.047; TEM, P = 0.038). Responses of rhEBNA1
+
+
+
CD4 TEFF cells were significantly lower than those of both CD4 TCM (P = 0.0058) and CD4 TEM (P = 0.019)
cells. P values were calculated using two-sided Mann-Whitney tests (all responders grouped) or ANOVA
(comparisons between all three groups), with a P value of <0.05 considered significant.
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Cytokine profile of rhLCV-specific T cells after vaccination
We assessed T cell functions after vaccination using Boolean gating to analyze seven
possible different combinations of IFN-γ, IL-2, and TNF-α production

257

.

Cytokine profiles

following vaccination were analyzed at weeks 2 and 8 after priming and at week 2 after the boost.
+

Vaccination caused transient shifts in the cytokine profile of rhEBNA1-specific CD8 T
+

cells (Figure 4-5A). At baseline, most rhEBNA1-specific CD8 T cells produced IFN-γ (light blue;
EFF, 65%; CM, 25%; EM, 36%) or IL-2 alone (pink; EFF, 26%; CM, 34%; EM, 22%). The
+

percentage of CD8 TCM and TEM cells producing IFN-γ increased significantly by 2 weeks after
priming (week 2; CM, 56%, P = 0.0006; EM, 71%, P = 0.0006) and 2 weeks after boosting (week
+

17; CM, 59%, P = 0.0005; EM, 71%, P = 0.0018). The average percentage of CD8 TCM cells
producing IL-2 alone, a cytokine generally associated with more resting T cells, significantly
decreased at weeks 2 (11%, P = 0.011), 8 (10%, P = 0.0049), and 17 (11%, P = 0.02) after
+

+

vaccination. In addition, there was a transient increase in the percentage of IFN-γ IL-2 CD8

+

TCM cells at week 8 (BL, 12%; week 8, 45%; P = 0.012). As a result, the proportion of
+

polyfunctional CD8 TCM responses increased at week 8. The proportion of cells producing single+

, double-, and triple- cytokine responses did not change at any time point for CD8 TEFF or TEM
cells. Overall, these results confirm that AdC vectors preferentially expanded rhEBNA1-specific T
cell responses that produced IFN-γ, a cytokine with potent anti-viral activity.
+

As expected, the cytokine profile of rhBZLF1-specific CD8 T cells did not markedly
+

change after vaccination. Most rhBZLF1-specific CD8 T cells produced IFN-γ alone (light blue;
EFF, 54%; CM, 47%; EM, 51%) or in combination with IL-2 (yellow; EFF, 11%; CM, 20%; EM,
20%) at baseline and at weeks 2, 8, and 17 after vaccination (Figure 4-5B). The only significant
+

+

change was a decrease in the percentage of IFN-γ CD8 TEM cells at week 8 (26%, P = 0.017)
and therefore a transient decrease in the proportion of single-cytokine-producing cells. This shift
was most likely caused by decreases in the magnitude of rhBZLF1 responses after vaccination.
+

Vaccination increased the absolute numbers of polyfunctional rhEBNA1-specific CD4 T
cells without changing the cytokine pattern.

RhEBNA1-specific CD4

+

T cells were highly

polyfunctional at baseline and at weeks 2, 8, and 17 after vaccination (Figure 4-5C). At each of
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these time points, large proportions of cells produced two or three cytokines (baseline CM, 44%;
EM, 49%) as well as IFN-γ (CM, 19%; EM, 28%) and IL-2 alone (CM, 25%; EM, 8%). The only
+

+

significant change after vaccination was an increase in the proportion of IFN-γ CD4 TEM cells at
week 17 (50%, P = 0.037), however, the ratio of triple, double, and single responses did not
+

change. Thus, vaccine-induced CD4 T cell responses remained highly polyfunctional.
+

Subtle changes in the cytokine profile of rhBZLF1-specific CD4 T cells over time indicate
+

that these cells may have shifted toward a response closer to resting memory. CD8 TCM cells
produced mostly IL-2 (pink, 47%) or TNF-α (purple, 18%) at baseline and at weeks 2, 8, and 17
+

+

after vaccination (Figure 4-5D). However, the proportion of IL-2 CD8 TCM cells increased
significantly at week 17 (73%) compared to all other time points before and after vaccination
(versus baseline, P = 0.0047; versus week 2, P < 0.0001; versus week 8, P = 0.0004).
+

Additionally, the large proportion of CD8 TEM cells that produced IFN-γ at baseline (30%) and at
week 2 after vaccination (27%) decreased significantly by week 8 (8%, P = 0.0013). IFN-γ is
typically associated with cells that are fully activated, and therefore such decreases further
+

support the notion that rhBZLF1 CD4 T cells were transitioning toward a response closer to
resting memory.
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Figure 4-5: Cytokine profiles of rhLCV-specific T cells upon vaccination

+

+

Figure 4-5: Pies represent the average percentage of CD8 and CD4 T cells making each combination of
IFN-γ (g), IL-2 (2), and TNF-α (a) following stimulation with specific peptides. RhEBNA1-specific (A) and
+
rhBZLF1-specific (B) CD8 TEFF, TCM, and TEM responses are shown at baseline and at weeks 2, 8, and 17
+
after vaccination. The same time points are shown for rhEBNA1-specific (C) and rhBZLF1-specific (D) CD4
+
TCM, and TEM responses. Numbers of peptide-specific CD4 TEFF responses were all very low and are
therefore not shown. For all responding animals, normalized cell counts were calculated for each function
within every subset. Values for each of the seven possible combinations of functions were then divided by
the sum of all seven, and pie charts reflect the ratio of those means. Changes in the size of the pie charts
reflect proportional changes in the magnitude of total cytokine responses relative to baseline. Significant
differences are described in the results section.
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Vaccination expands rhEBNA1-specific T cells with cytolytic potential
Target cell lysis is one of the most crucial T cell functions involved in clearing virusinfected cells. While cytokine production provides information on the T cells’ functional capacity, it
does not directly assess their ability to lyse target cells. We therefore measured production of
granzyme B, a lytic enzyme that promotes target cell apoptosis. Granzyme B was measured in
+

+

CD8 and CD4 T cells for all of the vaccine responders and two animals from the control group
using the same methods as those described above. Because granzyme B is stored in cytolytic
granules regardless of activation status, peptide-specific responses were considered positive only
if granzyme B was produced in combination with one or more cytokines.
+

We found that vaccine-induced rhEBNA1-specific CD8 T cells produced granzyme B.
+

+

Although the proportion of granzyme B CD8 memory T cells was largest at baseline (Figure 46A), absolute numbers of granzyme B-producing CD8

+

T cells tended to increase after

vaccination. At baseline, most cells produced granzyme B together with TNF-α (purple). After
vaccination, there was an increase in the number of cells producing granzyme B with IFN-γ (light
blue) (week 2, P < 0.0001; week 17/19, P = 0.05) and a decrease in the number of cells
producing granzyme B with TNF-α (week 8, P = 0.05; week 17/19, P = 0.046). There was also a
transient increase in the number of cells producing all four functions (red), which reached
significance at week 8 (P = 0.048).

Granzyme B-negative responses after vaccination were

composed largely of IFN-γ alone, followed by IFN-γ with IL-2 (not shown). In contrast, numbers
+

of rhBZLF1-specific memory CD8 T cells producing granzyme B tended to decrease after
vaccination (Figure 4-6B). At baseline, the most common cytokines produced with granzyme B
+

+

were TNF-α followed by IFN-γ. Numbers of granzyme B TNF-α T cells decreased significantly
from baseline at week 2 (P = 0.0003), week 8 (P = 0.0021), and week 17/19 (P = 0.0003). As a
+

result, the proportion of rhBZLF1-specific granzyme B responses decreased significantly at
weeks 8 (P = 0.04) and 17/19 (P = 0.003). Granzyme B-negative responses before and after
vaccination were composed largely of IFN-γ alone, followed by relatively equal proportions of T
cells that produced all remaining cytokine combinations except IL-2 with TNF-α; none of which
changed after vaccination (not shown).
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+

+

As expected, the majority of granzyme B rhEBNA1-specific CD8 T cells were low in
+

CCR7, a homing marker for lymphatic tissues, as is typical for CD8 TEM cells (Figure 4-7).
Expression of CCR7 on granzyme B

+

rhEBNA1-specific CD8

+

+

T cells was compared to

+

+

expression of CCR7 on effector CD8 T cells, memory CD8 T cells, and naïve CD8 T cells. As
+

expected, CCR7 expression on effector CD8 T cells (orange) was similar to that on granzyme B

+

+

rhEBNA1-specific CD8 T cells, both of which were reduced in comparison to CCR7 expression
+

+

on CD8 memory (blue) and CD8 naïve (green) T cells.
There were no significant changes in rhEBNA1-specific or rhBZLF1-specific CD8

+

effector T cell responses after vaccination. RhEBNA1-specific effector T cell responses were all
+

+

+

+

low, and granzyme B TNF-α as well as granzyme B IL-2 were detected most frequently
(Figure 4-6C).

+

The rhBZLF1-specific CD8 T cell responses detected most frequently with

granzyme B were TNF-α or IFN-γ (Figure 4-6D). RhBZLF1-specific granzyme B-negative T cell
responses were composed largely of IFN-γ alone, and the magnitude of this response decreased
at every time point after vaccination (not shown).
Vaccination induced a sustained increase in numbers of rhEBNA1-specific memory
+

CD4 T cells that produced granzyme B—mostly with TNF-α and/or IFN-γ (Figure 4-6E). The
+

+

+

+

+

+

numbers of granzyme B IFN-γ and granzyme B IFN-γ TNF-α memory CD4 T cells increased
more than 6 and 10 times from baseline, respectively. Responses were significantly larger than
+ +

+ + +

+ + +

baseline by 2 weeks (B γ , P = 0.0025), 8 weeks (B γ α , P = 0.0042), and 17/19 weeks (B γ α ,
P = 0.031) after vaccination. Despite these changes, the average proportion of granzyme B

+

responses did not significantly change from baseline, where more than one-quarter of specific
+

CD4 memory T cells produced granzyme B in combination with other factors. Granzyme Bnegative responses were also highly polyfunctional, and there were significant increases in the
+

magnitude of cells producing various cytokine combinations compared to baseline (week 2, γ ;
+ + +

+ +

+

+

week 8, γ 2 α , γ α , γ ; week 17/19, α ; P < 0.05) (not shown). In contrast, total numbers of
granzyme B

+

rhBZLF1-specific memory CD4

+

T cells did not change following vaccination

(Figure 4-6F). At baseline, the most common cytokines produced with granzyme B were TNF-α
+

or IL-2, and there was a significant decrease in the number of rhBZLF1-specific memory CD4 T
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cells that produced granzyme B with TNF-α at week 8 (P = 0.0096) and week 17/19 (P = 0.0089).
+

Most granzyme B-negative CD4 T cell responses were composed of either IFN-γ alone or IL-2
alone, and the number of cells producing IL-2 alone increased significantly at week 17/19 (P =
+

+

+

0.0001, data not shown). This decrease in rhBZLF1-specific granzyme B TNF-α CD4 T cells
+

+

and increase in rhBZLF1-specific IL-2 CD4 T cells further indicates differentiation towards a
more resting phenotype. RhLCV-specific cytolytic T cells are crucial for controlling the outgrowth
of virus-infected cells

258, 259

, and we have shown that rhEBNA1-specific T cells expanded through

vaccination produce the cytolytic molecule granzyme B.
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Figure 4-6: Granzyme B production by rhLCV-specific T cells
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Figure 4-6: Vaccine responders were evaluated for granzyme B-producing T cells. PBMCs were stimulated
with overlapping peptide pools, and ICS was used to measure production of granzyme B (denoted B), IFN-γ
+
(g), IL-2 (2), and TNF-α (a). Bars reflect the average magnitudes of granzyme B T cells producing each
+
combination of cytokines after stimulation with specific peptides. RhEBNA1-specific CD8 memory (A) and
+
effector (C) cell responses as well as rhBZLF1-specific CD8 memory (B) and effector (D) cell responses
+
+
are shown. RhEBNA1-specific CD4 memory (E) and rhBZLF1-specific CD4 memory (F) cell responses
(Continued on page 118)
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Figure 4-7: Expression of CCR7 before and after vaccination

+

Figure 4-7: CCR7 expression by rhEBNA1-specific memory CD8 T
cells that produce granzyme B with all combinations of cytokines (red) is
shown in comparison to total non-specific memory (blue), naïve (green),
and effector (orange) populations. Responses are shown at baseline
and week 8 for one representative vaccine responder. Responses at
weeks 2 and 17/19 were the same as week 8 and are therefore not
shown. Significant differences are described in the results section.

(Continued from page 117)
are also shown. The total sums of all peptide-specific cytokine responses at each time point are listed
above the bars. Total values reflect the sum of every combination of the four functions tested; cells that
produced only granzyme B were excluded. Responses are shown at baseline (BL) and at weeks 2, 8, and
17/19 after vaccination. All responses were normalized and background values were subtracted. Significant
differences are described in the results section.
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DISCUSSION
The development of a vaccine to prevent EBV infection or treat EBV-associated diseases
is of high priority

104

, but therapeutic vaccines that aim to expand ongoing immune responses to

persisting viruses like EBV face a unique set of challenges. Neutralizing antibodies are generally
ill suited to clear cells that have already been infected, and T cells may be difficult to expand if
recurrent antigen exposure by viral reactivations has caused terminal differentiation and
functional T cell impairments

260

. EBNA1 is an important target for immune responses that aim to

reduce EBV reservoirs in latently infected cells because it is the only antigen synthesized during
all stages of latency and in all EBV-associated malignancies. Despite its importance, the ability to
boost rhEBNA1-specific T cell responses in rhesus macaques has never been tested. In this
proof-of-concept study, we are the first to report that ongoing rhEBNA1-specific T cell responses
during persistent rhLCV infection in rhesus macaques can be expanded upon vaccination.
We tested two prime-boost vaccine regimens based on replication-defective AdC vectors
that express rhEBNA1. Vaccines expressed a GAr-deleted form of rhEBNA1 fused to HSV-gD to
potentially further promote T cell recall responses. The N-terminus of HSV-gD binds to the
bimodal HVEM

249

T cell activation

250

and prevents inhibitory molecules like BTLA from binding and signaling during
. To control for this effect, an HVEM-non-binding version of HSV-gD was also

tested. Animals were distributed as evenly as possible between vaccine groups based on age,
Mamu phenotype, and rhLCV-specific T cell responses. Because T cells to persisting viruses
tend to fluctuate in response to reactivations, we enumerated and characterized rhEBNA1- and
rhBZLF1-specific T cell responses at two time points prior to vaccination

257

and set stringent

criteria to assess if vaccination expanded rhEBNA1-specific T cells. We found that vaccination
+

+

increased numbers of circulating rhEBNA1-specific CD8 and CD4 T cells regardless of gD
binding ability and that booster immunization was relatively ineffective. Vaccination augmented
+

+

+

mainly CD8 TEM, CD4 TCM, and CD4 TEM cells. Responses were highly functional, and T cells
produced various combinations of the cytokines IFN-γ, IL-2, and TNF-α and the cytolytic molecule

	
  

119

granzyme B. Furthermore, responses were vaccine-specific, as T cell responses to the lytic
antigen rhBZLF1 did not increase following vaccination.
+

+

The ability to increase both CD8 and CD4 T cell responses through vaccination was an
+

+

important finding of this study. While CD8 T cells can eliminate virus-infected cells, CD4 T cells
+

can also target virus that persists in MHC class II cells. RhLCV-infected B cells and also some
261

EBV-associated malignancies express both MHC class I and II
+

CD4 T cells are both capable of lysing target cells in vitro

199, 209

+

, and EBNA1-specific CD8 and

. Vaccination expanded specific

+

CD8 T cell responses in 2/6 animals from group 1 and 4/6 animals from group 2. Two of the
vaccine responders from group 2 (RVw6, RTp4) developed significant changes within T cell
subsets (EM and CM, respectively) without changes in total numbers. This indicates a vaccinespecific effect on the phenotype of rhEBNA1-specific T cells. One animal (RZi7) developed a
response after vaccination that was not detected at baseline, which indicates that vaccination
may have induced new responses, although it is also possible that vaccination increased the
magnitude of ongoing responses from below to above our limit of detection in this animal.
Interestingly, the Mamu genotype may have influenced responsiveness, as all three of the Mamu
+

+

B*17 animals developed vaccine-specific CD8 T cell responses. In comparison, a larger number
+

of animals (11/12) developed specific CD4 T cell responses to vaccination, including all three
+

that did not have detectable rhEBNA1-specific CD4 T cells at baseline. About one-half of the
vaccine responders from each group (group 1, 3/5; group 2, 3/6) developed significant changes
within T cell subsets without changes in total numbers.
+

It is perhaps not surprising that

+

+

vaccination stimulated more CD4 versus CD8 T cell responses, as EBNA1-specific CD4 T cell
epitopes are more immunodominant in both humans

1, 67

and in rhesus macaques

257

.

RhLCV-specific cytolytic T cells are crucial for controlling the outgrowth of virus-infected
cells

93, 258, 259

specificity

, and utilization of the perforin/granzyme pathway is largely dependent on T cell

262, 263

+

. Importantly, we found that numbers of rhEBNA1-specific CD8 T cells producing

granzyme B increased after vaccination.

We also found large and sustained increases in

+

numbers of granzyme B-producing CD4 T cells. By just 2 weeks after vaccination, numbers of
+

+

specific CD8 and CD4 T cells producing granzyme B had increased about 3 times over baseline

	
  

120

levels. Most granzyme B was produced in combination with IFN-γ and/or TNF-α, which is typical
for cytolytic TEFF/TEM cells. While in vitro killing assays would have provided the most direct
functional analysis, granzyme B expression by flow cytometry serves as a surrogate assay that
provides a more quantitative assessment of numbers of potentially lytic cells.
+

Our findings

+

suggest that both CD8 and CD4 rhEBNA1-specific T cells may participate in the elimination of
rhLCV-infected cells.
+

It is also interesting that numbers of granzyme B rhBZLF1-specific T cells decreased
+

+

after vaccination. Within the same population, numbers of TNF-α cells decreased and IL-2 cells
increased. Together, this indicates that rhBZLF1-specific T cells were differentiating towards a
more resting phenotype. Such differentiation could reflect a vaccine-induced reduction in rhLCV
reactivation events. It would have been of interest to measure rhLCV loads before and after
vaccination, as this would have provided the most direct evidence of vaccine efficacy or lack
5

6

thereof. Only 1 in 10 to 10 peripheral B cells carries EBV in healthy subjects

264, 265

. Because

the viral genome is present at such low levels, it is difficult to detect viral load fluctuations in live
animal studies, in which peripheral blood samples are limited.
We were intrigued to find that differences in immune responses between animals
vaccinated with either rhEBNA1 vaccine regimen were too subtle to clearly demonstrate an effect
of HSV-gD. This is because we have previously shown that expression of antigen within HSV-gD
+

augments primary antigen-specific CD8 T cell responses in mice, and such responses were
larger than with antigen alone or when expressed within a non-binding HSV-gD

247

. This study

was the first to test the same approach for the expansion of ongoing T cell responses during a
persistent viral infection in rhesus macaques. While differences in T cell responses to rhEBNA1
expressed within the binding (group 1) or non-binding (group 2) version of gD were not
significant, it is interesting that only animals who received the vaccine with binding gD developed
+

increased CD8 TEM cell responses that were significantly larger than corresponding rhBZLF1
responses as well as rhEBNA1-specific responses of control animals. The opposite was found
+

for CD4 responses, whereby only animals that received the non-binding version of gD developed
significant increases in TCM and TEM cell responses.
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To determine if additional factors influenced whether or not an animal responded to
vaccination, we compared baseline immune responses between responders and non-responders.
+

+

Total numbers of rhEBNA1-specific CD8 or CD4 T cells were largely comparable at baseline
(data not shown), so it is unlikely that differences in pre-vaccination T cell responses influenced
whether or not an animal responded. In terms of cytokine production, vaccine responders tended
+

to have a higher proportion of polyfunctional rhEBNA1-specific CD8 TCM cells at baseline than
did non-responders (data not shown, P = 0.048), which could suggest a higher proliferative
capacity of polyfunctional T cells than of those with a more restricted functional profile.
To determine whether vaccination with AdC-SgD-rhEBNA1 or AdC-NBEFSgD-rhEBNA1
augmented pre-existing or de-novo responses, our collaborators generated T cell lines with
overlapping rhEBNA1 peptides and then measured IFN-γ production by ELISPOT after restimulating cells with pools, subpools, or single peptides derived from rhEBNA1

266

. They found

that vaccination expanded new and existing responses. They detected responses in 4 of 12
animals before vaccination and in 8 of 12 animals after vaccination. All of the responses detected
prior to vaccination were still detected after vaccination, but at much higher levels, and one
+

+

animal also developed a new response. Vaccination stimulated de-novo CD4 or CD8 T cell
responses in four additional animals. Again, it is difficult to interpret trends due to the small
number of animals in each group. Fewer animals were described as vaccine responders using
this approach compared to ICS, which highlights the importance of choosing appropriate assays
to study different aspects of the immune response. IFN-γ ELISPOT is an invaluable tool for
defining epitope-specific responses, but it does not account for additional cytokines or cytolytic
molecules that are produced in response to vaccination. Furthermore, extended stimulation can
change T cell functions and deplete T cells to sub-dominant epitopes.
A previous study explored the feasibility of EBNA1-specific immunotherapy for treatment of
EBV-associated cancer

267

. In this study, an Ad-based vaccine expressing a GAr-depleted

sequence of EBNA1 fused to epitopes of latent membrane protein (LMP) of EBV was tested for in
vitro expansion of T cells obtained from patients with EBV-associated recurrent metastatic
nasopharyngeal carcinoma. More than one-half of the T cell lines contained EBNA1-specific CD8
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+

+

T cells following in vitro expansion, demonstrating that humans develop EBNA1-specific CD8 T
cells, which can be expanded upon further antigenic stimulation. While adoptive transfer of ex vivoexpanded EBV-specific T cells has resulted in sustained clinical responses in some patients

268

,

adoptive immunotherapy is costly, requires access to highly specialized health care facilities, and
is therefore an impractical solution for the thousands of patients diagnosed annually with EBV+

associated diseases. Another study showed that EBNA1-specific CD8 T cells could be isolated
from healthy human adults as well as from patients with post-transplantation lymphoproliferative
disease

269

. These results are in agreement with our studies, which showed not only that rhLCV-

infected rhesus macaques mount an rhEBNA1-specific CD8

+

T cell response upon natural

+

infection, but also that these CD8 T cells can be expanded in vivo upon vaccination. Responses
were sufficiently robust to allow for their detection directly ex vivo without further expansion through
extended in vitro culture.
Our study is the first to assess rhEBNA1-based vaccines in seropositive non-human
primates.

We showed that rhEBNA1-specific T cells can be expanded through vaccination and

also that these T cells are highly functional. The main limitation of the vaccines was that only one+

half of the animals showed increases in CD8 T cell responses, and responsiveness appeared to
be influenced by the Mamu genotype. This suggests that the numbers of potently MHC class Ibinding epitopes are limited within rhEBNA1

266

. Our stringent criteria for responsiveness, which

stipulated that T cell counts had to increase significantly over baseline at three of the tested time
points, combined with the limited numbers of animals, may have prevented us from identifying
weak responders.
In summary, the results presented here confirm that rhEBNA1 is a valid target for a T cell
vaccine to rhLCV. Vaccination led to the expansion of rhEBNA1 immune cells that exhibited
functions fit for controlling viral infection. Future studies should aim at generating more robust
rhEBNA1-specific T cell responses through modified vaccines. It would be of interest to monitor
the effect of vaccination on viral load or on the frequency of virus-infected cells as a potential
readout for a positive vaccine response

264

. Additional testing of modified vaccines in rhLCV-
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seropositive and -seronegative rhesus macaques is also warranted to further explore rhEBNA1based vaccines for prevention and treatment of EBV-associated diseases.

	
  

124

CHAPTER 5: DISCUSSION
SIGNIFICANCE
EBV was the first human tumor-associated virus to be discovered. This common human
pathogen infects more than 95% of the human adult population worldwide and establishes a
persistent infection through latency in B cells. Although EBV infection is typically benign and is
well controlled by the host adaptive immune system, it can sometimes cause chronic disease and
malignant transformation. Thus, EBV is considered a carcinogen due to its strong association
with various lymphoid and epithelial cell malignancies.

Despite the large range of EBV-

associated diseases, neither prophylactic vaccines that block primary EBV infection nor
therapeutic vaccines that eliminate virus-positive lesions are currently available.
EBV’s ability to enter latency and avoid recognition by host immune cells is one of the
factors that makes designing an effective vaccine quite challenging, as it is unclear exactly what
type of immunity would provide the best protection against primary infection, IM, and associated
malignancies. Because a different repertoire of genes is expressed during EBV’s lytic and latent
phases, the selection of appropriate vaccine targets is contingent on a thorough understanding of
EBV, its life cycle, and associated pathogenesis. Considerable progress has been made towards
reaching such goals, beginning with an improved understanding of EBV biology and associated
diseases. The development of a successful vaccine largely depends on this knowledge.
EBV vaccines could be used to prevent infection, modify infection and reduce disease,
prevent disease, or treat disease.

Most preventative vaccine efforts focus on decreasing

acquisition or reducing the burden of IM through neutralizing antibodies or T cells. It has been
speculated that by re-defining virus-specific immune responses, vaccines that reduce the
incidence of IM may ultimately reduce the rate of some EBV-associated malignancies. In the only
phase II trial of an EBV vaccine, the rate of IM but not the rate of acquisition was reduced in
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healthy seronegative subjects who received soluble gp350 plus adjuvant
resulted from a peptide vaccine corresponding to EBV latency proteins

181

270

.

Similar findings

, which highlights the

importance of T cells for controlling infection. Therapeutic EBV vaccines aim to prevent or treat
EBV-associated malignancies by correcting for the selective loss of EBV-specific T cells, which
can target tumor cells and prevent or delay tumor progression. For this approach to be effective,
tumor cells must maintain viable antigen processing and presentation. The success of passive
immunization by adoptive transfer of EBV-specific T cells to treat PTLD highlights the importance
of this concept, as PTLD lesions maintain normal antigen processing and presentation. However,
the same approach has been less successful as treatment for NPC, BL, and HL, where antigen
expression is more restricted and local tumor environments differ

271

.

The infusion of epitope-

specific CTLs is one method for overcoming restricted antigen expression, and this has
demonstrated promising results, even following immunosuppressive treatments

136,

Antigen-loaded DCs have also been tested, and have shown mixed results in the clinic

268,

272

.

200, 201, 273

.

A therapeutic EBV vaccine could similarly be used to restore or enhance EBV-specific T cellmediated immunity directly in vivo.

The impact of such a vaccine could be staggering, as

vaccines are more accessible and less costly than adoptive transfer techniques.
EBNA1 is the only EBV antigen consistently expressed in all forms of latency and in all
known EBV-associated malignancies, and it is therefore an attractive target for vaccine
development. However, EBNA1 has only recently begun to be viewed as an appropriate vaccine
antigen. It was originally believed that EBNA1-specific CTL responses were either non-existent
or non-functional due to an internal repeat domain that had been shown to interfere with antigen
presentation by MHC class I molecules

194-196

. It has since been shown that functional EBNA1-

specific T cells are frequently detected in EBV-infected humans
+

197, 198

, and a loss of EBNA1-

+

specific CD4 and/or CD8 T cells has been correlated with numerous EBV-associated diseases,
including HL, NPC, and BL

62, 132-134

. These findings suggest that immune responses to EBNA1

play an important role in controlling EBV infection. In support of its potential as a vaccine target,
EBNA1 and other sub-dominant latent EBV T cell responses from both healthy and EBV-positive
tumor-bearing individuals have been recovered ex vivo
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.

The overarching goal
126

throughout this dissertation was to determine if EBNA1 is a suitable target for vaccine
development.

SUMMARY AND CONCLUSIONS
An improved understanding of EBNA1 T cell responses will benefit the preclinical
development of EBV vaccines. Herpesviruses generally drive T cell differentiation towards highly
activated effector-like cells rather than towards exhaustion, but this is highly variable and
depends on the quantity, location, and duration of a specific antigen

274, 275

.

Using the EBV

homolog rhLCV, I characterized T cell responses to rhEBNA1 in naturally infected rhesus
macaques to determine the effect of low-level, persistent antigen on the magnitude, phenotype,
and function of rhEBNA1-specific T cells. These studies also served to evaluate the capacity of
rhEBNA1-specific T cells to respond to vaccination, as T cells affected by persistent antigen
exposure may be difficult to expand, TCM cell pools are often depleted, and TEFF/TEM cells do not
function optimally276-278. In Chapter 2, we used ICS and flow cytometry to measure rhEBNA1specific responses directly ex vivo, which allowed us to quantitate responses and to directly
analyze their functional nature without expansion. In contrast, methods frequently used to study
EBV-specific T cell responses utilize EBV-specific T cell lines expanded in vitro after repetitive
antigenic stimulation, which can change T cell function and lead to selective proliferation of
specific clones.
By comparing our results to studies conducted in humans, we demonstrated that the
rhLCV animal model faithfully reproduces EBNA1-specific T cell responses and provides a
powerful tool for preclinical vaccine studies.

Despite the small sample size of 15 animals,

rhEBNA1-specific T cells were detected at a frequency of 93%, which is strikingly similar to the
global seroprevalence of EBV. Furthermore, trends in the magnitudes of these responses are
+

also similar to what has been observed in humans; numbers of rhEBNA1-specific CD4 T cells
+

were larger than CD8 T cells, and the opposite was observed for rhBZLF1. The relatively equal
+

proportions of rhEBNA1-specific CD4 TCM and TEM cells that we detected could be due to low-
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level expression of rhEBNA1 during latent rhLCV infection, since persistent antigen promotes the
+

differentiation of TEM and TEFF cells. RhEBNA1-specific CD4 T cell responses were also highly
functional and produced IFN-γ, IL-2, and TNF-α in various combinations. This indicates that cells
are not under constant TCR stimulation.

Their ability to produce IL-2, which stimulates cell

growth, survival, and proliferation and is a function lost during early stages of exhaustion, may
indicate that rhEBNA1-specific CD4

+

T cells maintain a proliferative capacity.

However,

proliferation assays would be needed to test this hypothesis. On the other hand, rhEBNA1+

specific CD8 T cells were primarily IFN-γ-producing effector cells that expressed low levels of the
inhibitory molecule PD-1. Cell surface expression of PD-1 is a measure of T cell activation. High
levels of PD-1 expression coupled with low functional capacity indicate T cell exhaustion and are
consistently correlated to poor proliferation and increased sensitivity to apoptosis. Thus, while the
+

majority of rhEBNA1-specific CD8 T cells displayed an effector phenotype, rhEBNA1-specific
+

CD8 T cells were not persistently activated.

Interestingly, PD-1 expression was higher on

+

rhEBNA1-specific CD4 memory T cells, which indicates that these T cells probably see antigen
more often. Since rhBZLF1 is only expressed during lytic replication, rhBZLF1-specific T cells
exhibited characteristics that more closely resembled responses to an acute infection with
occasional re-exposure, as expected.

+

RhBZLF1-specific CD4 T cells maintained a resting

phenotype of central memory and primarily produced single-cytokine responses.
+

As with
+

rhEBNA1, the CD8 T cell response against rhBZLF1 was more activated than the CD4 T cell
response, but contained a large proportion of memory cells as well.
The presence of rhEBNA1-specific TCM cells with the capacity for expansion of more
activated subsets indicates the potential to successfully target and expand rhEBNA1-specific T
cells by vaccination. Evidence of their capacity to expand and contract was described in the first
part of Chapter 2, where initially large numbers of rhEBNA1-specific TEFF/TEM cells decreased and
stabilized over time. We speculated that rhLCV reactivation could have caused the initial peaks
in T cell numbers. Data on viral loads might have allowed us to draw more solid conclusions,
although peak viral loads probably occurred prior to our first time point. It is also possible that the
initial large numbers of rhEBNA1-specific T cells were caused by cross-reactivity or general
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inflammation in animals with ongoing unrelated infections. Unfortunately, these studies were
conducted prior to our acquisition of the rhBZLF1 peptide pool, which would have provided further
insight into whether rhLCV had reactivated in some animals. Data from these early time points
were not used to characterize responses.
In Chapters 3 and 4, we designed and tested novel AdC-based prototype vaccines that
target rhEBNA1. To be effective, such a vaccine needs to elicit both protective CTL responses as
well as a strong central memory component. Ad vectors have been shown to induce potent,
multi-specific, and sustained transgene product-specific T cell responses, which is important for
targeting cells already infected with virus. Animals received AdC68-prime followed by AdC6booster vaccines that expressed rhEBNA1 fused to functional (group 1) and non-functional (group
2) versions of HSV-gD. HVEM-binding forms of HSV-gD have been shown to enhance transgene
+

product-specific CD8 T cell responses during vaccination by inhibiting the HVEM-BTLA immune
inhibitory signaling pathway. To facilitate antigen processing, we also removed the GAr domain
from the coding sequence of rhEBNA1. Using ICS and flow cytometry, we conducted in-depth
analyses to examine the effect of vaccination on T cell phenotype and function.
Our study is the first to assess rhEBNA1-based vaccines in a seropositive non-human
+

+

primate study, where we show that highly functional rhEBNA1-specific CD8 and CD4 T cells
can be expanded in vivo through vaccination. The results presented in Chapter 4 confirm that
rhEBNA1 is a valid target for a therapeutic T cell vaccine to rhLCV, as vaccination led to the
expansion of rhEBNA1 immune cells that exhibited functions fit for controlling viral infection.
To avoid misinterpreting viral reactivation or general immune fluctuations as vaccine
responses, we set stringent criteria to define vaccine-driven responses. While this may have
+

+

ultimately excluded animals with weaker responses to vaccination, total CD8 and CD4 T cells
increased in 33% and 83% of vaccinated animals, respectively. Two additional animals from
+

group 2 developed increases in CD8 TCM or TEM cells and one animal from group 1 developed an
+

increase in CD4 TEM cells without any changes in total numbers. This indicates vaccine-induced
+

+

shifts in cell phenotypes. The ability to expand both CD8 and CD4 T cell responses through
vaccination was an important finding of this study, since both T cell subtypes can target and lyse
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EBV-infected cells

199, 209

.

It is perhaps not surprising that vaccination stimulated higher CD4

+

+

+

than CD8 T cell responses, as EBNA1-specific CD4 T cell epitopes are more immunodominant
in both humans

1, 67

+

and in rhesus macaques

TCM, and CD4 TEM cells.

257

+

. Vaccination augmented mainly CD8 TEM, CD4

+

Responses were highly functional, and T cells produced various

combinations of the cytokines IFN-γ, IL-2, and TNF-α and the lytic enzyme granzyme B, which is
important for controlling outgrowth of virus-infected cells.
This was the first study to utilize the immune-stimulating effect of HSV-gD to expand
ongoing T cell responses in non-human primates. We were intrigued to find that vaccine-driven
immune responses were similar regardless of gD binding ability, since our laboratory has
consistently shown that vaccines that express antigens as fusion proteins with HSV-gD elicit more
potent T cell responses compared to vaccines that express antigens alone. HSV-gD has also
displayed an adjuvant-like effect under conditions of T cell stress in tumor-bearing

247

and aged

279

mice. However, these experiments utilized the HSV-gD adjuvant effect during priming of T cell
responses. In contrast, our results indicate that blockade of the HVEM signaling pathway fails to
augment T cell expansion of previously primed, ongoing responses.

Alternatively, the small

sample size of each vaccine group (n = 6) may not have provided enough power to assess
significant differences between groups. There were some intriguing differences in post-vaccination
frequencies of rhBZLF1-specific T cells, which contracted more in animals that received functional
versions of HSV-gD. This could potentially reflect a reduction in viral load, which in turn would
suggest functionally superior T cell responses. Additional studies that include measurements of
viral loads before and after vaccination would be needed to confirm or reject this hypothesis.
Expression of gD-rhEBNA1 fusion proteins in vitro was more than 100-fold lower than
rhEBNA1 alone. Since antigenic load influences the immune response, our recombinant Ad-based
vaccine that expressed rhEBNA1 alone was not an appropriate control for the Ad-gDrhEBNA1
vaccine. Instead, we chose to compare binding and non-binding versions of HSV-gD. It would be
interesting to test the Ad-rhEBNA1 vaccine in the presence or absence of additional adjuvants to
determine if higher levels of rhEBNA1 transgene expression generate higher responses or
responses in a larger number of animals.
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Another unexpected outcome was that peak responses occurred after the first
vaccination, rather than after boosting.

However, the peak immune response after boosting

typically occurs faster than after priming, and we waited the same length of time (2 weeks) to
collect blood after each administration. Thus, responses may have peaked before they were
measured. Furthermore, numbers of rhEBNA1-specific T cells after 21 weeks were still larger
than at baseline in many animals. There were also significant increases in PD-1 expression by
week 2 after vaccination, which slowly declined by week 8 and were maintained at a similar
percentage through conclusion of the study (data not shown).

The percentage of PD-1-

expressing cells at these later points in time still appeared higher than at baseline, although
differences did not reach significance. Finally, the reduced proliferative capacity of TEM cells
compared to TCM cells could be another factor that contributed to the low response following the
second vaccination, as TEM cell responses were still relatively high shortly before boosting.
It is important to note that our studies only assessed responses in peripheral blood, but
activated T cells can also reside in the lymph nodes, the spleen, or in the periphery. This is
especially true at locations where tissues express cognate antigen. As a result, there may have
been a more definitive effect of HSV-gD that was not detected by our employed assays. This
could also explain the lack of a significant increase following boost, as T cells may have already
been mobilized from the circulation. Animals were released back to YNPC upon completion of
the study and necropsies were therefore not an option.

This is definitely something that is

important to consider when designing future studies.

FUTURE DIRECTIONS
+

+

Ad vectors are capable of stimulating both CD4 and CD8 T cell responses, and their
inherent immunogenicity has the potential to elicit strong responses, but overall there is still a
need for more effective strategies that induce larger and more sustained responses. Future
studies should aim at generating more robust T cell responses through modified vaccines. This
can be accomplished through epitope vaccines that expand T cell responses against sub-
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dominant EBV T cell epitopes.

However, because epitope recognition depends on MHC

genotype, this approach is challenging for human vaccines that aim to target large populations.
Cytokines and signaling molecules can also be used to help shape and promote immune cell
responses. Vaccines can be designed to encode growth factors such as IL-2 and GM-CSF.
They can also be administered in the presence of cytokines such as IL-7, IL-10, and IL-21, which
have been shown to promote large central memory responses in some studies

280

.

Chemotherapeutic agents that effect signaling pathways during cell differentiation can be used in
a similar manner

281

.

Alternative antigen delivery systems for use in heterologous prime-boost regimens can
also be explored as a means of inducing larger and/or more sustained responses. For example,
a CMV-based SIV vaccine has been shown to induce potent, sustained, and broad TEM cell
responses that were able to suppress SIV viral loads to undetectable levels in 50% of rhesus
macaques after challenge

282

.

It is noteworthy that CMV-vaccinated animals with SIV

breakthrough infections did not achieve a lowering of viral loads, which presumably reflects that
CMV-based vaccines fail to induce TCM cells, which have a higher proliferative capacity than TEM
cells. Among animals unable to rapidly control viral load, those that were boosted with an Adbased vaccine had significantly reduced peak viremia, which was most likely due to SIV-specific
TCM cell responses induced by the Ad-based vaccines. A similar approach may be best suited to
prevent EBV acquisition. In a therapeutic context, the strong TEM cell responses induced by a
CMV-based vaccine could potentially be used to clear EBV viral reservoirs by inducing latent
virus reactivation after vaccination. This could be used as a preventative measure to eliminate
virus-infected cells among individuals at high risk of developing EBV-associated malignancies.
Ad-prime followed by poxvirus-based boost is another approach to explore, since pox vectors
have been shown to act as potent boosts in NHPs and humans

283

.

Additional factors to consider when designing vaccines to treat or prevent EBVassociated malignancies are deficiencies within the tumor site itself. For example, local immune
suppression in the tumor tissue may dampen the outcome of a therapeutic EBV vaccine, and we
may need to develop approaches that can overcome this. As one example, anti-PD-1 or anti-
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CTLA-4 treatment can sometimes be used to overcome local immune suppression for tumors that
express relevant ligands.
Optimal EBV vaccine targets are still unknown, and the continued testing of candidate
vaccines is fundamental for advancing the field. The ideal formulation is still unclear and may
depend on the desired application. One method for increasing overall vaccine effectiveness is to
include epitopes from additional EBV latency proteins such as LMP1 and/or LMP2, which are
expressed by tumors such as NPC, GC, and HL. Although neither LMP1 nor LMP2 are dominant
+

targets during natural infection, they contain subdominant CD8 T cell epitopes, and studies
suggest that vaccinating against these responses may have clinical benefit. For example, an Adbased vaccine expressing random overlapping peptides from EBNA1, LMP1, and LMP2
stimulated epitope-specific responses that inhibited LCL outgrowth in cell lines generated from
both healthy EBV seropositive individuals as well as NPC patients

184

. This indicates that infected

cells in diseases such as NPC may be accessible targets for activated EBV-specific T cells. Hui
et al. expanded upon this concept and designed a recombinant modified vaccinia Ankara (MVA)
vaccine that expressed portions of EBNA1 and LMP2. The objective of this phase I study was to
measure safety and immunogenicity and not to test clinical effect, but results were promising, as
+

+

vaccination increased numbers of circulating CD4 and CD8 T cell responses to EBNA1 and/or
LMP2 in 15 of 18 recent NPC chemotherapy patients in remission

284

. The size of responses

generated by their vaccine was similar to or higher than effector frequencies following adoptive
transfer. However, responses were only sustained in half of the highest dose group. Thus, more
durable and lasting responses are needed. It is possible that virus-neutralizing antibodies limited
the effectiveness of their MVA-based vaccine, whereas our use of two distinct chimpanzee-based
Ad vectors avoids this limitation.
As demonstrated in this thesis, the rhLCV model has proven to be a highly relevant and
useful tool for the preclinical testing of EBV-related rhLCV vaccines. Recently, virus-like replicon
particle vaccines expressing rhEBNA3A, B and/or gp350 of rhLCV were tested in rhLCV
seronegative rhesus macaques, where gp350 was shown to induce antibodies, while the
immunodominant rhEBNA3 latency proteins induced detectable CD4

	
  

+

and CD8

+

T cell
133

responses

183, 285

. In comparison, immunization with soluble rhLCV gp350 alone induced a larger

antibody response, animals were better protected from infection, and those that did become
infected had reduced viral loads in the blood compared to animals that received the VRP
vaccines. A vaccine that induces NAbs against gp350 and T cell responses against important
latency proteins is an interesting concept that merits further exploration, as this approach could
be more effective than vaccines that target either one alone. Adenovirus-based vaccines would
be an interesting platform for exploring this approach since they can induce potent B cell and
+

+

antibody responses in addition to transgene product-specific CD4 and CD8 T cells.
As the field progresses, we need to define better markers of disease and correlates of
protection. Levels of EBV DNA in the blood can be predictive of some types of lymphomas, and
a vaccine that reduces viral DNA load may ultimately reduce the incidence of certain cancers. As
discussed previously, data on rhLCV loads before and after vaccination would have provided the
most direct evidence of vaccine efficacy or lack thereof. However, direct measurement of EBV
replication in the oropharynx through saliva is difficult, and very low levels of viral genome in the
peripheral blood of healthy individuals make it difficult to detect viral load fluctuations in live
animal studies with limited samples.

A more thorough analysis of viral loads would provide

clarity, but this hinges on the development of more sensitive assays. Alternatively, larger cohorts
can provide more samples for testing viral loads. It will be important to explore correlations
between viral load and specific immune responses or between viral load and PD-1 expression in
order to define prognostic markers and correlates or surrogates of protection. Larger cohorts
would also provide more statistical power for interpreting results.
The field of therapeutic EBV vaccines is still relatively young, and there are many
questions that need answers before such vaccines will have success in a clinical setting. We
have shown that rhEBNA1-specfic T cells can be expanded through vaccination, but we do not
yet know whether they confer protection or can be used to target tumor cells. Future studies
using SIV-infected rhesus macaques or tumor challenge models can be used to address some of
these questions, but the absence of good surrogate markers for the development of most EBVassociated tumors, the long length of time between primary acquisition and development of most

	
  

134

tumors, and the lack of immune correlates of protection make clinical trials difficult to conduct.
Furthermore, it is not yet clear what combination of viral antigens would be needed for a vaccine
to effectively prevent or treat EBV-associated malignancies, but it will likely be a combination of
+

+

relevant CD4 and CD8 T cell antigens expressed in a variety of tumors. By continuing to study
the intricacies of different EBV-associated malignancies and testing various candidate vaccines in
animals and humans, we can begin to answer the aforementioned questions, and we can use this
information to design more effective vaccines.
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CHAPTER 6: MATERIALS AND METHODS
6.1 T CELL RESPONSES TO LATENT ANTIGEN EBNA1 AND LYTIC
ANTIGEN BZLF1 DURING PERSISTENT RHLCV INFECTION OF RHESUS
MACAQUES

Non-Human Primates (NHPs)	
  
Adult, healthy, and simian immunodeficiency virus (SIV)-uninfected Indian-origin Macaca mulatta
animals were housed at the Yerkes National Primate Research Center (YNPRC; Atlanta, GA).
Most animals with the exception of PH1019 and PWw were born at YNPRC. Animals were either
housed at a field station or at the main station. All animals were female adults ranging from 5-19
years of age at the start of the study. Animals were tested for Mamu-A*01, -A*02, -A*08, -B*01, B*04, -B*08, and -B*17. All animals included in the analyses tested positive for rhLCV infection
by serologic testing for serum antibodies against the rhLCV small viral capsid antigen

265

.

Characteristics are shown in Table 2-1. Additional samples were obtained from five rhLCVseronegative rhesus macaques in the extended specific-pathogen-free colony housed at the New
England National Primate Research Center, Harvard Medical School, Southborough, MA. All
procedures involving handling of animals were performed according to approved protocols and
upon review by the Institutional Animal Care and Usage Committees. 	
  
Isolation and Preservation of Lymphocytes	
  
Peripheral blood mononuclear cells (PBMCs) were isolated from blood as described

158

. Briefly,

whole blood collected in CPT tubes was centrifuged at 2600 rpm for 30 minutes. The clear
plasma layer (top layer) was transferred to cryo tubes (about 1 ml per tube) and frozen at -80°C.
The remaining plasma layer was then gently mixed with the cloudy lymphocyte layer below and
transferred to a new 50 ml conical tube. Remnants of the mixed cell layer within the CPT tube
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were gently washed twice with 5 ml of HBSS and transferred to the same 50 mL conical tube.
The tube was topped with HBSS and spun at 1200 rpm for 10 minutes.

After discarding

supernatant, cells were resuspended in 5 ml ACK lysis buffer and incubated for 5 minutes at
room temperature. Cells were washed twice with HBSS and resuspended in RPMI complete
medium (RPMI 1640 supplemented with 10% fetal bovine serum [FBS; Tissue Culture Biological],
10 mM HEPES, penicillin-streptomycin, and gentamicin [Cellgro]).

Samples were tested

7

immediately after isolation or 1x10 cells per ml were frozen in 90% fetal bovine serum (FBS) and
10% dimethyl sulfoxide (DMSO) (Sigma, St. Louis, MO) at -80°C until testing.
Intracellular Cytokine Staining (ICS)
The function of rhEBNA1- and rhBZLF1-specific T cells was assessed by intracellular cytokine
staining (ICS) after stimulation with peptide pools

286

. RhEBNA1 was used at a final concentration

of 2µg of each peptide per ml, and rhBZLF1 was used at a final concentration of 1µg of each
peptide per ml. Frozen cells were thawed and immediately washed with Hank's balanced salt
solution (HBSS; Mediatech Inc., Herndon, VA) supplemented with 2 units/ml DNase I,
resuspended with RPMI medium and stimulated for 6 h with anti-CD28, anti-CD49d, and
Brefeldin A. Cells were stained with violet-fluorescent reactive dye Pacific Blue, anti-CD14-Pacific
Blue, anti-CD16-Pacific Blue, anti-CD20-Pacific Blue, anti-CD8-allophycocyanin (APC)-H7, antiCD4-Alexa 700, anti-CD95-phycoerythrin (PE)-Cy5, and anti-CD28-PE-Texas Red (ECD) for 30
min at 4°C (solution prepared in PBS). Additionally, cells were stained with anti-CCR7-PE. After
fixation and permeabilization with Cytofix/Cytoperm (BD Biosciences, San Jose, CA) for 30 min at
4°C, cells were stained with anti-interferon gamma (IFN-γ)-APC, anti-interleukin-2–fluorescein
isothiocyanate (anti-IL-2–FITC), anti-tumor necrosis factor alpha (TNF-α)–PE–Cy7, and anti-CD3peridinin chlorophyll protein (PerCp)-Cy5.5 for 30 min at 4°C (solution prepared in 1x perm wash).
Cells were washed twice, fixed with BD Stabilizing Fixative (BD Biosciences, San Jose, CA), and
then analyzed by fluorescence-activated cell sorting (FACS) using an LSRII instrument (BD
Biosciences, San Jose, CA) and DiVa software. Flow cytometric acquisition and analysis of
samples were performed on at least 500,000 events. Single-color controls used CompBeads Anti-
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Mouse Igk (BD Biosciences, San Jose, CA) for compensation. The same protocol was repeated
for cell surface staining of PD-1, except cells were stained for 30 minutes with anti human
CD279-brilliant violot (BV) 605 and washed prior to the 6 h stimulation.

Table 6-1 is a

comprehensive list of all antibodies used in these studies, including item numbers, clones, and
concentrations used for staining.
Postacquisition analyses were performed with FlowJo software (TreeStar, Ashland, OR). Figure
6-1A shows the gating strategy. Briefly, single cells were gated from PBMCs (a) followed by
+

+

+

lymphocytes (b), live CD3 T cells (c), CD4 versus CD8 T cells (d), and differentiation within
each T cell population (e). Figures 6-1B and 6-1C show responses to the rhEBNA1 peptide pool
exemplified by one rhLCV-seropositive (B) and one rhLCV-seronegative (C) animal.
6

Results

+

were normalized to numbers of responding cells per 10 live CD3 cells. Data shown on graphs
represent values of peptide-stimulated cells from which background values have been subtracted.
To calculate the sum of peptide-specific responses, we subtracted normalized background
activity and then summed the seven possible different combinations of functions. We define a
positive response as any value greater than the mean plus two standard deviations of total CD4
+

6

+

+

+

6

+

+

(183 CD4 cells per 10 CD3 T cells) or CD8 (216 CD8 cells per 10 CD3 T cells) cytokine
responses from five seronegative subjects from the New England Primate Research Center. In
part II, peptide-specific responses were measured at two time points spaced two months apart,
and analyses were based on the average response of each subject. RhEBNA1- and rhBZLF1specific total cytokine responses for each time point can be seen in Tables 2-3A and 2-3B,
respectively. Polyfunctionality pie-chart graphs were generated using SPICE software (NIH,
Bethesda, MD).
Synthetic peptides
Two different rhEBNA1 peptide pools were used in the ICS experiments conducted in this
chapter. The rhEBNA1 peptide pool used in part I consists of 51 15-mer peptides that overlap by
5 amino acids (Genemed Syn, San Antonio, TX). The rhEBNA1 peptide pool used in part II
consists of 85 15-mer peptides that overlap by 10 amino acids except for the GA repeat domain,
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which overlaps by 5 amino acids. Additional rhEBNA1 peptides used in part II were purchased
from NeoBioSci (Cambridge, MA). Table 6-2 shows a list of the rhEBNA1 peptides used in parts
I and II. To account for its large size, rhEBNA1 was divided into two pools for all ICS experiments
conducted in part II: pool one with peptides 1-42 and pool two with peptides 43-85. Responses
were combined after normalization and subtraction of background values. The rhBZLF1 peptide
pool consists of 60 15-mer peptides with an 11 amino acid overlap and was provided by A. Kaur.
Peptides were reconstituted in DMSO.
Statistical analysis:
+

+

RhEBNA1- and rhBZLF1-specific immune responses were compared between CD4 and CD8 T
cells. IFN-γ, IL-2, and TNF-α cytokine production as well as effector, central memory (TCM), and
+

+

effector memory (TEM) cell subset analyses within both CD4 and CD8 T cell populations was
also compared. All comparisons were performed using a two-tailed Wilcoxon’s signed-rank test
unless otherwise noted. A Bonferroni adjustment was applied to all multiple comparisons in order
to control for a type I error rate.

A P-value <0.05 was considered statistically significant.

Graphpad Prism version 6 (La Jolla, CA) and SPICE version 5.22 (NIH, Bethesda, MD) were
used for calculations and illustrations.
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Table 6-1: List of antibodies
Antibody

Clone

Company

Mouse anti-human CD28

CD28.2

Mouse anti-human CD49d

9F10

BD Biosciences,
San Jose, CA
BD Biosciences,
San Jose, CA
Invitrogen,
Carlsbad, CA
BD Biosciences,
San Jose, CA
BD Biosciences,
San Jose, CA
AbD Serotec,
Raleigh, NC
BD Biosciences,
San Jose, CA
BD Biosciences,
San Jose, CA
BD Biosciences,
San Jose, CA
Beckman Coulter,
Fullerton, CA
R&D Systems,
Minneapolis, MN
BD Biosciences,
San Jose, CA
BD Biosciences,
San Jose, CA
BD Biosciences,
San Jose, CA
BD Biosciences,
San Jose, CA
BioLegend, San
Diego, CA

violet-fluorescent reactive dye PacBlue
Mouse anti-human CD14-PacBlue

M5E2

Mouse anti-human CD16-PacBlue

3G8

Mouse anti-human CD20-PacBlue

2H7

Mouse anti-human CD8-APC-H7

SK1

Mouse anti-human CD4-Alexa 700

OKT4

Mouse anti-human CD95-PE-Cy5

DX2

Mouse anti-human CD28-ECD

CD28.2

Mouse anti-human CCR7-PE

150503

Mouse anti-human IFN-γ-APC

B27

Mouse anti-human IL-2–FITC
Mouse anti-human TNF-α–PE–Cy7

MQ117H12
MAb11

Mouse anti-human CD3-PerCp-Cy5.5

SP34-2

Mouse anti-human CD279 (PD-1)-BV 605

EH12.2H7

	
  

Catalog
number
555725

Ratio
used
1µl/ml

555501

1µl/ml

L34955

1:400

558121

1:50

558122

1:50

MCA1710PB

1:50

560179

1:25

557922

1:20

559773

1:10

6607111

1:20

FAB197P

1:50

554702

1:50

554566

1:50

557647

1:20

552852

1:50

329923

1:20
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Figure 6-1: Gating strategy and representative examples

	
  

	
  

Figure 6-1: Gating strategy for multiparameter flow cytometry and representative examples
(A) The following gating strategy was used to identify rhEBNA1-specific T cells: Cells were initially gated on
the basis of their forward scatter (FSC) area versus FSC height profile to remove doublets (a), followed by a
lymphocyte gate based on FSC area versus side scatter (SSC) area profile (b). Dead cells were then
excluded by gating CD3 versus a live-cell stain (Pacific blue). The amine reactive live/dead stain was in the
+
+
+
same channel as CD14 , CD16 and/or CD20 , so that non-T cell populations were also gated out at this
+
+
step (c). CD4 and CD8 T cell differentiation (d) was based on CD28 and CD95 expression (effector,
hi
lo
hi
hi
CD95 CD28 ; memory, CD95 CD28 ) (e). Memory cells were further differentiated into central memory
hi
lo
and effector memory with CCR7 (central memory, CCR7 ; effector memory, CCR7 ). A gate was then set
+
for each stain identifying intracellular-accumulated IFN-γ, IL-2, or TNF-α. RhEBNA1-specific CD4 and
+
CD8 T cell multi-subset analysis from the peripheral blood of one seropositive (B) and one seronegative (C)
animal was performed. The analyses were performed with samples immediately frozen after blood collection
and PBMC isolation. Phorbol myristate acetate and ionomycin were used as positive controls, and medium
with DMSO was used as a negative control (data not shown). Numbers represent the frequency of cytokineproducing cells in the corresponding quadrant. Samples were analyzed by FACS using LSRII and DiVa
software. Post-acquisition analyses were performed with FlowJo.


hi

hi

lo

287

Some groups refer to the CD95 CD28 CCR7 population as transitional effector memory (TTrEM) cells ,
lo
which differ from other CD28 TEM cells by showing superior homing to peripheral sites and increased
production of IL-2.
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Table 6-2: rhEBNA1 peptide sequences

	
  
Position

#

Sequence

1-15
6-20
11-25
16-30
21-35
26-40
31-45
36-50
41-55
46-60
51-65
56-70
61-75
66-80
71-85
76-90
81-95
86-100
91-105
101-115
111-125
121-135
131-145
141-155
151-165
161-175
171-185
181-195
191-205
201-215
211-225
221-235
231-245
241-255
251-265
256-270
261-275
266-280
271-285
276-290
281-295
286-300
291-305
296-310
301-315
306-320
311-325
316-330
321-335
326-340
331-345
336-350
341-355
346-360

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

MSDGRGPGNGLGYTG
GPGNGLGYTGPGLES
LGYTGPGLESRPGGA
PGLESRPGGASGSGS
RPGGASGSGSGGNRG
SGSGSGGNRGRGAHG
GGNRGRGAHGRGRGR
RGAHGRGRGRGRGRG
RGRGRGRGRGRGGGG
GRGRGRGGGGVLGET
RGGGGVLGETGEFGG
VLGETGEFGGHGSES
GEFGGHGSESETRHG
HGSESETRHGNGHRD
ETRHGNGHRDKKRRS
NGHRDKKRRSCVGCK
KKRRSCVGCKGGTGG
CVGCKGGTGGSSAGG
GGTGGSSAGGAGGNS
AGGNSRGGGGAGVGS
AGVGSGRGAGGSGGA
GSGGAGGGAGGSLGG
GSLGGGAGGSSGGSG
SGGSGAGGSGAGGSG
AGGSGAGGSGAGGSR
AGGSRGRGRGRGGSA
RGGSAGGRGGRGGGG
RGGGGGGGSRGRGRG
GRGRGRGGGSRGRGR
RGRGRGRGRGRGRGE
RGRGEGPSKGEKRPR
EKRPRSPSGRSSSQS
SSSQSSSRSSSSSRS
SSSRSSSNGSDSSDF
DSSDFPGFPGHRPLP
PGFPGHRPLPTSFPG
HRPLPTSFPGSPLGG
TSFPGSPLGGYRGTD
SPLGGYRGTDGTDGG
YRGTDGTDGGDEQPP
GTDGGDEQPPGAVEQ
DEQPPGAVEQGPGED
GAVEQGPGEDPGEGP
GPGEDPGEGPSRQTT
PGEGPSRQTTTSGGR
SRQTTTSGGRGSGKK
TSGGRGSGKKGGWFG
GSGKKGGWFGRRRGE
GGWFGRRRGEGGRGF
RRRGEGGRGFKKFEN
GGRGFKKFENMAKNL
KKFENMAKNLKVLLA
MAKNLKVLLARCQAE
KVLLARCQAERTNTT

	
  

Part Part Molecular
I
II
Weight
1
1438.53
1
1375.45
2
1431.57
2
1315.36
3
1273.27
3
1313.29
4
1520.62
4
1562.71
5
1468.59
5
1385.49
6
1349.41
6
1462.49
7
1543.53
7
1675.65
8
1833.98
8
1744
9
1493.74
9
1197.28
10
1093.01
11
1160.14
12
1117.12
13
1017.98
14
1064.01
15
1021.93
16
1105.07
17
1358.43
18
1215.23
19
1300.34
20
1498.62
21
1639.8
22
1666.86
23
1645.76
24
1503.47
25
1506.42
26
1625.77
10
1563.79
27
1519.73
11
1511.62
28
1409.43
12
1564.55
29
1456.44
13
1524.52
30
1395.4
14
1484.51
31
1487.56
15
1507.62
32
1438.54
16
1634.8
33
1651.8
17
1794
34
1696.97
18
1747.15
35
1688.07
19
1703.98
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351-365
356-370
361-375
366-380
371-385
376-390
381-395
386-400
391-405
396-410
401-415
406-420
411-425
416-430
421-435
426-440
431-445
436-450
441-455
446-460
451-465
456-470
461-475
466-480
471-485
476-490
481-495
486-500
491-505
496-510
501-511

55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85

RCQAERTNTTGNWPF
RTNTTGNWPFGVFVY
GNWPFGVFVYGPKTS
GVFVYGPKTSCYNLR
GPKTSCYNLRRCIAC
CYNLRRCIACCIPEC
RCIACCIPECRLTPL
CIPECRLTPLGRLPF
RLTPLGRLPFGYAPE
GRLPFGYAPEPGPQP
GYAPEPGPQPGPMRE
PGPQPGPMRESTDCY
GPMRESTDCYFIVFL
STDCYFIVFLQTMIF
FIVFLQTMIFAECVK
QTMIFAECVKDALRD
AECVKDALRDYIMTK
DALRDYIMTKPLPTS
YIMTKPLPTSSVQVT
PLPTSSVQVTVITFE
SVQVTVITFEDPVML
VITFEDPVMLPVFFP
DPVMLPVFFPPHLPA
PVFFPPHLPAAAVAA
PHLPAAAVAAEGGEG
AAVAAEGGEGAEGDD
EGGEGAEGDDGDEGG
AEGDDGDEGGEGGDG
GDEGGEGGDGNEGDE
EGGDGNEGDEGAAGQ
NEGDEGAAGQE

36
20
37
21
38
22
39
23
40
24
41
25
42
26
43
27
44
28
45
29
46
30
47
31
48
32
49
33
50
34
51

1780.94
1758.95
1655.86
1703.97
1685.01
1760.16
1691.13
1715.12
1686.99
1582.79
1582.77
1634.82
1778.09
1828.19
1789.23
1740.03
1756.07
1721.02
1664.99
1617.87
1677.98
1751.13
1677.05
1504.8
1346.46
1318.27
1350.18
1336.15
1393.2
1362.23
1075.99

	
  
Table 6-2: The rhEBNA1 overlapping peptide library contains a total of 85 peptides synthesized at 85-90%
purity. Peptides are 15 aa in length and overlap by 5 or 10 amino acids. The 51 peptides used in part I
were ordered from Genemed Synthesis (San Antonio, TX) and overlap by 10 amino acids. An additional 34
peptides were ordered from NeoBio Sciences (Cambridge, MA) so that the complete peptide library used in
part II was composed of 85 peptides that overlapped by 5 amino acids except for the GAr domain, which
overlapped by 10 amino acids. The GAr region is highlighted in grey, and colors represent the hydrophobic
classification of each amino acid: red, very hydrophobic; orange, hydrophobic; green, hydrophilic; blue, very
hydrophilic. Figure was generated using the Sigma-Aldrich PEPscreen® library design tool.
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6.2 ADENOVIRUS-BASED VACCINES TO RHEBNA1: VECTOR DESIGN,
MOUSE STUDIES, IN VITRO TESTING

Vaccine vectors
The rhEBNA1 gene was deleted of the GAr domain and a flag epitope was inserted using
conventional cloning techniques as described

288

. Start and stop codons were also removed, and

the final gene product was amplified by PCR with the following primers: Fw5’- ACCGGT
AGGGAGGGTGGTTTGGGAGG-3’ and Rv5’- ACGCGTCGACCTCCTGCCCCGCCGCGTCGAC
-3’. Primers were purchased from Integrated DNA Technologies (Coralville, IA). DNA fragments
were cloned into the ApaI site of the pRE4 vector as described

248

. The correct in frame cloning of

the rhEBNA1 encoding gene was confirmed by restriction enzyme digest followed by visualization
of bands by gel electrophorese and DNA sequencing. To generate pSh-SgD-rhEBNA1 and pShNBEFSgD-rhEBNA1 vectors, the GAr-deleted rhEBNA1 gene was ligated into pShuttle vectors
containing sequences encoding the previously described

247

mutated versions of HSV-1 gD, which

either showed increased (SgD) or reduced (NBEFSgD) binding to HVEM

248

. Transgenes were

under control by the CMV enhancer and promoter. Restriction enzyme digests followed by gel
electrophoresis and nucleotide sequencing confirmed correct insertion of the rhEBNA1
sequences into pShuttle.
We then cloned the inserts including the regulatory elements from the pShuttle vectors into the
E1 domain of molecular clones of E1-deleted AdC vectors of simian serotype 25 (SAdV-25;
AdC68) and serotype 23 (SAdV-23; AdC6) used for primary and booster immunizations,
respectively, as described

289

.

Recombinant AdC vectors were rescued and propagated on HEK 293 cells as described
was purified and titrated as previously described

289

289

. Virus

. Vector batches were quality controlled by

determining virus particle (vp) to infectious units (moi) ratios. They were tested for replicationcompetent Ad and endotoxin contaminations. Genetic integrity of AdC vectors was determined by

	
  

144

restriction enzyme digest of purified viral DNA. AdC-gD-NP and AdC-gD vectors have been
described previously

247, 279

.

Vectors used in mouse experiments were cloned as described above, except rhEBNA1 was first
ligated into an empty pShuttle vector (to generate AdC-rhEBNA1) or a pShuttle that contained
wild-type HSV-1 gD without the transmembrane domain (to generate AdC-gD-rhEBNA1).
Immunoblotting
Expression of the different forms of rhEBNA1 from recombinant AdC vectors was confirmed upon
infection of CHO cells stably transfected to express the coxsackie adenovirus receptor (CAR) by
Western Blot analysis. An AdC68 vector expressing gD was used as a control vector. Briefly,
CHO-CAR cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal calf serum (FBS), 1% penicillin/streptomycin, 1% pyruvate and 1% non-essential amino
acids at 37°C in 5% CO2 until 80% confluence in wells of a 6-well plate. Medium was then
6

11

10

replaced with 1ml of serum-free DMEM, and about 10 cells were infected with either 10 , 10 ,
9

10

9

8

or 10 vp of vector per well or 10 , 10 , or 10 vp of vector per well. After 2 hours, 1ml complete
DMEM was added to each well, and cells were harvested after 48 hours.
Total cellular protein was prepared by washing cells 2x with phosphate-buffered saline (PBS).
They were then suspended in RIPA buffer (InVitrogen, Grand Island, NY) supplemented with
Complete Protease Inhibitor (Roche, Indianapolis, IN). Cells were transferred to a new tube and
incubated for 1 hour on ice. Tubes were spun for 30 minutes at 4°C to pellet debris, and lysate
was transferred to new tubes. 10ul of lysate was mixed with 10ul 2X loading buffer (laemmli blue
dye, 2-mercaptoethanol) and boiled for 5 minutes. Protein samples were then separated with 415% gradient sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
proteins were transferred to a 0.45 um PVDF transfer membrane (Millipore, Billerica, MA). The
membranes were blocked for 1 hour at room temperature in 5% fat-free milk dissolved in PBS
containing 0.1% Tween-20.

After washing, expression of chimeric rhEBNA1 proteins was

detected with a mouse monoclonal antibody specific for the Flag epitope (M2; Sigma, St Louis,
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MO), diluted 1:1,000 in 5% milk, PBS, 0.1% Tween 20 and incubated at 4°C overnight. Blots
were then washed, incubated for 1 hour with a horseradish peroxidase-conjugated goat antimouse IgG antibody (1:30,000, KPL), and developed with Super Signal West Pico
chemiluminescence substrate (Thermo Scientific, Waltham, MA).

Membranes were washed

extensively between all steps. Some membranes were treated with stripping buffer (Thermo
Scientific) for 15 minutes, washed in PBS-Tween, blocked and re-probed as described above. To
detect gD, membranes were probed with a polyclonal anti-gD serum R6 (R45) diluted 1:500.
Donkey anti-rabbit IgG horseradish peroxidase (HRP) (Amersham Biosciences, Little Chalfont,
Buckinghamshire, UK) was used as a secondary antibody at 1:10,000. For loading control, we
stripped and re-probed with a 1:20,000 dilution of a β-actin-specific antibody (AC-15; Sigma, St
Louis, MO), and then 1:30,000 goat anti-mouse IgG-HRP as described above.
Immunofluorescence
Expression of transgene products by AdC vectors was further measured by immunofluorescence.
6

10

9

Cells (10 ) were infected as described above with 10 or 10 vp of vector and washed.

PBS (1

ml) supplemented with 10 mM EDTA was added to each well, and cells were incubated at 37°C
for 5 minutes. Cells were harvested, washed, and transferred to a 96-well plate where they were
stained with mouse anti-Flag antibody for 30 minutes, washed, and probed with goat anti-mouse
IgG-Alexa700 (Molecular Probes, Eugene, OR). Cells were washed twice more, fixed with BD
Stabilizing Fixative (BD Biosciences, San Jose, CA), and then analyzed by FACS using LSRII
(BD Biosciences, San Jose, CA) and DiVa software.
HVEM binding assay
6

CHO-CAR cells (10 ) were infected with 10

10

vps of AdC vectors as described above. After 48

hours, cells were harvested and total cellular protein was prepared as described above. Protein
extracts were kept at -80°C until use. Western blotting and densitometry (AlphaEaseFC
software version 3.3.0; Alpha Innotech, San Leandro, CA) were used to normalize the amount of
chimeric protein in the extracts.
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To measure the gD fusion proteins’ ability to bind HVEM, ELISA plates were coated with 50 ul per
well of a 5ug/ml concentration of HVEM

247

diluted in 0.1 M carbonate coating buffer (pH 9.6) and

incubated overnight at 4°C. Plates were washed 5 times and then blocked for 1.5 hours in 5%
milk-PBST (0.05% Tween20) at room temperature. After washing, normalized protein extract
was serially diluted in blocking solution and added to the plates for 1.5 hours. To detect captured
chimeric protein, 50uL mouse anti-Flag antibody diluted 1:1,000 in 5% milk-PBST was added for
1 hour, followed by 50ul goat anti-mouse IgG-HRP diluted 1:1,000 for 30 minutes with washings
after each step. TMB substrate solution (Calbiochem, San Diego, CA) was then added to each
well, plates were stored in the dark for 15 minutes, and the reaction was stopped by adding 2N
HCl. The optical density at 450 nm was determined using a microtiter plate reader.
Electrophoretic mobility shift assays (EMSA)
Adenovirus vaccines expressing gD, rhEBNA1, or gD-rhEBNA1 were used to infect CHO/CAR
10

cells at 10 VPS in order to measure DNA-binding ability of rhEBNA1 transgenes. Infected cells
were harvested and then prepared as total cell lysates. Lysates were assayed by electrophoretic
mobility shift assays (EMSA) with a
as previously described

290

32

P labeled probe for rhEBNA1 binding sites at rhLCV OriP.

.

Animals and immunization regimen
Dose-escalation study: Four to six week old female BALB/c mice were purchased from the
National Cancer Institute.

9

10

Groups of 4 mice each received 10 , 10 , or 10

11

vp of AdC68

vaccines that expressed either rhEBNA1 or gD-rhEBNA1. As a control, animals were vaccinated
with 10

11

vp of AdC68 expressing HIV-gag.

Blood was collected at weeks 2 and 4 after

vaccination.
Kinetics studies: Groups of 5 female BALB/c mice received 10

11

vp of AdC68-expressing

rhEBNA1 or gD-rhEBNA1. Blood was collected every other week after vaccination. Vaccinenaïve mice were included as an additional control starting at week 4 in order to measure general
immune fluctuation.

Similar experiments were conducted with C57/bl6 mice and ICR mice.

Three to four week old female C57/bl6 mice were purchased from Taconic labs (NY, Hudson),

	
  

147

and 6-8 week old female ICR mice were purchased from ACE Animals Inc. (Boyertown, PA).
Groups of 5 C57/bl6 mice and 10 ICR mice received 10

11

vp of AdC68-expressing rhEBNA1 or

gD-rhEBNA1. Blood was collected at weeks 2, 4, 10, and 12 after vaccination. The same studies
were repeated with AdC68-rhEBNA1-M vaccines.

All vaccines were diluted in PBS and

administered intramuscularly to the tibialis anterior muscle of each hindlimb (50 µL per leg).
Animals were house at the Wistar Institute Animal Facility (Philadelphia, PA), and all procedures were
performed according to institutionally approved protocols.

	
  

Isolation of lymphocytes	
  
Blood was collected in 1mL of 4% sodium citrate, and 1mL of L-15 media (Cellgro, Herndon, VA)
was then added. Lymphocytes were purified through a Histopaque (Sigma-Aldrich, St. Louis,
MO) gradient solution and washed in PBS supplemented with 1% FBS. Cells were then treated
with 1mL lysis buffer (ebioscience, San Diego, CA) for 5 min on ice to rupture red blood cells. 1%
FBS in PBS was added and cells were centrifuged at 1500 rpm for 10 minutes. Pellets were
washed again and cells were resuspended in 2% MLC/DMEM (DMEM, 2% heat-inactivated FBS,
6

1% Pen–Strep, 10 mM Hepes, 1 mM sodium pyruvate, 0.1 mM non-essential amino acids, 10 M
2-mercaptoethanol)(Cellgro, Herndon, VA) to a final volume of 200 µl.
Intracellular cytokine staining (ICS)
Induction of rhEBNA1-specific T cells was assessed by intracellular cytokine staining (ICS) after
stimulation of PBMCs with overlapping peptide pools. RhEBNA1 was used at a final
concentration of 2µg of each peptide per ml. As a control, cells were stimulated with an HIV-gag
6

peptide pool at the same concentration. PBMCs (10 cells/well) were incubated with peptide
pools and Brefeldin A (1 ml/ml; GolgiPlug; BD Biosciences, San Jose, CA) for 5 hrs at 37 °C in a
96-well round bottom microtiter plate at a final volume of 200 µl/well in 2%MLC/DMEM. After
washing, cells were incubated for 30 min at 4°C in 50µl/well of staining solution (in PBS)
composed of LIVE/DEAD fixable aqua dead cell stain (AmCyan), anti-CD8-PercP-Cy5.5, and in
some experiments either anti-CD4-FITC and anti-CD44-APC or anti-CD44-Alexa700, antiCD62L-FITC, and anti-CD127-PacBlue. After several washings, cells were fixed and
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permeabilized with Cytofix/Cytoperm (BD Biosciences, San Jose, CA) for 20 min at 4°C, and then
stained with 50µl/well of staining solution (in 1x Perm Wash) composed of anti-IFN-γ-PE, and in
some experiments with anti-IL-2-APC and anti-TNF-α-PE-Cy7. Cells were washed twice, fixed
with BD Stabilizing Fixative (BD Biosciences, San Jose, CA), and then analyzed by FACS using
LSRII (BD Biosciences, San Jose, CA) and DiVA software. Flow cytometric acquisition and
analysis of samples was performed on at least 500,000 events. Post-acquisition analyses were
performed with FlowJo (TreeStar, Ashland, OR). Data shown on graphs represent values of
peptide-stimulated cells from which background values have been subtracted, unless negative
control data is shown. Single color controls used CompBeads anti-rat and anti-hamster Igk (BD
Biosciences, San Jose, CA) for compensation. Table 6-3 is a comprehensive list of all antibodies
used in these studies, including item numbers, clones, and concentrations used for staining.
In vitro stimulation
Dendritic cells (DCs) were generated from peripheral blood mononuclear cells (PBMCs) of a
rhLCV seropositive rhesus macaque by culturing in the presence of GM-CSF and IL-4 (R&D
Systems, Minneapolis, MN). They were subsequently matured in the presence of monocyteconditioned medium as previously described

291

. Matured DCs were infected with recombinant
+

AdC vectors at 50 moi per cell and cultured overnight. Effector CD8 T cells were generated by
stimulating PBMCs from the same animal with a rhEBNA1 peptide pool followed by depletion of
+

CD4 T cells as described

215

. Twenty thousand AdC vector- or rhEBNA1 peptide-pulsed DCs
+

were used as APCs in the presence or absence of 50,000 CD8 T cells in an IFN-γ ELISPOT
assay. After a 16h incubation, IFN-γ-secreting cells were visualized following the manufacturer’s
instructions (Mabtech, Cincinnati, OH) as described previously

215

. The number of activated CD8

+

T cells was enumerated by counting the number of spots using an automated reader and analysis
software (Zellnet, Fort Lee, NJ) and the results were expressed as the number of spot forming
6

+

+

cells per 10 CD8 T cells. Positive and negative controls were CD8 T cells cultured in the
presence of PHA or medium alone.

	
  
Synthetic peptides

	
  

149

The rhEBNA1 peptide pool consists of 85 15-mer peptides overlapping by 10 amino acids
(Genemed Synthesis Inc. San Antonio, TX). The peptide pools used for testing of pre-vaccination
samples contained peptides to the GAr domain and we continued to use these pools although the
vaccine does not carry these sequences of rhEBNA1. The HIV-gag peptide pool consists of
(123) 15-mer peptides overlapping by 11 amino acids (National Institutes of Health AIDS
Research and Reference Reagent Program). All peptides were reconstituted in DMSO.
Statistical analysis
Experiments were conducted repeatedly using 4-5 mice per group. Results show the means ±
SD. Significances between two groups were analyzed by one-tailed Student's t-test or a one-way
ANOVA, depending on the number of comparisons made.

A p-value <0.05 was considered

significant. All multiple comparisons were Bonferroni-adjusted to control for type I errors.
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Table 6-3: List of antibodies for ICS (mouse studies)
Antibody

Clone

LIVE/DEAD fixable aqua dead cell stain
Rat anti-mouse CD8-PerCp-Cy5.5

53-6.7

Rat anti-mouse CD4-FITC

RM4-4

Rat anti-mouse CD44-APC

IM7

Rat anti-mouse CD44-Alexa 700

IM7

Rat anti-mouse CD62L-FITC

MEL-14

Rat anti-mouse CD127-PacBlue

A7R34

Rat anti-mouse IFN-γ-PE

XMG1.2

Rat anti-mouse IL-2–APC

JES6-5H4

Rat anti-mouse TNF-α–PE–Cy7

MP6XT22

	
  

Company
Invitrogen,
Carlsbad, CA
BioLegend,
San Diego, CA	
  
BD Biosciences,
San Jose, CA
BioLegend,
San Diego, CA
BioLegend,
San Diego, CA
BD Biosciences,
San Jose, CA
eBioScience,	
  
San Diego, CA
BD Biosciences,
San Jose, CA
BD Biosciences,
San Jose, CA
BioLegend,
San Diego, CA

Catalog
number
L34957

Ratio
used
1:500

100734

1:100

553055

1:100

103011

1:100

103026

1:100

553150

1:100

48-1271-82

1:100

554412

1:100

554429

1:100

506324

1:100
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6.3 ADENOVIRUS-BASED VACCINES TO RHEBNA1 INDUCE EXPANSION
OF CD8+ AND CD4+ T CELLS IN PERSISTENTLY INFECTED RHESUS
MACAQUES
	
  
Microneutralization assay for Ad virus-specific neutralizing antibodies (NA)
NA titers were determined as described previously

167

on HEK 293 cells infected with AdC vectors

expressing green fluorescent protein (GFP).

	
  
Non-human primates
Fifteen female adult, healthy, and SIV-uninfected rhesus macaques (Macaca mulatta) of Indian
origin aged 6 to 20 years were enrolled into the study. Animals were housed at the Yerkes
National Primate Research Center (YNPRC, Atlanta, GA) at either the field station or the main
station. All animals except PH1019 and PWw were born at YNPRC. Animals were negative for
NAs to AdC68 and AdC6, except for one animal (RZi7) with a low titer (1:10) to AdC6. All
animals tested positive for rhLCV infection by serologic testing for serum antibodies against the
rhLCV small viral capsid antigen

265

.

Mamu phenotypes were also determined.

A detailed

analysis of baseline rhEBNA1- and rhBZLF1-specific immune responses was conducted and is
discussed in chapter 2.
Additional samples were obtained from five rhLCV-seronegative rhesus macaques housed in the
extended specific-pathogen-free colony at the New England Primate Research Center, Harvard
Medical School, Southborough, MA.

All procedures involving handling of animals were

performed according to approved protocols and upon review by the respective Institutional Animal
Care and Usage Committees. 	
  
Immunization regimen of rhesus macaques
Fifteen animals were divided into 3 groups with similar age distribution and rhEBNA1 immune
response status. Group 1 animals (n = 6) received 10

	
  

11

vps of AdC68-SgD-rhEBNA1, group 2
152

animals (n = 6) received 10
received 10

11

11

vps of AdC68-NBEFSgD-rhEBNA1, and group 3 animals (n = 3)

vps of an AdC68 vector expressing an irrelevant antigen (i.e., nucleoprotein of

influenza A virus) fused into gD (AdC68-gD-NP). Animals were boosted 15 weeks after priming
with 10

11

vps of the corresponding AdC6 vectors expressing the same antigens used for priming.

All vaccines were given intramuscularly (i.m.). See Table 4-3 for basic characteristics of the
animals enrolled in the study and the vaccines they received.

	
  

Isolation and preservation of lymphocytes	
  
Peripheral blood mononuclear cells (PBMCs) were isolated from blood as described

257

. Briefly,

whole blood collected in CPT tubes was centrifuged at 2600 rpm for 30 minutes. The clear
plasma layer (top layer) was transferred to cryo tubes (about 1 ml per tube) and frozen at -80°C.
The remaining plasma layer was then gently mixed with the cloudy lymphocyte layer below and
transferred to a new 50 ml conical tube. Remnants of the mixed cell layer within the CPT tube
were gently washed twice with 5 ml of HBSS and transferred to the same 50 mL conical tube.
The tube was topped with HBSS and spun at 1200 rpm for 10 minutes.

After discarding

supernatant, cells were resuspended in 5 ml ACK lysis buffer and incubated for 5 minutes at
room temperature. Cells were washed twice with HBSS and resuspended in RPMI complete
7

medium. Samples were tested immediately after isolation or 1x10 cells per ml were frozen in
90% FBS and 10% dimethyl sulfoxide (Sigma, St. Louis, MO) at -80°C until testing.
Intracellular cytokine staining (ICS)
The magnitude and function of rhEBNA1- and rhBZLF1-specific T cells was assessed by
intracellular cytokine staining (ICS) after stimulation with peptide pools

257

. Samples collected at

different time points were tested in parallel for each animal to minimize variability. RhEBNA1 was
used at a final concentration of 2µg of each peptide per ml, and rhBZLF1 was used at a final
concentration of 1µg of each peptide per ml. Frozen cells were thawed and immediately washed
with HBSS supplemented with 2 units/ml DNase I, resuspended with RPMI medium, and
stimulated for 6 hrs with anti-CD28, anti-CD49d, and Brefeldin A. Cells were stained with violetfluorescent reactive dye-Pacific Blue, anti-CD14-Pacific Blue, anti-CD16-Pacific Blue, anti CD20	
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Pacific Blue, anti-CD8-APC-H7, anti-CD4-Alexa700, anti-CD95-PE-Cy5, and anti-CD28-Texas
Red for 30 min at 4°C (solution prepared in PBS). Additionally, cells were stained with anti-CCR7PE. After fixation and permeabilization with Cytofix/Cytoperm (BD Biosciences, San Jose, CA) for
30 min at 4°C, cells were stained with anti-IFN-γ-APC, anti-IL-2-FITC, anti-TNF-α-PE-Cy7, and
anti-CD3-PerCp-Cy5.5 for 30 min at 4°C (solution prepared in 1x perm wash). Cells were washed
twice, fixed with BD Stabilizing Fixative (BD Biosciences, San Jose, CA), and then analyzed by
FACS using LSRII (BD Biosciences, San Jose, CA) and DiVA software. Flow cytometric
acquisition and analysis of samples were performed on at least 500,000 events. Post-acquisition
analyses were performed with FlowJo (TreeStar, Ashland, OR). Data shown on graphs represent
values of peptide-stimulated cells from which background values have been subtracted.
Polyfunctionality pie chart graphs were generated using SPICE software (NIH, Bethesda MD,
http://exon.niaid.nih.gov/spice/). Single-color controls used CompBeads Anti-Mouse Igk (BD
Biosciences, San Jose, CA) for compensation. See Table 6-1 for a comprehensive list of all
antibodies used in these studies, including item numbers, clones, and concentrations used for
staining.
The above-described experiment was repeated for 11 of the 12 animals (excluding RLz5) with the
addition of an antibody for staining of intracellular granzyme B. Anti-granzyme B PE-Cy5.5 (clone
GB11; Life Science Products, Chestertown, MD) was added after the fixation and
permeabilization steps at a dilution of 1:40 (determined by titration). Responses were tested at
weeks 0, 2, 8, and either week 17 or week 19 after vaccination, depending on sample availability.

	
  
Synthetic peptides
The rhEBNA1 peptide pool consists of 85 15-mer peptides overlapping by 10 amino acids except
for the GAr domain, where peptides overlap by 5 amino acids (Genemed Synthesis Inc., San
Antonio, TX; NeoBioSci, Cambridge, MA). The peptide pools used for testing of pre-vaccination
samples contained peptides to the GAr domain and we continued to use these pools although the
vaccine does not carry these sequences of rhEBNA1. To account for its large size, the rhEBNA1
peptide pool was divided into two pools, one with peptides 1 to 42 and the other with peptides 43
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to 85. Responses were combined after normalization and subtraction of background values. The
rhBZLF1 peptide pool consists of 60 15-mer peptides with 11 amino acid overlap and was
provided by A. Kaur. Peptides were reconstituted in DMSO.
Statistical analysis
For statistical analyses of data several comparisons were made. To assess the overall magnitude
of vaccine responses, areas under the curve (AUC) using increases of cytokine producing T cells
(normalized after subtraction of background responses) over baseline counts (normalized after
subtraction of background responses) were calculated. For these calculations negative values
were set at 0. The AUCs for animals belonging to both rhEBNA1 vaccine groups were compared
to the AUCs of control animals by using unpaired Mann-Whitney tests. Comparisons between all
three groups or between the three types of T cell subsets were conducted by analysis of variance
(ANOVA). Comparisons for individual patterns of functions were made by Fischer’s least
significant difference test by ANOVA.

All multiple comparisons were Bonferroni adjusted to

control for type I error rate, and P values of < 0.05 were considered significant. Data were
analyzed using Prism version 6a software.
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